U.S. patent application number 11/839950 was filed with the patent office on 2008-01-17 for cycloalkylmethoxy-substituted acetic acid derivatives, processes for their preparation and their use as pharmaceuticals.
This patent application is currently assigned to SANOFI-AVENTIS DEUTSCHLAND GMBH. Invention is credited to Eugen FALK, Heiner GLOMBIK, Jochen GOERLITZER, Dirk GRETZKE, Stefanie KEIL, Hans-Ludwig SCHAEFER, Christian STAPPER, Wolfgang WENDLER.
Application Number | 20080015238 11/839950 |
Document ID | / |
Family ID | 32920629 |
Filed Date | 2008-01-17 |
United States Patent
Application |
20080015238 |
Kind Code |
A1 |
STAPPER; Christian ; et
al. |
January 17, 2008 |
CYCLOALKYLMETHOXY-SUBSTITUTED ACETIC ACID DERIVATIVES, PROCESSES
FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS
Abstract
Provided herein are methods for the treatment of metabolic
diseases such as disorders of fatty acid metabolism and glucose
utilization as well as disorders in which insulin resistance is
involved, in a patient. comprising the administration of novel
compounds of formula I below: ##STR1## in which the substituents
are defined herein including their physiologically acceptable
salts,
Inventors: |
STAPPER; Christian; (Mainz,
DE) ; KEIL; Stefanie; (Hofheim, DE) ; GLOMBIK;
Heiner; (Hofheim, DE) ; FALK; Eugen;
(Frankfurt, DE) ; GOERLITZER; Jochen; (Frankfurt
am Main, DE) ; GRETZKE; Dirk; (Frankfurt, DE)
; SCHAEFER; Hans-Ludwig; (Hochheim, DE) ; WENDLER;
Wolfgang; (Selters, DE) |
Correspondence
Address: |
ANDREA Q. RYAN;SANOFI-AVENTIS U.S. LLC
1041 ROUTE 202-206
MAIL CODE: D303A
BRIDGEWATER
NJ
08807
US
|
Assignee: |
SANOFI-AVENTIS DEUTSCHLAND
GMBH
Bruningstrasse 50
Frankfurt
DE
65929
|
Family ID: |
32920629 |
Appl. No.: |
11/839950 |
Filed: |
August 16, 2007 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
10788996 |
Feb 27, 2004 |
7259177 |
|
|
11839950 |
Aug 16, 2007 |
|
|
|
60487510 |
Jul 15, 2003 |
|
|
|
Current U.S.
Class: |
514/374 |
Current CPC
Class: |
A61P 3/08 20180101; C07D
413/02 20130101; A61P 3/10 20180101; A61P 5/00 20180101; A61P 43/00
20180101; C07D 263/32 20130101; A61P 3/00 20180101; A61P 5/50
20180101; A61P 7/12 20180101; A61P 3/06 20180101; A61P 9/10
20180101 |
Class at
Publication: |
514/374 |
International
Class: |
A61K 31/421 20060101
A61K031/421; A61P 3/00 20060101 A61P003/00 |
Foreign Application Data
Date |
Code |
Application Number |
Feb 27, 2003 |
DE |
10308355.3 |
Claims
1. A method for treating or preventing a disorder of fatty acid
metabolism or glucose utilization in a patient, comprising
administering to said patient a therapeutically effective amount of
a compound having the formula I: ##STR224## in which: Ring A is a
(C.sub.3-C.sub.8)-cycloalkanediyl ring or a
(C.sub.3-C.sub.8)-cycloalkenediyl ring, wherein one or more carbon
atoms of the (C.sub.3-C.sub.8)-cycloalkanediyl ring or the
(C.sub.3-C.sub.8)-cycloalkenediyl ring are optionally replaced by
oxygen atoms; R1 and R2 are: (a) independently of one another H, F,
Cl, Br, CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O--(C.sub.1-C.sub.6)-alkyl, SCF.sub.3, SF.sub.5,
OCF.sub.2--CHF.sub.2, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.10)-aryloxy, OH, or NO.sub.2; or (b) together with
the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form
fused, partially or unsaturated bicyclic (C.sub.6-C.sub.10)-aryl or
(C.sub.5-C.sub.11)-heteroaryl; R3 is: H, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.3-C.sub.8)-cycloalkyl, phenyl,
(C.sub.1-C.sub.3)-alkyl-phenyl, (C.sub.5-C.sub.6)-heteroaryl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-heteroaryl, or
(C.sub.1-C.sub.3)-alkyl fully or partially substituted by F; W is:
(a) is CH or N if o=1, or (b) is O, S or NR10 if o=0; X is
(C.sub.1-C.sub.6)-alkanediyl, wherein one or more carbon atoms of
the (C.sub.1-C.sub.6) alkanediyl may be replaced by oxygen atoms;
Y1 is (CR13R14).sub.p, wherein p is 1 or 2; Y2 is CH2, O, S, SO,
SO.sub.2 or NR9; n is 0-2; R4 is H, (C.sub.1-C.sub.6)-alkyl, NR9,
or F if Y2 is not O; R5 is H, (C.sub.1-C.sub.6)-alkyl, NR9, or F if
Y2 is not O; R6 is H, (C.sub.1-C.sub.6)-alkyl; or F if n is not O;
R7 is: H, F (if n is not 0), (C.sub.1-C.sub.6)-alkoxy,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl that may be
unsubstituted or substituted by one or more radicals selected from
the group consisting of: hydroxyl, phenyl,
(C.sub.5-C.sub.11)-heteroaryl, (C.sub.1-C.sub.6)-alkoxy and
NR11R12, or phenyl that may be unsubstituted or substituted by one
or more radicals from the group consisting of hydroxy,
(C.sub.1-C.sub.6)-alkoxy, F and CF.sub.3, with the proviso that R7
is not NR11R12 or (C.sub.1-C.sub.6)-alkoxy if R6=F; R6 and R7 are
together with the carbon atom that carries them
(C.sub.3-C.sub.8)-cycloalkyl; R8 is H or (C.sub.1-C.sub.6)-alkyl;
R9 is: H, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.2-C.sub.6)-alkynyl, aryl-(C.sub.1-C.sub.4)-alkyl,
CO--(C.sub.1-C.sub.6)-alkyl, CO--(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.5-C.sub.11)-heteroaryl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.5-C.sub.11)-heteroaryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.5-C.sub.11)-heteroaryl, wherein aryl or
heteroaryl, or both may be unsubstituted or substituted by
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, F, Cl,
CO--(C.sub.1-C.sub.6)-alkyl; R10 is H, (C.sub.1-C.sub.6)-alkyl or
(C.sub.1-C.sub.6)-alkyl-phenyl; R11 is H, (C.sub.1-C.sub.6)-alkyl
or (C.sub.1-C.sub.6)-alkyl-phenyl; R12 is H,
(C.sub.1-C.sub.6)-alkyl or (C.sub.1-C.sub.6)-alkyl-phenyl; R13 is H
or (C.sub.1-C.sub.6)-alkyl; and R14 is H or
(C.sub.1-C.sub.6)-alkyl; or a physiologically acceptable salt of
the compound; a solvate of the compound; or a physiologically
active derivative of the compound.
2. The method of claim 1 for treating or preventing a disorder
involving insulin resistance in a patient, comprising the
administration of a therapeutically effective amount of the
compound of formula I of claim 1 to the patient.
3. The method of claim 1 for treating or preventing diabetes
mellitus and its sequelae in a patient, comprising the
administration of a therapeutically effective amount of the
compound of formula I of claim 1 to the patient.
4. The method of claim 1 for treating or preventing dysipidemias
and their sequelae in a patient, comprising the administration of a
therapeutically effective amount of the compound of formula I of
claim 1 to the patient.
5. The method of claim 1 for treating or preventing a physiological
state associated with a metabolic syndrome in a patient, comprising
the administration of a therapeutically effective amount of the
compound formula I of claim 1 to the patient.
6. The method of claim 1, further comprising the administration of
a therapeutically effective amount of a second active compound for
treating or preventing disorders of the fatty acid metabolism and
glucose utilization disorders to the patient.
7. The method of claim 2, further comprising administering to the
patient a therapeutically effective amount of a second compound for
treating or preventing a disorder in which insulin resistance is
involved.
8. A method for treating or preventing a disorder of fatty acid
metabolism or glucose utilization in a patient, comprising the
administration of a therapeutically effective amount of a compound
comprised of formula I to the patient: ##STR225## in which: ring A
is a (C.sub.3-C.sub.8)-cycloalkanediyl or a
(C.sub.3-C.sub.8)-cycloalkenediyl, wherein one or more carbon atoms
of the (C.sub.3-C.sub.8)-cycloalkanediyl or the
(C.sub.3-C.sub.8)-cycloalkenediyl may be replaced by oxygen atoms;
R1 and R2 are: (a) independently of one another H, F, Cl, Br,
CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O-(C.sub.1-C.sub.6)-alkyl, SCF.sub.3, SF.sub.5,
OCF.sub.2--CHF.sub.2, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.10)-aryloxy, OH, or NO.sub.2; or (b) together with
the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form
fused, partially or unsaturated bicyclic (C.sub.6-C.sub.10)aryl, or
(C.sub.5-C.sub.11)-heteroaryl; R3 is: H, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.3-C.sub.8)-cycloalkyl, phenyl,
(C.sub.1-C.sub.3)-alkyl-phenyl, (C.sub.5-C.sub.6)-heteroaryl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-heteroaryl, or
(C.sub.1-C.sub.3)-alkyl fully or partially substituted by F; W is:
(a) is CH or N if o=1, or (b) is O, S or NR10 if o=0; X is
(C.sub.1-C.sub.6)-alkanediyl, wherein the C.sub.1 or C.sub.2 carbon
atom to Ring A may be replaced by an oxygen atom; Y1 is
(CR13R14).sub.p, wherein p is 1 or 2; Y2 is CH2, O, S, SO, SO2 or
NR9; n is 0-2; R4 is H, (C1-C6)-alkyl, NR9, or F if Y2 is not O; R5
is H, (C.sub.1-C.sub.6)-alkyl, NR9, or F if Y2 is not O; R6 is H,
(C.sub.1-C.sub.6)-alkyl; or F if n is not 0; R7 is: H, F (if n is
not 0), (C.sub.1-C.sub.6)-alkoxy, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.2-C.sub.6)-alkynyl, (C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.6)-alkyl that may be unsubstituted or substituted by
one or more radicals selected from the group consisting of:
hydroxyl, phenyl, (C.sub.5-C.sub.11)-heteroaryl,
(C.sub.1-C.sub.6)-alkoxy and NR11R12, or phenyl that may be
unsubstituted or substituted by one or more radicals from the group
consisting of hydroxy, (C.sub.1-C.sub.6)-alkoxy, F and CF.sub.3,
with the proviso that R7 is not NR11R12 or (C.sub.1-C.sub.6)-alkoxy
if R6=F; R6 and R7 are together with the carbon atom that carries
them (C.sub.3-C.sub.8)-cycloalkyl; R8 is H or
(C.sub.1-C.sub.6)-alkyl; R9 is: H, (C.sub.1-C.sub.6)-alkyl,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl,
aryl-(C.sub.1-C.sub.4)-alkyl, CO--(C.sub.1-C.sub.6)-alkyl,
CO--(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.5-C.sub.11)-heteroaryl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.5-C.sub.11)-heteroaryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.5-C.sub.11)-heteroaryl, wherein aryl or
heteroaryl, or both may be unsubstituted or substituted by
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, F, Cl,
CO--(C.sub.1-C.sub.6)-alkyl; R10 is H, (C.sub.1-C.sub.6)-alkyl or
(C.sub.1-C.sub.6)-alkyl-phenyl; R11 is H, (C.sub.1-C.sub.6)-alkyl
or (C.sub.1-C.sub.6)-alkyl-phenyl; R12 is H,
(C.sub.1-C.sub.6)-alkyl or (C.sub.1-C.sub.6)-alkyl-phenyl; R13 is H
or (C.sub.1-C.sub.6)-alkyl; and R14 is H or
(C.sub.1-C.sub.6)-alkyl; or a physiologically acceptable salt of
the compound; a solvate of the compound; or a physiologically
active derivative of the compound.
9. The method of claim 8 for treating or preventing a disorder of
fatty acid metabolism or glucose utilization in a patient,
comprising the administration of a therapeutically effective amount
of the compound of formula I of claim 8 to the patient.
10. The method of claim 8 for treating or preventing a disorder
involving insulin resistance in a patient, comprising the
administration of a therapeutically effective amount of the
compound of formula I of claim 8 to the patient.
11. The method of claim 8 for treating or preventing diabetes
mellitus and its sequelae in a patient, comprising the
administration of a therapeutically effective amount of the
compound of formula I of claim 8 to the patient.
12. The method of claim 8 for treating or preventing dyslpidemias
and their sequelae in a patient, comprising the administration of a
therapeutically effective amount of the compound of claim 2 to the
patient.
13. A method for treating or preventing a physiological state
associated with a metabolic syndrome in a patient, comprising
administering a therapeutically effective amount of the compound of
claim 2 to the patient.
14. The method of claim 8, further comprising administering the
patient a therapeutically effective amount of a second active
compound for treating and/or preventing disorders of the fatty acid
metabolism and glucose utilization disorders.
15. The method of claim 8, further comprising administering to the
patient a therapeutically effective amount of a second compound for
treating and/or preventing a disorder in which insulin resistance
is involved.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This Application is a division of U.S. application Ser. No.
10/788,996 filed Feb. 27, 2004, now U.S. Pat. No. 7,259,177, issued
Aug. 21, 2007, which claims the benefit of U.S. Provisional
Application No. 60/487,510 filed Jul. 15, 2003, both of which are
incorporated herein by reference in their entirety, which claims
the benefit of priority of German Application No. 10308355.3 filed
Feb. 27, 2003.
FIELD OF INVENTION
[0002] The invention relates to cycloalkylmethoxy-substituted
acetic acid derivatives, processes for their preparation and to
their use as pharmaceuticals, and to their physiologically
acceptable salts and physiologically functional derivatives.
BACKGROUND OF THE INVENTION
[0003] Compounds of a similar structure have already been described
in the prior art for the treatment of hyperlipidemia and diabetes
(WO 2000/64876).
[0004] The citation of any reference herein should not be construed
as an admission that such reference is available as "Prior Art" to
the instant application.
SUMMARY OF THE INVENTION
[0005] The present invention extends to a compound having the
formula I: ##STR2## in which: Ring A is a
(C.sub.3-C.sub.8)-cycloalkanediyl ring or a
(C.sub.3-C.sub.8)-cycloalkenediyl ring, wherein one or more carbon
atoms of the (C.sub.3-C.sub.8)-cycloalkanediyl ring or the
(C.sub.3-C.sub.8)-cycloalkenediyl ring may be replaced by oxygen
atoms; R1 and R2 are: [0006] (a) Independently of one another H, F,
Cl, Br, CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O--(C.sub.1-C.sub.6)-alkyl, SCF.sub.3, SF.sub.5,
OCF.sub.2--CHF.sub.2, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.10)-aryloxy, OH, NO.sub.2; or [0007] (b) together
with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form
fused, partially or unsaturated bicyclic (C.sub.6-C.sub.10)-aryl,
(C.sub.5-C.sub.11)-heteroaryl; R3 is: H, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.3-C.sub.8)-cycloalkyl, phenyl,
(C.sub.1-C.sub.3)-alkyl-phenyl, (C.sub.5-C.sub.6)-heteroaryl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-heteroaryl, or
(C.sub.1-C.sub.3)-alkyl fully or partially substituted by F; W is:
[0008] (a) is CH or N if o=1, or [0009] (b) is O, S or NR10 if o=0;
X is (C.sub.1-C.sub.6)-alkanediyl, wherein one or more carbon atoms
of the (C.sub.1-C.sub.6) alkanediyl may be replaced by oxygen
atoms; Y1 is (CR13R14).sub.p, wherein p is 1 or 2; Y2 is CH.sub.2,
O, S, SO, SO.sub.2 or NR9; n is 0-2; R4 is H, (C1-C6)-alkyl, NR9,
or F if Y2 is not O; R5 is H, (C.sub.1-C.sub.6)-alkyl, NR9, or F if
Y2 is not O; R6 is H, (C.sub.1-C.sub.6)-alkyl; or F if n is not 0;
R7 is: [0010] H, F (if n is not 0), (C.sub.1-C.sub.6)-alkoxy,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl that may be
unsubstituted or substituted by one or more radicals selected from
the group consisting of: [0011] hydroxyl, phenyl,
(C.sub.5-C.sub.11)-heteroaryl, (C.sub.1-C.sub.6)-alkoxy and
NR11R12, or [0012] phenyl that may be unsubstituted or substituted
by one or more radicals from the group consisting of hydroxy,
(C.sub.1-C.sub.6)-alkoxy, F and CF.sub.3, with the proviso that R7
is not NR11R12 or (C.sub.1-C.sub.6)-alkoxy if R6=F; R6 and R7 are
together with the carbon atom that carries them
(C.sub.3-C.sub.8)-cycloalkyl; R8 is H or (C.sub.1-C.sub.6)-alkyl;
R9 is: H, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.2-C.sub.6)-alkynyl, aryl-(C.sub.1-C.sub.4)-alkyl,
CO--(C.sub.1-C.sub.6)-alkyl, CO--(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.5-C.sub.11)-heteroaryl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.5-C.sub.11)-heteroaryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.5-C.sub.11)-heteroaryl, wherein aryl or
heteroaryl, or both may be unsubstituted or substituted by
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, F, Cl,
CO--(C.sub.1-C.sub.6)-alkyl; R10 is H, (C.sub.1-C.sub.6)-alkyl or
(C.sub.1-C.sub.6)-alkyl-phenyl; R11 is H, (C.sub.1-C.sub.6)-alkyl
or (C.sub.1-C.sub.6)-alkyl-phenyl; R12 is H,
(C.sub.1-C.sub.6)-alkyl or (C.sub.1-C.sub.6)-alkyl-phenyl; R13 is H
or (C.sub.1-C.sub.6)-alkyl; and R14 is H or
(C.sub.1-C.sub.6)-alkyl.
[0013] Furthermore, the present invention extends to a
physiologically acceptable salt of a compound of the formula I as
described above, to a solvate of a compound of the formula I as
described above, and to a physiologically functional derivative of
a compound of formula I as described above.
[0014] In a particular embodiment, the present invention extends to
a compound of the formula I as described above, wherein:
Ring A is (C.sub.3-C.sub.8)-cycloalkanediyl or
(C.sub.3-C.sub.8)-cycloalkenediyl, wherein one carbon atom of the
(C.sub.3-C.sub.8)-cycloalkanediyl ring or the (C.sub.3-C.sub.8)
cycloalkenediyl ring may be replaced by an oxygen atom; and
X is (C.sub.1-C.sub.6)-alkanediyl, wherein the C.sub.1 or C.sub.2
carbon atom (to Ring A) may be replaced by an oxygen atom.
[0015] Naturally, the present invention extends to a
physiologically acceptable salt of a compound of the formula I
described above, a solvate of a compound of the formula I described
above, and a physiologically functional derivative of a compound of
the formula I described herein, wherein:
Ring A is (C.sub.3-C.sub.8)-cycloalkanediyl or
(C.sub.3-C.sub.8)-cycloalkenediyl, wherein one carbon atom of the
(C.sub.3-C.sub.8)-cycloalkanediyl ring or the (C.sub.3-C.sub.8)
cycloalkenediyl ring may be replaced by an oxygen atom; and
X is (C.sub.1-C.sub.6)-alkanediyl, wherein the C.sub.1 or C.sub.2
carbon atom (to Ring A) may be replaced by an oxygen atom.
[0016] The present invention further extends to a compound of
formula I as described above, in which one or more radicals of the
compound are as defined follows:
Ring A is a cyclohexane-1,3-diyl;
R1 is F, Br, CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O--(C.sub.1-C.sub.6)-alkyl, or phenyl;
R1 and R2 together with a phenyl ring of the compound form a
naphthyl;
R1 is in the meta- or in the para-position;
R2 is hydrogen;
R3 is H, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-cycloalkyl, phenyl, or
(C.sub.1-C.sub.3)-alkyl-phenyl;
W is CH if o=1;
X is CH.sub.2--O or CH.sub.2--O--CH.sub.2;
n is 0;
R6 is H or (C.sub.1-C.sub.6)-alkyl;
R6 and R7 together with the carbon atom that carries them are
(C.sub.3-C.sub.6)-cycloalkyl, and in particular a cyclopentyl;
or
R7 is (C.sub.1-C.sub.6)-alkyl unsubstituted or substituted by one
or more radicals selected from the group consisting of hydroxyl,
phenyl, (C.sub.5-C.sub.11)-heteroaryl, (C.sub.1-C.sub.6)-alkoxy and
NR11R12, wherein:
[0017] (i) R11 and R12 are H, or (C1-C6)-alkyl; or [0018] (ii) R13
and R14 are hydrogen.
[0019] In addition, the present invention extends to a
physiologically acceptable salt of a compound of the formula I
described above, a solvate of a compound of the formula I described
above, and a physiologically functional derivative of a compound of
the formula I described above, wherein one or more radicals of the
compound are as defined follows:
Ring A is a cyclohexane-1,3-diyl;
R1 is F, Br, CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O--(C.sub.1-C.sub.6)-alkyl, or phenyl;
R1 and R2 together with a phenyl ring of the compound form a
naphthyl;
R1 is in the meta- or in the para-position;
R2 is hydrogen;
R3 is H, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-cycloalkyl, phenyl, or
(C.sub.1-C.sub.3)-alkyl-phenyl;
W is CH if o=1;
X is CH.sub.2-0 or CH.sub.2--O--CH.sub.2;
n is 0;
R6 is H or (C.sub.1-C.sub.6)-alkyl;
R6 and R7 together with the carbon atom that carries them are
(C.sub.3-C.sub.6)-cycloalkyl, and in particular a cyclopentyl;
or
R7 is (C.sub.1-C.sub.6)-alkyl unsubstituted or substituted by one
or more radicals selected from the group consisting of hydroxyl,
phenyl, (C.sub.5-C.sub.11)-heteroaryl, (C.sub.1-C.sub.6)-alkoxy and
NR11R12, wherein:
[0020] (i) R11 and R12 are H, or (C1-C6)-alkyl; or [0021] (ii) R13
and R14 are hydrogen.
[0022] The present invention further extends to a compound of
formula I as described herein, wherein R7 is
(C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkyl-O--(C.sub.1-C.sub.4)-alkyl or benzyl.
[0023] Moreover, the present invention extends to a physiologically
acceptable salt of a compound of the formula I as described above,
a solvate of a compound of the formula I described above, and a
physiologically functional derivative of a compound of the formula
I described above, in which R7 is (C.sub.1-C.sub.4)-alkyl,
(C.sub.1-C.sub.4)-alkyl-O--(C.sub.1-C.sub.4)-alkyl or benzyl.
[0024] In a particular embodiment, the present invention extends to
a compound of the formula I as described above, as well as a
physiologically acceptable salt of the compound, a solvate of the
compound, and a physiologically acceptable derivative of the
compound, wherein R7 is (C1-C4)-alkyl or benzyl.
[0025] Furthermore, the present invention extends to a compound of
the formula I as described above, in which
Ring A is cis-cyclohexane-1,3-diyl;
R1 and R2 are:
independently of one another H, F, CF.sub.3,
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, or phenyl;
or
together with a phenyl ring of the compound form a naphthyl;
R3 is (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, or
phenyl;
W is:
CH if o=1, or
O or S if o=0;
X is CH.sub.2--O or CH.sub.2--O--CH.sub.2;
Y1 is CH.sub.2;
Y2 is CH.sub.2, O, S, SO, SO.sub.2 or NR9;
n is 0;
R4 is H;
R5 is H;
R6 is H, (C.sub.1-C.sub.6)-alkyl, or benzyl;
R7 is H, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl,
phenyl, or benzyl,
R6 and R7 together with the carbon atom that carries them are
(C.sub.3-C.sub.6)-cycloalkyl;
R8 is H; and
R9 is:
[0026] H, or [0027] (C.sub.1-C.sub.6)-alkyl, which may be
unsubstituted or substituted by: [0028]
(C.sub.3-C.sub.6)-cycloalkyl, phenyl, (C.sub.5-C.sub.6)-heteroaryl;
CO--(C.sub.1-C.sub.6)-alkyl, CO--(C.sub.1-C.sub.6)-alkyl-phenyl,
CO-phenyl, C(O)--O--(C.sub.1-C.sub.6)-alkyl, CO--NH-phenyl,
SO.sub.2--(C.sub.1-C.sub.4)-alkyl,
SO.sub.2--(C.sub.1-C.sub.4)-alkyl-SO.sub.2--(C.sub.1-C.sub.4)-alkyl,
SO.sub.2-tolyl, or a combination thereof, [0029] wherein the phenyl
of the substituent for its part may be substituted by
O--(C.sub.1-C.sub.3)-alkyl.
[0030] Naturally, the present invention extends to a
physiologically acceptable salt, a solvate and a physiologically
functional derivative of a compound of the formula I described
above, in which
Ring A is cis-cyclohexane-1,3-diyl;
R1 and R2 are:
independently of one another H, F, CF.sub.3,
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, or phenyl;
or
R1 and R2 together with a phenyl ring of the compound form a
naphthyl;
R3 is (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.8)-cycloalkyl, or
phenyl;
W is:
CH if o=1, or
O or S if o=0;
X is CH.sub.2--O or CH.sub.2--O--CH.sub.2;
Y1 is CH.sub.2;
Y2 is CH.sub.2, O, S, SO, SO.sub.2 or NR9;
n is 0;
R4 is H;
R5 is H;
R6 is H, (C.sub.1-C.sub.6)-alkyl, or benzyl;
R7 is H, (C.sub.1-C.sub.6)-alkyl, (C.sub.3-C.sub.6)-cycloalkyl,
phenyl, or benzyl,
R6 and R7 together with the carbon atom that carries them are
(C.sub.3-C.sub.6)-cycloalkyl;
R8 is H; and
R9 is:
[0031] H, or [0032] (C.sub.1-C.sub.6)-alkyl, which may be
unsubstituted or substituted by: [0033]
(C.sub.3-C.sub.6)-cycloalkyl, phenyl, (C.sub.5-C.sub.6)-heteroaryl;
CO--(C.sub.1-C.sub.6)-alkyl, CO--(C.sub.1-C.sub.6)-alkyl-phenyl,
CO-phenyl, C(O)--O--(C.sub.1-C.sub.6)-alkyl, CO--NH-phenyl,
SO.sub.2--(C.sub.1-C.sub.4)-alkyl,
SO.sub.2--(C.sub.1-C.sub.4)-alkyl-SO.sub.2--(C.sub.1-C.sub.4)-alkyl,
SO.sub.2-tolyl, or a combination thereof, [0034] wherein the phenyl
of the substituent for its part may be substituted by
O--(C.sub.1-C.sub.3)-alkyl.
[0035] Furthermore, the present invention extends to a compound as
described above, as well as to a physiological salt of the
compound, a solvate of the compound, or a physiologically
functional derivative of the compound, wherein the alkyl radicals
in the substituents R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11,
R12, R13 and R14 of the compound may be either straight-chain or
branched.
[0036] Furthermore, the present invention extends to a
pharmaceutical composition comprising a compound of formula I as
described above and a pharmaceutically acceptable carrier. Also
encompassed by the present invention is a pharmaceutical
composition comprising a physiologically acceptable salt of a
compound of formula I described above, a solvate of a compound of
formula I described above, or a physiologically functional
derivative of a compound of formula I described above, and a
pharmaceutically acceptable carrier.
[0037] In another embodiment, the present invention extends to a
method of treating and/or preventing a disorder or condition in a
patient comprising administering a therapeutically effective amount
of a compound of formula I described above, a physiologically
effective salt of a compound of formula I described above, a
solvate of a compound of formula I described above, or a
physiologically acceptable derivative of a compound of formula I
described above, to the patient. Particular examples of disorders
and conditions that can be treated and/or prevented with the
administration of a compound of the present invention are described
infra.
[0038] A method for treating and/or preventing a disorder of fatty
acid metabolism or glucose utilization in a patient, comprising
administering a therapeutically effective amount of the compound of
claim 1 to the patient.
[0039] Moreover, the present invention extends to a method for
treating and/or preventing a disorder involving insulin resistance
in a patient, comprising administering a therapeutically effective
amount of a compound of the formula I above to the patient.
[0040] The present invention also extends to a method for treating
and/or preventing diabetes mellitus and its sequelae in a patient,
comprising administering a therapeutically effective amount of a
compound of claim 1 to the patient.
[0041] In another embodiment, the present invention extends to a
method for treating and/or preventing dyslipidemias and their
sequelae in a patient, comprising administering a therapeutically
effective amount of a compound of formula I above to the
patient.
[0042] Similarly, the present invention extends to a method for
treating and/or preventing a physiological state associated with a
metabolic syndrome in a patient, comprising administering a
therapeutically effective amount of a compound of formula I to the
patient.
[0043] Furthermore, the present invention extends to a for treating
a patient as described above, wherein a therapeutically effective
amount of a second active compound for treating and/or preventing
the particular disorder or condition is administered.
[0044] Accordingly, It is an aspect of the present invention to
provide compounds that permit a therapeutically exploitable
modulation of the lipid and/or carbohydrate metabolism and are thus
suitable for the prevention and/or treatment of disorders such as
type 2 diabetes and atherosclerosis and their multifarious
sequelae.
[0045] This and other aspects of the present invention will be
better appreciated by reference to the following Detailed
Description.
DETAILED DESCRIPTION OF THE INVENTION
[0046] The present invention is based upon the discovery of
heretofore unknown compounds that surprisingly and unexpectedly,
are modulators of the activity of peroxisome proliferator-activated
receptors (PPARs). PPARs are transcription factors which can be
activated by ligands and belong to the class of nuclear hormone
receptors. There are three PPAR isoforms, PPARalpha, PPARgamma and
PPARdelta, which are encoded by different genes (Peroxisome
proliferator-activated receptor (PPAR): structure, mechanisms of
activation and diverse functions: Motojima K, Cell Struct Funct.
1993 October; 18(5): 267-77).
[0047] Two variants of PPARgamma exist, PPARgamma.sub.1 and
gamma.sub.2, which are the result of alternative use of promoters
and differential mRNA splicing (Vidal-Puig et al. J. Clin. Invest.,
97:2553-2561, 1996). Different PPARs have different tissue
distribution and modulate different physiological functions. The
PPARs play a key role in various aspects of the regulation of a
large number of genes, the products of which genes are directly or
indirectly crucially involved in lipid and carbohydrate metabolism.
Thus, for example, PPARalpha receptors play an important part in
the regulation of fatty acid catabolism or lipoprotein metabolism
in the liver, while PPARgamma is crucially involved for example in
regulating adipose cell differentiation. In addition, however,
PPARs are also involved in the regulation of many other
physiological processes, including those which are not directly
connected with carbohydrate or lipid metabolism. The activity of
different PPARs can be modulated by various fatty acids, fatty acid
derivatives and synthetic compounds to varying extents. For
relevant reviews about functions, physiological effect and
pathophysiology, see: Joel Berger et al., Annu. Rev. Med. 2002, 53,
409-435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4,
527-550; Steven Kliewer et al., Recent Prog Horm Res. 2001; 56:
239-63.
[0048] Broadly, the present invention extends to a compound having
the formula I: ##STR3## in which: Ring A is a
(C.sub.3-C.sub.8)-cycloalkanediyl ring or a
(C.sub.3-C.sub.8)-cycloalkenediyl ring, wherein one or more carbon
atoms of the (C.sub.3-C.sub.8)-cycloalkanediyl ring or the
(C.sub.3-C.sub.8)-cycloalkenediyl ring may be replaced by oxygen
atoms; R1 and R2 are: [0049] (a) Independently of one another H, F,
Cl, Br, CF.sub.3, OCF.sub.3, (C.sub.1-C.sub.6)-alkyl,
O--(C.sub.1-C.sub.6)-alkyl, SCF.sub.3, SF.sub.5,
OCF.sub.2--CHF.sub.2, (C.sub.6-C.sub.10)-aryl,
(C.sub.6-C.sub.10)-aryloxy, OH, NO.sub.2; or [0050] (b) together
with the phenyl, pyridine, 1H-pyrrole, thiophene or furan ring form
fused, partially or unsaturated bicyclic (C.sub.6-C.sub.10)-aryl,
(C.sub.5-C.sub.11)-heteroaryl; R3 is: H, (C.sub.1-C.sub.6)-alkyl,
(C.sub.3-C.sub.8)-cycloalkyl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.3-C.sub.8)-cycloalkyl, phenyl,
(C.sub.1-C.sub.3)-alkyl-phenyl, (C.sub.5-C.sub.6)-heteroaryl,
(C.sub.1-C.sub.3)-alkyl-(C.sub.5-C.sub.6)-heteroaryl, or
(C.sub.1-C.sub.3)-alkyl fully or partially substituted by F; W is:
[0051] (a) is CH or N if o=1, or [0052] (b) is O, S or NR10 if o=0;
X is (C.sub.1-C.sub.6)-alkanediyl, wherein one or more carbon atoms
of the (C.sub.1-C.sub.6) alkanediyl may be replaced by oxygen
atoms; Y1 is (CR13R14).sub.p, wherein p is 1 or 2; Y2 is CH2, O, S,
SO, SO.sub.2 or NR9; n is 0-2; R4 is H, (C1-C6)-alkyl, NR9, or F if
Y2 is not O; R5 is H, (C.sub.1-C.sub.6)-alkyl, NR9, or F if Y2 is
not O; R6 is H, (C.sub.1-C.sub.6)-alkyl; or F if n is not O; R7 is:
[0053] H, F (if n is not 0), (C.sub.1-C.sub.6)-alkoxy,
(C.sub.2-C.sub.6)-alkenyl, (C.sub.2-C.sub.6)-alkynyl,
(C.sub.3-C.sub.8)-cycloalkyl, (C.sub.1-C.sub.6)-alkyl that may be
unsubstituted or substituted by one or more radicals selected from
the group consisting of: [0054] hydroxyl, phenyl,
(C.sub.5-C.sub.11)-heteroaryl, (C.sub.1-C.sub.6)-alkoxy and
NR11R12, or [0055] phenyl that may be unsubstituted or substituted
by one or more radicals from the group consisting of hydroxy,
(C.sub.1-C.sub.6)-alkoxy, F and CF.sub.3, with the proviso that R7
is not NR11R12 or (C.sub.1-C.sub.6)-alkoxy if R6=F; R6 and R7 are
together with the carbon atom that carries them
(C.sub.3-C.sub.8)-cycloalkyl; R8 is H or (C.sub.1-C.sub.6)-alkyl;
R9 is: H, (C.sub.1-C.sub.6)-alkyl, (C.sub.2-C.sub.6)-alkenyl,
(C.sub.2-C.sub.6)-alkynyl, aryl-(C.sub.1-C.sub.4)-alkyl,
CO--(C.sub.1-C.sub.6)-alkyl, CO--(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
CO--(C.sub.5-C.sub.11)-heteroaryl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl,
C(O)--O--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.6-C.sub.10)-aryl,
C(O)--O--(C.sub.5-C.sub.11)-heteroaryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.1-C.sub.6)-alkyl-SO.sub.2--(C.sub.1-C.sub.6)-alkyl,
SO.sub.2--(C.sub.6-C.sub.10)-aryl,
SO.sub.2--(C.sub.5-C.sub.11)-heteroaryl, wherein aryl or
heteroaryl, or both may be unsubstituted or substituted by
(C.sub.1-C.sub.6)-alkyl, O--(C.sub.1-C.sub.6)-alkyl, F, Cl,
CO--(C.sub.1-C.sub.6)-alkyl; R10 is H, (C.sub.1-C.sub.6)-alkyl or
(C.sub.1-C.sub.6)-alkyl-phenyl; R11 is H, (C.sub.1-C.sub.6)-alkyl
or (C.sub.1-C.sub.6)-alkyl-phenyl; R12 is H,
(C.sub.1-C.sub.6)-alkyl or (C.sub.1-C.sub.6)-alkyl-phenyl; R13 is H
or (C.sub.1-C.sub.6)-alkyl; and R14 is H or
(C.sub.1-C.sub.6)-alkyl; .a physioloigically acceptable salt of the
compound; a solvate of the compound, or a physiologically active
derivative of the compound.
[0056] Numerous terms and phrases are used throughout the instant
specification and Claims. Accordingly:
[0057] As used herein, "aryl" refers an aromatic carbocyclic mono-
or bicyclic ring system which comprises 6 to 10 atoms in the ring
or rings.
[0058] As used herein, "heteroaryl" refers to a mono- or bicyclic
aromatic ring system having 4 to 11 ring members, in which at least
one atom in the ring system is a heteroatom from the series N, O
and S.
[0059] As used herein, the term "a" refers to one or more than
one.
[0060] In addition, a compound of the formula I described above
(also referred to as "a compound of the present invention")
comprises at least two centers of asymmetry and may comprise more
in addition. Thus, a compound of the present invention may exist in
the form of its racemate, as a racemic mixture, as a pure
enantiomer, a diastereomer or as a mixture of diastereomers. The
present invention encompasses all these isomeric forms of a
compound of the formula I. These isomeric forms can be obtained by
known methods using routine laboratory techniques, even if not
specifically described in some cases.
[0061] Pharmaceutically acceptable salts are, because their
solubility in water is greater than that of the initial or basic
compounds, particularly suitable for medical applications. These
salts must have a pharmaceutically acceptable anion or cation.
Suitable pharmaceutically acceptable acid addition salts of a
compound of the present invention are salts of inorganic acids such
as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric,
nitric and sulfuric acid, and of organic acids such as, for
example, acetic acid, benzenesulfonic, benzoic, citric,
ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic,
lactobionic, maleic, malic, methanesulfonic, succinic,
p-toluenesulfonic and tartaric acid. Suitable pharmaceutically
acceptable basic salts are ammonium salts, alkali metal salts (such
as sodium and potassium salts), alkaline earth metal salts (such as
magnesium and calcium salts), and salts of trometamol
(2-amino-2-hydroxymethyl-1,3-propanediol), diethanolamine, lysine
or ethylenediamine.
[0062] Salts with a pharmaceutically unacceptable anion such as,
for example, trifluoroacetate likewise belong within the framework
of the invention as useful intermediates for the preparation or
purification of pharmaceutically acceptable salts and/or for use in
nontherapeutic, for example in vitro, applications.
[0063] As used herein, the term "physiologically functional
derivative" refers to any physiologically tolerated derivative of a
compound of the formula I of the invention, for example an ester,
which on administration to a mammal such as, for example, a human
is able to form (directly or indirectly) a compound of the formula
I or an active metabolite thereof.
[0064] Physiologically functional derivatives also include prodrugs
of a compound of the present invention, as described, for example,
in H. Okada et al., Chem. Pharm. Bull. 1994, 42, 57-61. Such
prodrugs can be metabolized in vivo to a compound of the invention.
These prodrugs may themselves be active or not.
[0065] A compound of the present invention may also exist in
various polymorphous forms, for example as amorphous and
crystalline polymorphous forms. All polymorphous forms of a
compound of the present invention belong within the framework of
the present invention and are a further aspect of the present
invention.
[0066] All references to "compound(s) of formula I" hereinafter
refer to compound(s) of the formula I as described above, and their
salts, solvates and physiologically functional derivatives as
described herein.
Formulations
[0067] As explained above, the present invention extends to a
pharmaceutical composition comprising a compound of the present
invention, a physiologically acceptable salt of a compound of the
present invention, a solvate of a compound of the present
invention, or a physiologically acceptable derivative of a compound
of the present invention, and a pharmaceutically acceptable
carrier.
[0068] The phrase "pharmaceutically acceptable" refers to molecular
entities and compositions that are physiologically tolerable and do
not typically produce an allergic or similar untoward reaction,
such as gastric upset, dizziness and the like, when administered to
a human. Preferably, as used herein, the term "pharmaceutically
acceptable" means approved by a regulatory agency of the Federal or
a state government or listed in the U.S. Pharmacopeia or other
generally recognized pharmacopeia for use in animals, and more
particularly in humans. The term "carrier" refers to a diluent,
adjuvant, excipient, or vehicle with which the compound is
administered. Such pharmaceutical carriers can be sterile liquids,
such as water and oils, including those of petroleum, animal,
vegetable or synthetic origin, such as peanut oil, soybean oil,
mineral oil, sesame oil and the like. Water or aqueous solution
saline solutions and aqueous dextrose and glycerol solutions are
preferably employed as carriers, particularly for injectable
solutions. Suitable pharmaceutical carriers are described in
"Remington's Pharmaceutical Sciences" by E. W. Martin.
[0069] The carrier may be a solid or a liquid or both and is
preferably formulated with the compound as a single dose, for
example as a tablet, which may contain from 0.05% to 95% by weight
of the active ingredient. Other pharmaceutically active substances
may likewise be present, including other compounds of formula I.
The pharmaceutical compositions of the invention can be produced by
one of the known pharmaceutical methods, which essentially consist
of mixing the ingredients with pharmacologically acceptable
carriers and/or excipients.
[0070] Pharmaceutical compositions of the invention are those
suitable for oral, rectal, topical, peroral (for example
sublingual) and parenteral (for example subcutaneous,
intramuscular, intradermal or intravenous) administration, although
the most suitable mode of administration depends in each individual
case on the nature and severity of the condition to be treated and
on the nature of the compound of formula I used in each case.
Coated formulations and coated slow-release formulations also
belong within the framework of the invention. Preference is given
to acid- and gastric juice-resistant formulations. Suitable
coatings resistant to gastric juice comprise cellulose acetate
phthalate, polyvinyl acetate phthalate,
hydroxypropylmethylcellulose phthalate and anionic polymers of
methacrylic acid and methyl methacrylate.
[0071] Suitable pharmaceutical preparations for oral administration
may be in the form of separate units such as, for example,
capsules, cachets, suckable tablets or tablets, each of which
contain a defined amount of the compound of formula I; as powders
or granules, as solution or suspension in an aqueous or nonaqueous
liquid; or as an oil-in-water or water-in-oil emulsion. These
compositions may, as already mentioned, be prepared by any suitable
pharmaceutical method which includes a step in which the active
ingredient and the carrier (which may consist of one or more
additional ingredients) are brought into contact. The compositions
are generally produced by uniform and homogeneous mixing of the
active ingredient with a liquid and/or finely divided solid
carrier, after which the product is shaped if necessary. Thus, for
example, a tablet can be produced by compressing or molding a
powder or granules of the compound, where appropriate with one or
more additional ingredients. Compressed tablets can be produced by
tableting the compound in free-flowing form such as, for example, a
powder or granules, where appropriate mixed with a binder, glidant,
inert diluent and/or one (or more) surface-active/dispersing
agent(s) in a suitable machine. Molded tablets can be produced by
molding the compound, which is in powder form and is moistened with
an inert liquid diluent, in a suitable machine.
[0072] Pharmaceutical compositions which are suitable for peroral
(sublingual) administration comprise suckable tablets which contain
a compound of formula I with a flavoring, normally sucrose and gum
arabic or tragacanth, and pastilles which comprise the compound in
an inert base such as gelatin and glycerol or sucrose and gum
arabic.
[0073] Pharmaceutical compositions suitable for parenteral
administration comprise preferably sterile aqueous preparations of
a compound of formula I, which are preferably isotonic with the
blood of the intended recipient. These preparations are preferably
administered intravenously, although administration may also take
place by subcutaneous, intramuscular or intradermal injection.
These preparations can preferably be produced by mixing the
compound with water and making the resulting solution sterile and
isotonic with blood. Injectable compositions of the invention
generally contain from 0.1 to 5% by weight of the active
compound.
[0074] Pharmaceutical compositions suitable for rectal
administration are preferably in the form of single-dose
suppositories. These can be produced by mixing a compound of the
formula I with one or more conventional solid carriers, for example
cocoa butter, and shaping the resulting mixture.
[0075] Pharmaceutical compositions suitable for topical use on the
skin are preferably in the form of ointment, cream, lotion, paste,
spray, aerosol or oil. Carriers which can be used are petrolatum,
lanolin, polyethylene glycols, alcohols and combinations of two or
more of these substances. The active ingredient is generally
present in a concentration of from 0.1 to 15% by weight of the
composition, for example from 0.5 to 2%.
[0076] Transdermal administration is also possible. Pharmaceutical
compositions suitable for transdermal uses can be in the form of
single plasters which are suitable for long-term close contact with
the patient's epidermis. Such plasters suitably contain the active
ingredient in an aqueous solution which is buffered where
appropriate, dissolved and/or dispersed in an adhesive or dispersed
in a polymer. A suitable active ingredient concentration is about
1% to 35%, preferably about 3% to 15%. A particular possibility is
for the active ingredient to be released by electrotransport or
iontophoresis as described, for example, in Pharmaceutical
Research, 2(6): 318 (1986).
[0077] The compounds of the formula I are distinguished by
favorable effects on metabolic disorders. They beneficially
influence lipid and sugar metabolism, in particular they lower the
triglyceride level and are suitable for the prevention and
treatment of type II diabetes and arteriosclerosis and the diverse
sequalae thereof.
Methods for Treating and/or Preventing Disease or Condition
[0078] This invention relates further to the use of compounds of
the formula I and their pharmaceutical compositions as PPAR
ligands. The PPAR ligands of the invention are suitable as
modulators of PPAR activity. As explained above, PPARs are
transcription factors which can be activated by ligands and belong
to the class of nuclear hormone receptors. There are three PPAR
isoforms, PPARalpha, PPARgamma and PPARdelta, which are encoded by
different genes (Peroxisome proliferator-activated receptor (PPAR):
structure, mechanisms of activation and diverse functions: Motojima
K, Cell Struct Funct. 1993 October; 18(5): 267-77).
[0079] Two variants of PPARgamma exist, PPARgamma.sub.1 and
gamma.sub.2, which are the result of alternative use of promoters
and differential mRNA splicing (Vidal-Puig et al. J. Clin. Invest.,
97:2553-2561, 1996). Different PPARs have different tissue
distribution and modulate different physiological functions. The
PPARs play a key role in various aspects of the regulation of a
large number of genes, the products of which genes are directly or
indirectly crucially involved in lipid and carbohydrate metabolism.
Thus, for example, PPARalpha receptors play an important part in
the regulation of fatty acid catabolism or lipoprotein metabolism
in the liver, while PPARgamma is crucially involved for example in
regulating adipose cell differentiation. In addition, however,
PPARs are also involved in the regulation of many other
physiological processes, including those which are not directly
connected with carbohydrate or lipid metabolism. The activity of
different PPARs can be modulated by various fatty acids, fatty acid
derivatives and synthetic compounds to varying extents. For
relevant reviews about functions, physiological effect and
pathophysiology, see: Joel Berger et al., Annu. Rev. Med. 2002, 53,
409-435; Timothy Wilson et al. J. Med. Chem., 2000, Vol. 43, No. 4,
527-550; Steven Kliewer et al., Recent Prog Horm Res. 2001; 56:
239-63.
[0080] The present invention relates to compounds of the formula I
suitable for modulating the activity of PPARs, especially the
activity of PPARalpha and PPARgamma. Depending on the modulation
profile, the compounds of the formula I are suitable for the
treatment, control and prophylaxis of the indications described
hereinafter, and for a number of other pharmaceutical applications
connected thereto (see, for example, Joel Berger et al., Annu. Rev.
Med. 2002, 53, 409-435; Timothy Wilson et al. J. Med. Chem., 2000,
Vol. 43, No. 4, 527-550; Steven Kliewer et al., Recent Prog Horm
Res. 2001; 56: 239-63; Jean-Charles Fruchart, Bart Staels and
Patrick Duriez: PPARS, Metabolic Disease and Arteriosclerosis,
Pharmacological Research, Vol. 44, No. 5, 345-52; 2001; Sander
Kersten, Beatrice Desvergne & Walter Wahli: Roles of PPARs in
health and disease, NATURE, VOL 405, 25 MAY 2000; 421-4; Ines
Pineda Torra, Giulia Chinetti, Caroline Duval, Jean-Charles
Fruchart and Bart Staels: Peroxisome proliferator-activated
receptors: from transcriptional control to clinical practice, Curr
Opin Lipidol 12: 2001, 245-254).
[0081] Thus, the present invention extends to a method of treating
and/or preventing a disease or condition in a patient, comprising
administering a therapeutically effective amount of a compound of
formula I to the patient. As used herein, the phrase
"therapeutically effective amount" is used herein to mean an amount
sufficient to cause an improvement in a clinically significant
condition in the patient or even prevent the a disease, disorder or
condition in a patient. The amount of a compound of formula I
necessary to achieve the desired biological effect depends on a
number of factors, for example the specific compound chosen, the
intended use, the mode of administration and the clinical condition
of the patient. The daily dose is generally in the range from 0.001
mg to 100 mg (typically from 0.01 mg to 50 mg) per day and per
kilogram of bodyweight, for example 0.1-10 mg/kg/day. An
intravenous dose may be, for example, in the range from 0.001 mg to
1.0 mg/kg, which can suitably be administered as infusion of 10 ng
to 100 ng per kilogram and per minute. Suitable infusion solutions
for these purposes may contain, for example, from 0.1 ng to 10 mg,
typically from 1 ng to 10 mg, per milliliter. Single doses may
contain, for example, from 1 mg to 10 g of the active ingredient.
Thus, ampules for injections may contain, for example, from 1 mg to
100 mg, and single-dose formulations which can be administered
orally, such as, for example, capsules or tablets, may contain, for
example, from 0.05 to 1000 mg, typically from 0.5 to 600 mg. For
the therapy of the above-mentioned conditions, a compound of
formula I may be used as the compound itself, but they are
preferably in the form of a pharmaceutical composition with a
pharmaceutically acceptable carrier.
[0082] Numerous diseases, disorders or conditions can be treated or
prevented with a method of the present invention. Particular
examples include, but certainly are not limited to: [0083]
1.--disorders of fatty acid metabolism and glucose utilization
disorders [0084] disorders in which insulin resistance is involved
[0085] 2. Diabetes mellitus, especially type 2 diabetes, including
the prevention of the sequelae associated therewith.
[0086] Particular aspects in this connection are [0087]
hyperglycemia, [0088] improvement in insulin resistance, [0089]
improvement in glucose tolerance, [0090] protection of the
pancreatic .beta. cells [0091] prevention of macro- and
microvascular disorders [0092] 3. Dyslipidemias and their sequelae
such as, for example, atherosclerosis, coronary heart disease,
cerebrovascular disorders etc, especially those (but not restricted
thereto) which are characterized by one or more of the following
factors: [0093] high plasma triglyceride concentrations, high
postprandial plasma triglyceride concentrations, [0094] low HDL
cholesterol concentrations [0095] low ApoA lipoprotein
concentrations [0096] high LDL cholesterol concentrations [0097]
small dense LDL cholesterol particles [0098] high ApoB lipoprotein
concentrations [0099] 4. Various other conditions which may be
associated with the metabolic syndrome, such as: [0100] obesity
(excess weight), including central obesity [0101] thromboses,
hypercoagulable and prothrombotic states (arterial and venous)
[0102] high blood pressure [0103] heart failure such as, for
example (but not restricted thereto), following myocardial
infarction, hypertensive heart disease or cardiomyopathy [0104] 5.
Other disorders or conditions in which inflammatory reactions or
cell differentiation may for example be involved are: [0105]
atherosclerosis such as, for example (but not restricted thereto),
coronary sclerosis including angina pectoris or myocardial
infarction, stroke [0106] vascular restenosis or reocclusion [0107]
chronic inflammatory bowel diseases such as, for example, Crohn's
disease and ulcerative colitis [0108] pancreatitis [0109] other
inflammatory states [0110] retinopathy [0111] adipose cell tumors
[0112] lipomatous carcinomas such as, for example, liposarcomas
[0113] solid tumors and neoplasms such as, for example (but not
restricted thereto), carcinomas of the gastrointestinal tract, of
the liver, of the biliary tract and of the pancreas, endocrine
tumors, carcinomas of the lungs, of the kidneys and the urinary
tract, of the genital tract, prostate carcinomas etc [0114] acute
and chronic myeloproliferative disorders and lymphomas [0115]
angiogenesis [0116] neurodegenerative disorders [0117] Alzheimer's
disease [0118] multiple sclerosis [0119] Parkinson's disease [0120]
erythemato-squamous dermatoses such as, for example, psoriasis
[0121] acne vulgaris [0122] other skin disorders and dermatological
conditions which are modulated by PPAR [0123] eczemas and
neurodermitis [0124] dermatitis such as, for example, seborrheic
dermatitis or photodermatitis [0125] keratitis and keratoses such
as, for example, seborrheic keratoses, senile keratoses, actinic
keratosis, photo-induced keratoses or keratosis follicularis [0126]
keloids and keloid prophylaxis [0127] warts, including condylomata
or condylomata acuminata [0128] human papilloma viral (HPV)
infections such as, for example, venereal papillomata, viral warts
such as, for example, molluscum contagiosum, leukoplakia [0129]
papular dermatoses such as, for example, Lichen planus [0130] skin
cancer such as, for example, basal-cell carcinomas, melanomas or
cutaneous T-cell lymphomas [0131] localized benign epidermal tumors
such as, for example, keratoderma, epidermal naevi [0132]
chilblains [0133] high blood pressure [0134] syndrome X [0135]
polycystic ovary syndrome (PCOS) [0136] asthma [0137]
osteoarthritis [0138] lupus erythematosus (LE) or inflammatory
rheumatic disorders such as, for example, rheumatoid arthritis
[0139] vasculitis [0140] wasting (cachexia) [0141] gout [0142]
ischemia/reperfusion syndrome [0143] acute respiratory distress
syndrome (ARDS) Combinations with Other Medicaments
[0144] In a method of the present invention for treating and/or
preventing a disease, disorder, or condition in a patient, a
compound of the formula I can be administered alone or in
combination with one or more further pharmacologically active
substances which have, for example, favorable effects on metabolic
disturbances or disorders frequently associated therewith. Examples
of such medicaments are [0145] 1. medicaments which lower blood
glucose, antidiabetics, [0146] 2. active ingredients for the
treatment of dyslipidemias, [0147] 3. antiatherosclerotic
medicaments, [0148] 4. antiobesity agents, [0149] 5.
antiinflammatory active ingredients [0150] 6. active ingredients
for the treatment of malignant tumors [0151] 7. antithrombotic
active ingredients [0152] 8. active ingredients for the treatment
of high blood pressure [0153] 9. active ingredients for the
treatment of heart failure and [0154] 10. active ingredients for
the treatment and/or prevention of complications caused by diabetes
or associated with diabetes.
[0155] They can be combined with a compound of the formula I in
particular for a synergistic improvement in the effect.
Administration of the active ingredient combination can take place
either by separate administration of the active ingredients to the
patient or in the form of combination products in which a plurality
of active ingredients are present in one pharmaceutical
preparation.
[0156] Examples which may be mentioned are:
Antidiabetics
[0157] Suitable antidiabetics are disclosed for example in the Rote
Liste 2001, chapter 12 or in the USP Dictionary of USAN and
International Drug Names, US Pharmacopeia, Rockville 2001.
Antidiabetics include all insulins and insulin derivatives such as,
for example, Lantus.RTM. (see www.lantus.com) or Apidra.RTM., and
other fast-acting insulins (see U.S. Pat. No. 6,221,633), GLP-1
receptor modulators as described in WO 01/04146 or else, for
example, those disclosed in WO 98/08871 of Novo Nordisk A/S.
[0158] The orally effective hypoglycemic active ingredients
include, preferably, sulfonylureas, biguanides, meglitinides,
oxadiazolidinediones, thiazolidinediones, glucosidase inhibitors,
glucagon antagonists, GLP-1 agonists, DPP-IV inhibitors, potassium
channel openers such as, for example, those disclosed in WO
97/26265 and WO 99/03861, insulin sensitizers, inhibitors of liver
enzymes involved in the stimulation of gluconeogenesis and/or
glycogenolysis, modulators of glucose uptake, compounds which alter
lipid metabolism and lead to a change in the blood lipid
composition, compounds which reduce food intake, PPAR and PXR
modulators and active ingredients which act on the ATP-dependent
potassium channel of the beta cells.
[0159] In one embodiment of the present invention, a compound of
the formula I is administered in combination with insulin.
[0160] In one embodiment of the present invention, a compound of
the formula I is administered in combination with substances which
influence hepatic glucose production such as, for example, glycogen
phosphorylase inhibitors (see: WO 01/94300, WO 02/096864, WO
03/084923, WO 03/084922, WO 03/104188)
[0161] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a sulfonylurea
such as, for example, tolbutamide, glibenclamide, glipizide or
glimepiride.
[0162] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an active
ingredient which acts on the ATP-dependent potassium channel of the
beta cells, such as, for example, tolbutamide, glibenclamide,
glipizide, glimepiride or repaglinide.
[0163] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a biguanide such
as, for example, metformin.
[0164] In a further embodiment of the present invention, a compound
of the formula I is administered in combination with a meglitinide
such as, for example, repaglinide.
[0165] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a
thiazolidinedione such as, for example, ciglitazone, pioglitazone,
rosiglitazone or the compounds disclosed in WO 97/41097 of Dr.
Reddy's Research Foundation, in particular
5-[[4-[(3,4-dihydro-3-methyl-4-oxo-2-quinazolinylmethoxy]phenyl]methyl]-2-
,4-thiazolidinedione.
[0166] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a DPPIV inhibitor
as described, for example, in WO98/19998, WO99/61431, WO99/67278,
WO99/67279, WO01/72290, WO 02/38541, WO03/040174, in particular P
93/01 (1-cyclopentyl-3-methyl-1-oxo-2-pentanammonium chloride),
P-31/98, LAF237
(1-[2-[3-hydroxyadamant-1-ylamino)acetyl]pyrrolidine-2-(S)-carbonitrile),
TS021
((2S,4S)-4-fluoro-1-[[(2-hydroxy-1,1-dimethylethyl)amino]-acetyl]py-
rrolidine-2-carbonitrile monobenzenesulfonate).
[0167] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a PPARgamma
agonist such as, for example, rosiglitazone, pioglitazone.
[0168] In one embodiment of the present invention, a compound of
the formula I is administered in combination with compounds with an
inhibitory effect on SGLT-1 and/or 2, as disclosed directly or
indirectly for example in PCT/EP03/06841, PCT/EP03/13454 and
PCT/EP03/13455.
[0169] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an
.alpha.-glucosidase inhibitor such as, for example, miglitol or
acarbose.
[0170] In one embodiment of the present invention, a compound of
the formula I is administered in combination with more than one of
the aforementioned compounds, e.g. in combination with a
sulfonylurea and metformin, a sulfonylurea and acarbose,
repaglinide and metformin, insulin and a sulfonylurea, insulin and
metformin, insulin and troglitazone, insulin and lovastatin,
etc.
Lipid Modulators
[0171] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an HMGCoA
reductase inhibitor such as lovastatin, fluvastatin, pravastatin,
simvastatin, ivastatin, itavastatin, atorvastatin,
rosuvastatin.
[0172] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a bile acid
reabsorption inhibitor (see, for example, U.S. Pat. No. 6,245,744,
U.S. Pat. No. 6,221,897, U.S. Pat. No. 6,277,831, EP 0683 773, EP
0683 774).
[0173] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a polymeric bile
acid adsorbent such as, for example, cholestyramine,
colesevelam.
[0174] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a cholesterol
absorption inhibitor as described for example in WO 0250027, or
ezetimibe, tiqueside, pamaqueside.
[0175] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an LDL receptor
inducer (see, for example, U.S. Pat. No. 6,342,512).
[0176] In one embodiment of the present invention, a compound of
the formula I is administered in combination with bulking agents,
preferably insoluble bulking agents (see, for example,
carob/Caromax.RTM. (Zunft H J; et al., Carob pulp preparation for
treatment of hypercholesterolemia, ADVANCESIN THERAPY (2001
September-October), 18(5), 230-6.) Caromax is a carob-containing
product from Nutrinova, Nutrition Specialties & Food
Ingredients GmbH, Industriepark Hoechst, 65926 Frankfurt/Main)).
Combination with Caromax.RTM. is possible in one preparation or by
separate administration of compounds of the formula I and
Caromax.RTM.. Caromax.RTM. can in this connection also be
administered in the form of food products such as, for example, in
bakery products or muesli bars.
[0177] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a PPARalpha
agonist.
[0178] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a mixed PPAR
alpha/gamma agonist such as, for example, AZ 242 (Tesaglitazar,
(S)-3-(4-[2-(4-methanesulfonyloxyphenyl)ethoxy]phenyl)-2-ethoxypropionic
acid), BMS 298585
(N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5-methyl-2-phenyl-4-oxazolyl)et-
hoxy]phenyl]methyl]glycine) or as described in WO 99/62872, WO
99/62871, WO 01/40171, WO 01/40169, WO96/38428, WO 01/81327, WO
01/21602, WO 03/020269, WO 00/64888 or WO 00/64876.
[0179] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a fibrate such
as, for example, fenofibrate, gemfibrozil, clofibrate,
bezafibrate.
[0180] In one embodiment of the present invention, a compound of
the formula I is administered in combination with nicotinic acid or
niacin.
[0181] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a CETP inhibitor,
e.g. CP-529, 414 (torcetrapib).
[0182] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an ACAT
inhibitor.
[0183] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an MTP inhibitor
such as, for example, implitapide.
[0184] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an
antioxidant.
[0185] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a lipoprotein
lipase inhibitor.
[0186] In one embodiment of the present invention, a compound of
the formula I is administered in combination with an ATP citrate
lyase inhibitor.
[0187] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a squalene
synthetase inhibitor.
[0188] In one embodiment of the present invention, a compound of
the formula I is administered in combination with a lipoprotein(a)
antagonist.
Antiobesity Agents
[0189] In another embodiment of the invention, a compound of the
formula I is administered in combination with a lipase inhibitor
such as, for example, orlistat.
[0190] In one embodiment of the present invention, the further
active ingredient is fenfluramine or dexfenfluramine.
[0191] In another embodiment of the present invention, the further
active ingredient is sibutramine.
[0192] In a further embodiment, a compound of the formula I is
administered in combination CART modulators (see
"Cocaine-amphetamine-regulated transcript influences energy
metabolism, anxiety and gastric emptying in mice" Asakawa, A, et
al., M.: Hormone and Metabolic Research (2001), 33(9), 554-558),
NPY antagonists, e.g. naphthalene-1-sulfonic acid
{4-[(4-aminoquinazolin-2-ylamino)methyl]-cyclohexylmethyl}amide
hydrochloride (CGP 71683A)), MC4 agonists (e.g.
1-amino-1,2,3,4-tetrahydronaphthalene-2-carboxylic acid
[2-(3a-benzyl-2-methyl-3-oxo-2,3,3a,4,6,7-hexahydropyrazolo[4,3-c]pyridin-
-5-yl)-1-(4-chlorophenyl)-2-oxoethyl]-amide; (WO 01/91752)), orexin
antagonists (e.g.
1-(2-methylbenzoxazol-6-yl)-3-[1,5]naphthyridin-4-ylurea
hydrochloride (SB-334867-A)), H3 agonists
(3-cyclohexyl-1-(4,4-dimethyl-1,4,6,7-tetrahydroimidazo[4,5-c]pyridin-5-y-
l)propan-1-one oxalic acid salt (WO 00/63208)); TNF agonists, CRF
antagonists (e.g.
[2-methyl-9-(2,4,6-trimethylphenyl)-9H-1,3,9-triazafluoren-4-yl]dipropyla-
mine (WO 00/66585)), CRF BP antagonists (e.g. urocortin), urocortin
agonists, P3 agonists (e.g.
1-(4-chloro-3-methanesulfonylmethylphenyl)-2-[2-(2,3-dimethyl-1H-indol-6--
yloxy)ethylamino]-ethanol hydrochloride (WO 01/83451)), MSH
(melanocyte-stimulating hormone) agonists, CCK-A agonists (e.g.
{2-[4-(4-chloro-2,5-dimethoxyphenyl)-5-(2-cyclohexylethyl)thiazol-2-ylcar-
bamoyl]-5,7-dimethylindol-1-yl}acetic acid trifluoroacetic acid
salt (WO 99/15525)), serotonin reuptake inhibitors (e.g.
dexfenfluramine), mixed serotoninergic and noradrenergic compounds
(e.g. WO 00/71549), 5HT agonists e.g.
1-(3-ethylbenzofuran-7-yl)piperazine oxalic acid salt (WO
01/09111), bombesin agonists, galanin antagonists, growth hormone
(e.g. human growth hormone), growth hormone-releasing compounds
(6-benzyloxy-1-(2-diisopropylaminoethylcarbamoyl)-3,4-dihydro-1H-isoquino-
line-2-carboxylic acid tertiary butyl ester (WO 01/85695)), TRH
agonists (see, for example, EP 0 462 884), uncoupling protein 2 or
3 modulators, leptin agonists (see, for example, Lee, Daniel W.;
Leinung, Matthew C.; Rozhavskaya-Arena, Marina; Grasso, Patricia.
Leptin agonists as a potential approach to the treatment of
obesity. Drugs of the Future (2001), 26(9), 873-881), DA agonists
(bromocriptine, Doprexin), lipase/amylase inhibitors (e.g. WO
00/40569), PPAR modulators (e.g. WO 00/78312), RXR modulators or
TR-.beta. agonists.
[0193] In one embodiment of the present invention, the further
active ingredient is leptin.
[0194] In one embodiment of the present invention, the further
active ingredient is dexamphetamine, amphetamine, mazindole or
phentermine.
[0195] In one embodiment of the present invention, a compound of
the formula I is administered in combination with medicaments
having effects on the coronary circulation and the vascular system,
such as, for example, ACE inhibitors (e.g. ramipril), medicaments
which act on the angiotensin-renine system, calcium antagonists,
beta blockers etc.
[0196] In one embodiment of the present invention, a compound of
the formula I is administered in combination with medicaments
having an antiinflammatory effect.
[0197] In one embodiment of the present invention, a compound of
the formula I is administered in combination with medicaments which
are employed for cancer therapy and cancer prevention.
[0198] It will be appreciated that every suitable combination of a
compound of the present invention with one or more of the
aforementioned compounds and optionally one or more other
pharmacologically active substances is regarded as falling within
the protection conferred by the present invention.
[0199] The activity of the compounds was tested as follows:
Determination of EC50 Values of PPAR Agonists in the Cellular
PPARalpha Assay
Principle
[0200] The potency of substances that bind to human PPAR.alpha. and
activate in an agonistic manner is analyzed using a stably
transfected HEK cell line (HEK=human embryo kidney) which is
referred to here as PPARalpha reporter cell line. It contains two
genetic elements, a luciferase reporter element
(p.DELTA.M-GAL4-Luc-Zeo) and a PPARalpha fusion protein
(GR-GAL4-humanPPAR.alpha.-LBD) that mediates expression of the
luciferase reporter element depending on a PPARalpha ligand. The
stably and constitutively expressed fusion protein
GR-GAL4-humanPPARalpha-LBD binds in the cell nucleus of the
PPARalpha reporter cell line via the GAL4 protein portion to the
GAL4 DNA binding motifs 5'-upstream of the luciferase reporter
element which is integrated in the genome of the cell line. There
is only little expression of the luciferase reporter gene without
addition of a PPARalpha ligand if fafty acid-depleted fetal calf
serum (cs-FCS) is used in the assay. PPAR.alpha. ligands bind and
activate the PPAR.alpha. fusion protein and thereby bring about
expression of the luciferase reporter gene. The luciferase which is
formed can be detected by means of chemiluminescence via an
appropriate substrate.
Construction of the Cell Line
[0201] The PPARalpha reporter cell line was prepared in 2 stages.
Firstly, the luciferase reporter element was constructed and stably
transfected into HEK cells. For this purpose, five binding sites of
the yeast transcription factor GAL4 (each 5'-CGGAGTACTGTCCTCCGAG-3'
(SEQ ID NO:1)) were cloned in 5'-upstream of a 68 bp-long minimal
MMTV promoter (Genbank Accession # V01175). The minimal MMTV
promoter section contains a CCAAT box and a TATA element in order
to enable efficient transcription by RNA polymerase II. The cloning
and sequencing of the GAL4-MMTV construct took place in analogy to
the description of Sambrook J. et. al. (Molecular cloning, Cold
Spring Harbor Laboratory Press, 1989). Then the complete Photinus
pyralis gene (Genbank Accession # M15077) was cloned in
3'-downstream of the GAL4-MMTV element. After sequencing, the
luceriferase reporter element consisting of five GAL4 binding
sites, MMTV promoter and luciferase gene was recloned into a
plasmid which confers zeocin resistance in order to obtain the
plasmid p.DELTA.M-GAL4-Luc-Zeo. This vector was transfected into
HEK cells in accordance with the statements in Ausubel, F. M. et
al. (Current protocols in molecular biology, Vol. 1-3, John Wiley
& Sons, Inc., 1995). Then zeocin-containing medium (0.5 mg/ml)
was used to select a suitable stable cell clone that showed very
low basal expression of the luceriferase gene. In a second step,
the PPARalpha fusion protein (GR-GAL4-humanPPARalpha-LBD) was
introduced into the stable cell clone described. For this purpose,
initially the cDNA coding for the N-terminal 76 amino acids of the
glucocorticoid receptor (Genbank Accession # P04150) was linked to
the cDNA section coding for amino acids 1-147 of the yeast
transcription factor GAL4 (Genbank Accession # P04386). The cDNA of
the ligand-binding domain of the human PPARalpha receptor (amino
acids S167-Y468; Genbank Accession # S74349) was cloned in at the
3'-end of this GR-GAL4 construct. The fusion construct prepared in
this way (GR-GAL4-humanPPARalpha-LBD) was recloned into the plasmid
pcDNA3 (from Invitrogen) in order to enable constitutive expression
therein by the cytomegalovirus promoter. This plasmid was
linearized with a restriction endonuclease and stably transfected
into the previously described cell clone containing the luciferase
reporter element. The finished PPARalpha reporter cell line that
contains a luciferase reporter element and constitutively expresses
the PPARalpha fusion protein (GR-GAL4-human PPARalpha-LBD) was
isolated by selection with zeocin (0.5 mg/ml) and G418 (0.5
mg/ml).
Assay Procedure
[0202] The activity of PPARalpha agonists is determined in a 3-day
assay described below:
Day 1
[0203] The PPAR.alpha. reporter cell line is cultivated to 80%
confluence in DMEM (# 41965-039, Invitrogen) which is mixed with
the following additions: 10% cs-FCS (fetal calf serum;
#SH-30068.03, Hyclone), 0.5 mg/ml zeocin (#R250-01, Invitrogen),
0.5 mg/ml G418 (#10131-027, Invitrogen), 1% penicillin-streptomycin
solution (#15140-122, Invitrogen) and 2 mM L-glutamine (#25030-024,
Invitrogen). The cultivation takes place in standard cell culture
boftles (# 353112, Becton Dickinson) in a cell culture incubator at
37.degree. C. in the presence of 5% CO.sub.2. The 80%-confluent
cells are washed once with 15 ml of PBS (#14190-094, Invitrogen),
treated with 3 ml of trypsin solution (#25300-054, Invitrogen) at
37.degree. C. for 2 min, taken up in 5 ml of the DMEM described and
counted in a cell counter. After dilution to 500.000 cells/ml,
35,000 cells are seeded in each well of a 96 well microtiter plate
with a clear plastic base (#3610, Corning Costar). The plates are
incubated in the cell culture incubator at 37.degree. C. and 5%
CO.sub.2 for 24 h.
Day 2
[0204] PPARalpha agonists to be tested are dissolved in DMSO in a
concentration of 10 mM. This stock solution is diluted in DMEM
(#41965-039, Invitrogen) which is mixed with 5% cs-FCS
(#SH-30068.03, Hyclone), 2 mM L-glutamine (#25030-024, Invitrogen)
and the previously described antibiotics (zeocin, G418, penicillin
and streptomycin).
[0205] Test substances are tested in 11 different concentrations in
the range from 10 .mu.M to 100 .mu.M. More potent compounds are
tested in concentration ranges from 1 .mu.M to 10 pM or between 100
nM and 1 pM.
[0206] The medium of the PPARalpha reporter cell line seeded on day
1 is completely removed by aspiration, and the test substances
diluted in medium are immediately added to the cells. The dilution
and addition of the substances is carried out by a robot (Beckman
FX). The final volume of the test substances diluted in medium is
100 .mu.l per well of a 96 well microtiter plate. The DMSO
concentration in the assay is less than 0.1% v/v in order to avoid
cytotoxic effects of the solvent.
[0207] Each plate was charged with a standard PPARalpha agonist,
which was likewise diluted in 11 different concentrations, in order
to demonstrate the functioning of the assay in each individual
plate. The assay plates are incubated in an incubator at 37.degree.
C. and 5% CO2 for 24 h.
Day 3
[0208] The PPAR.alpha. reporter cells treated with the test
substances are removed from the incubator, and the medium is
aspirated off. The cells are lyzed by pipetting 50 .mu.l of Bright
Glo reagent (from Promega) into each well of a 96 well microtiter
plate. After incubation at room temperature in the dark for 10
minutes, the microtiter plates are measured in the luminometer
(Trilux from Wallac). The measuring time for each well of a
microtiter plate is 1 sec.
Evaluation
[0209] The raw data from the luminometer are transferred into a
Microsoft Excel file. Dose-effect plots and EC50 values of PPAR
agonists are calculated using the XL.Fit program as specified by
the manufacturer (IDBS).
[0210] The PPARalpha EC50 values for the compounds of Examples 1 to
85 in this assay are in the range from 0.07 nm to >10 .mu.M.
[0211] The results for the activity of some compounds of the
invention of the formula I are indicated in Table I below:
TABLE-US-00001 TABLE 1 Example No. EC50 PPARalpha [nM] 4 25 8a 1.8
9 4.3 16 4.0 22 0.07 24 0.3 33 17 38 8.5 42 79 51 12 64 0.4 74
0.4
[0212] It is evident from Table I that the compounds of the
invention of the formula I activates the PPARalpha receptor and
thus bring about for example in analogy to fibrates in clinical use
a lowering of triglycerides in the body (see, for example, J. -Ch.
Fruchard et al.: PPARS, Metabolic Disease and Atherosclerosis,
Pharmacological Research, Vol. 44, No. 5, 345-52, 2001; S. Kersten
et al.: Roles of PPARs in health and disease, NATURE, VOL 405, 25
MAY 2000, 421-4; I. Pineda et al.: Peroxisome
proliferator-activated receptors: from transcriptional control to
clinical practice, Curr Opin Lipidol 12: 2001, 245-254).
Determination of EC50 Values of PPAR Agonists in the Cellular
PPARgamma Assay
Principle
[0213] A transient transfection system is employed to determine the
cellular PPARgamma activity of PPAR agonists. It is based on the
use of a luciferase reporter plasmid (pGL3basic-5xGAL4-TK) and of a
PPARgamma expression plasmid (pcDNA3-GAL4-humanPPARgammaLBD). Both
plasmids are transiently transfected into human embryonic kidney
cells (HEK cells). There is then expression in these cells of the
fusion protein GAL4-humanPPARgammaLBD which binds to the GAL4
binding sites of the reporter plasmid. In the presence of a
PPARgamma-active ligand, the activated fusion protein
GAL4-humanPPARgammaLBD induces expression of the luciferase
reporter gene, which can be detected in the form of a
chemiluminescence signal after addition of a luciferase substrate.
As a difference from the stably transfected PPARalpha reporter cell
line, in the cellular PPAR.gamma. assay the two components
(luciferase reporter plasmid and PPARgamma expression plasmid) are
transiently transfected into HEK cells because stable and permanent
expression of the PPARgamma fusion protein is cytotoxic.
Construction of the Plasmids
[0214] The luciferase reporter plasmid pGL3basic-5xGAL4-TK is based
on the vector pGL3basic from Promega. The reporter plasmid is
prepared by cloning five binding sites of the yeast transcription
factor GAL4 (each binding site with the sequence
5'-CTCGGAGGACAGTACTCCG-3' (SEQ ID NO:1)), together with a 160
bp-long thymidine kinase promoter section (Genbank Accession #
AF027128) 5'-upstream into pGL3basic. 3'-downstream of the
thymidine kinase promoter is the complete luciferase gene from
Photinus pyralis (Genbank Accession # M15077), which is already a
constituent of the plasmid pGL3basic used. The cloning and
sequencing of the reporter plasmid pGL3basic-5xGAL4-TK took place
in analogy to the description in Sambrook J. et al. (Molecular
cloning, Cold Spring Harbor Laboratory Press, 1989).
[0215] The PPARgamma expression plasmid
pcDNA3-GAL4-humanPPAR.gamma.LBD was prepared by first cloning the
cDNA coding for amino acids 1-147 of the yeast transcription factor
GAL4 (Genbank Accession # P04386) into the plasmid pcDNA3 (from
Invitrogen) 3'-downstream of the cytomegalovirus promoter.
Subsequently, the cDNA of the ligand-binding domain (LBD) of the
human PPAR.gamma. receptor (amino acids 1152-Y475; Accession #
g1480099) 3'-downstream of the GAL4 DNA binding domain. Cloning and
sequencing of the PPARgamma expression plasmid
pcDNA3-GAL4-humanPPARgammaLBD again took place in analogy to the
description in Sambrook J. et. al. (Molecular cloning, Cold Spring
Harbor Laboratory Press, 1989). Besides the luciferase reporter
plasmid pGL3basic-5.times.GAL4-TK and the PPAR.gamma. expression
plasmid pcDNA3-GAL4-humanPPARgammaLBD, also used for the cellular
PPARgamma assay are the reference plasmid pRL-CMV (from Promega)
and the plasmid pBluescript SK(+) from Stratagene. All four
plasmids were prepared using a plasmid preparation kit from Qiagen,
which ensured a plasmid quality with a minimal endotoxin content,
before transfection into HEK cells.
Assay Procedure
[0216] The activity of PPARgamma agonists is determined in a 4-day
assay which is described below. Before the transfection, HEK cells
are cultivated in DMEM (# 41965-039, Invitrogen) which is mixed
with the following additions: 10% FCS (#16000-044, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM
L-glutamine (#25030-024, Invitrogen).
Day 1
[0217] Firstly, solution A, a transfection mixture which contains
all four plasmids previously described in addition to DMEM, is
prepared. The following amounts are used to make up 3 ml of
solution A for each 96 well microtiter plate for an assay: 2622
.mu.l of antibiotic- and serum-free DMEM (# 41965-039, Invitrogen),
100 .mu.l of reference plasmid pRL-CMV (1 ng/.mu.l), 100 .mu.l of
luciferase reporter plasmid pGL3basic-5.times.GAL4-TK (10
ng/.mu.l), 100 .mu.l of PPAR.gamma. expression plasmid
pcDNA3-GAL4-humanPPAR.gamma.LBD (100 ng/.mu.l) and 78 .mu.l of
plasmid pBluescript SK(+) (500 ng/.mu.l). Then 2 ml of solution B
are prepared by mixing 1.9 ml of DMEM (# 41965-039, Invitrogen)
with 100 .mu.l of PolyFect transfection reagent (from Qiagen) for
each 96 well microtiter plate. Subsequently, 3 ml of solution A are
mixed with 2 ml of solution B to give 5 ml of solution C, which is
thoroughly mixed by multiple pipetting and incubated at room
temperature for 10 min.
[0218] 80%-confluent HEK cells from a cell culture bottle with a
capacity of 175 cm.sup.2 are washed once with 15 ml of PBS
(#14190-094, Invitrogen) and treated with 3 ml of trypsin solution
(#25300-054, Invitrogen) at 37.degree. C. for 2 min. The cells are
then taken up in 15 ml of DMEM (# 41965-039, Invitrogen), which is
mixed with 10% FCS (# 16000-044, Invitrogen), 1%
penicillin-streptomycin solution (#15140-122, Invitrogen) and 2 mM
L-glutamine (#25030-024, Invitrogen). After the cell suspension has
been counted in a cell counter, the suspension is diluted to
250,000 cells/ml. 15 ml of this cell suspension are mixed with 5 ml
of solution C for one microtiter plate. 200 .mu.l of the suspension
are seeded in each well of a 96 well microtiter plate with a clear
plastic base (#3610, Corning Costar). The plates are incubated in a
cell culture incubator at 37.degree. C. and 5% CO.sub.2 for 24
h.
Day 2
[0219] PPAR agonists to be tested are dissolved in DMSO in a
concentration of 10 mM. This stock solution is diluted in DMEM (#
41965-039, Invitrogen) which is mixed with 2% Ultroser (#12039-012,
Biosepra), 1% penicillin-streptomycin solution (#15140-122,
Invitrogen) and 2 mM L-glutamine (#25030-024, Invitrogen). Test
substances are tested in a total of 11 different concentrations in
the range from 10 .mu.M to 100 pM. More potent compounds are tested
in concentration ranges from 1 .mu.M to 10 pM.
[0220] The medium of the HEK cells transfected and seeded on day 1
is completely removed by aspiration, and the test substances
diluted in medium are immediately added to the cells. The dilution
and addition of the substances is carried out by a robot (Beckman
FX). The final volume of the test substances diluted in medium is
100 .mu.l per well of a 96 well microtiter plate. Each plate is
charged with a standard PPAR.gamma. agonist, which is likewise
diluted in 11 different concentrations, in order to demonstrate the
functioning of the assay in each individual plate. The assay plates
are incubated in an incubator at 37.degree. C. and 5% CO.sub.2.
Day 4
[0221] After removal of the medium by aspiration, 50 .mu.l of
Dual-Glo.TM. reagent (Dual-Glo.TM. Luciferase Assay System;
Promega) are added to each well in accordance with the
manufacturer's instructions in order to lyze the cells and provide
the substrate for the firefly luciferase (Photinus pyralis) formed
in the cells. After incubation at room temperature in the dark for
10 minutes, the firefly luciferase-mediated chemiluminescence is
measured in a measuring instrument (measuring time/well 1 sec;
Trilux from Wallac). Then 50 .mu.l of the Dual-Glo.TM. Stop &
Glo reagent (Dual-Glo.TM. Luciferase Assay System; Promega) is
added to each well in order to stop the activity of the firefly
luciferase and provide the substrate for the Renilla luciferase
expressed by the reference plasmid pRL-CMV. After incubation at
room temperature in the dark for a further 10 minutes, a
chemiluminescence mediated by the Renilla luciferase is again
measured for 1 sec/well in the measuring instrument.
Evaluation
[0222] The crude data from the luminometer are transferred into a
Microsoft Excel file. The firefly/Renilla luciferase activity ratio
is determined for each measurement derived from one well of the
microtiter plate. The dose-effect plots and EC50 values of PPAR
agonists are calculated from the ratios by the XL.Fit program as
specified by the manufacturer (IDBS).
[0223] PPARgamma EC50 values in the range from 0.08 nM to >10
.mu.M were measured for the PPAR agonists described in this
application.
[0224] The examples below serve to illustrate the invention, but
without limiting it. TABLE-US-00002 TABLE II ##STR4## Ex. R1 R2 R3
W X Y1 Y2 n R6 R7 R9 1 p-CH3 H CH3 CH CH2O CH2 O 0 H n-C3H7 -- 2
p-CH3 H CH3 CH CH2O CH2 O 0 H CH3 -- 3 p-CH3 H CH3 CH CH2O CH2 O 0
H C2H5 -- 4 p-CH3 H CH3 CH CH2O CH2 O 0 H PhCH2 -- 5 m-OCH3 H CH3
CH CH2O CH2 O 0 H CH3 -- 6 m-CH3 H CH3 CH CH2O CH2 O 0 H CH3 -- 7
m-CF3 H CH3 CH CH2O CH2 O 0 H CH3 -- 8 p-CH3 H CH3 CH CH2O CH2 O 0
CH3 CH3 -- 8a p-CH3 H CH3 CH CH2O CH2 O 0 CH3 CH3 -- 9 p-CH3 H CH3
CH CH2O CH2 O 0 cyclopentyl -- 10 p-F H CH3 CH CH2O CH2 O 0 CH3 CH3
-- 11 m-OCH3 H CH3 CH CH2O CH2 O 0 CH3 CH3 -- 12 m-CF3 H CH3 CH
CH2O CH2 O 0 CH3 CH3 -- 13 5-CH3 H CH3 O CH2O CH2 O 0 CH3 CH3 -- 14
p-OCH3 m- CH3 CH CH2O CH2 O 0 CH3 CH3 -- OCH3 15 p-CH3 H Ph CH CH2O
CH2 O 0 CH3 CH3 -- 16 p-CF3 H CH3 CH CH2O CH2 O 0 CH3 CH3 -- 17
p-OCH3 H CH3 CH CH2O CH2 O 0 CH3 CH3 -- 18 H H CH3 S CH2O CH2 O 0
CH3 CH3 -- 19 m-OCF3 H CH3 CH CH2O CH2 O 0 CH3 CH3 -- 20 p-i-C3H7 H
CH3 CH CH2O CH2 O 0 CH3 CH3 -- 21 m-CH3 H CH3 CH CH2O CH2 O 0 CH3
CH3 -- 22 p-CH3 H CH3 CH CH2O CH2 S 0 H H -- 23 p-CH3 H CH3 CH CH2O
CH2 S 0 H CH3 -- 24 p-CH3 H CH3 CH CH2O CH2 S 0 H C2H5 -- 25 p-CH3
H CH3 CH CH2O CH2 S 0 H n-C5H11 -- 26 p-CH3 H CH3 CH CH2O CH2 S 0 H
i-C3H7 -- 27 p-CH3 H CH3 CH CH2O CH2 S 0 CH3 CH3 -- 28 p-CH3 H CH3
CH CH2O CH2 S 0 H Ph -- 29 p-CH3 H CH3 CH CH2O CH2 S 0 H cycl-C6H11
-- 30 p-CH3 H CH3 CH CH2O CH2 S 0 H n-C3H7 -- 31 p-CH3 H CH3 CH
CH2O CH2 S 0 cyclobutyl -- 32 p-CH3 H CH3 CH CH2O CH2 SO 0 H H --
33 p-CH3 H CH3 CH CH2O CH2 SO 0 H n-C5H11 -- 34 p-CH3 H CH3 CH CH2O
CH2 SO 0 CH3 CH3 -- 35 p-CH3 H CH3 CH CH2O CH2 SO 0 H i-C3H7 -- 36
p-CH3 H CH3 CH CH2O CH2 SO 0 H n-C3H7 -- 37 p-CH3 H CH3 CH CH2O CH2
SO2 0 H H -- 38 p-CH3 H CH3 CH CH2O CH2 SO2 0 H n-C5H11 -- 39 p-CH3
H CH3 CH CH2O CH2 SO2 0 CH3 CH3 -- 40 p-CH3 H CH3 CH CH2O CH2 SO2 0
H i-C3H7 -- 41 p-CH3 H CH3 CH CH2O CH2 SO2 0 H n-C3H7 -- 42 p-CH3 H
CH3 CH CH2O CH2 NH 0 H (S)-i-C3H7 -- 43 p-CH3 H CH3 CH CH2O CH2 NR9
0 H (S)-i-C3H7 COCH3 44 p-CH3 H CH3 CH CH2O CH2 NR9 0 H (S)-i-C3H7
COPh 45 p-CH3 H CH3 CH CH2O CH2 NR9 0 H (S)-i-C3H7 SO2CH3 46 p-CH3
H CH3 CH CH2O CH2 NR9 0 H (S)-i-C3H7 SO2CH2- SO2CH3 47 p-CH3 H CH3
CH CH2O CH2 NR9 0 H (S)-i-C3H7 SO2(p-Tol) 48 p-CH3 H CH3 CH CH2O
CH2 NR9 0 H (S)-i-C3H7 COOMe 49 p-CH3 H CH3 CH CH2O CH2 NR9 0 H H H
50 p-CH3 H CH3 CH CH2O CH2 NR9 0 H (S)-i-C3H7 CH3 51 p-CH3 H CH3 CH
CH2O CH2 NR9 0 H (S)-i-C3H7 CH2Ph 52 p-CH3 H CH3 CH CH2O CH2 NR9 0
H H CH2Ph 53 p-CH3 H CH3 CH CH2O CH2 NR9 0 H H 2-thienylmethyl 54
p-CH3 H CH3 CH CH2O CH2 NR9 0 H H CH2(C6H11) 55 p-CH3 H CH3 CH
CH2OCH2 CH2 O 0 CH3 CH3 -- 56 p-CH3 H CH3 CH CH2OCH2 CH2 O 0 CH3
C2H5 -- 57 p-Ph H CH3 CH CH2OCH2 CH2 O 0 CH3 CH3 -- 58 H H CH3 CH
CH2OCH2 CH2 O 0 CH3 CH3 -- 59 2-naphthyl CH3 CH CH2OCH2 CH2OCH2 O 0
CH3 CH3 -- 60 m-OMe H C2H5 CH CH2OCH2 CH2 O 0 CH3 CH3 -- 61
p-i-C3H7 H CH3 CH CH2OCH2 CH2 O 0 CH3 CH3 -- 62 p-CH3 H Cy CH
CH2OCH2 CH2 O 0 CH3 CH3 -- 63 p-i-C3H7 H C2H5 CH CH2OCH2 CH2 O 0
CH3 CH3 -- 64 2-naphthyl C2H5 CH CH2OCH2 CH2OCH2 O 0 CH3 CH3 -- 65
p-CH3 H C2H5 CH CH2OCH2 CH2 O 0 CH3 CH3 -- 66 m-CF3 H i- CH CH2OCH2
CH2 O 0 CH3 CH3 -- C3H7 67 m-OCH3 H CH3 CH CH2O CH2 CH2 0 H H -- 68
m-OCH3 H CH3 CH CH2O CH2 CH2 0 H CH3 -- 69 m-OCH3 H CH3 CH CH2O CH2
CH2 0 H C2H5 -- 70 m-OCH3 H CH3 CH CH2O CH2 CH2 0 H n-C3H7 -- 71
p-CH3 H CH3 CH CH2O CH2 CH2 0 CH3 CH3 -- 72 m-CF3 H CH3 CH CH2O CH2
CH2 0 CH3 CH3 -- 73 p-CH3 H CH3 CH CH2O CH2 CH2 0 H i-C3H7 -- 74
m-OCH3 H CH3 CH CH2O CH2 CH2 0 H i-C3H7 -- 75 p-CH3 H CH3 CH CH2O
CH2 CH2 0 H PhCH2 -- 76 p-CH3 H CH3 CH CH2O CH2 CH2 0 H i-C4H9 --
77 m-CF3 H CH3 CH CH2O CH2 CH2 0 n- n-C3H7 -- C3H7 78 p-CH3 H CH3
CH CH2O CH2 CH2 0 cyclopentyl -- 79 m-CH3 H CH3 CH CH2O C2H4 NR9 0
H (S)-i-C3H7 ##STR5## 80 m-CH3 H CH3 CH CH2O C2H4 NR9 0 cyclopentyl
##STR6## 81 m-CH3 H CH3 CH CH2O C2H4 NR9 0 cyclopentyl ##STR7## 82
m-CH3 H CH3 CH CH2O C2H4 NR9 0 (R)- Me ##STR8## PhCH2 83 m-CH3 H
CH3 CH CH2O C2H4 NR9 0 H H ##STR9## 84 m-CH3 H CH3 CH CH2O C2H4 NR9
0 H H ##STR10## 85 m-CH3 H CH3 CH CH2O C2H4 NR9 0 H H ##STR11## The
broken line indicates the point of attachment.
Processes
[0225] The compounds of the formula I according to the invention
can be obtained according to the reaction schemes below:
[0226] Process A: ##STR12##
[0227] The compound A-1 is reacted in an alcohol R-8OH. The
resulting product is protected on the secondary hydroxyl group (for
example by stirring with TBDPSCl and imidazole in DMF at room
temperature), giving the compound A-2, where R8 has the meaning
described above. A-2 is, in an ethereal solvent and using lithium
aluminum hydride, reduced to give compound A-3. Compound A-3 is
reacted in a two-phase system of toluene and 50% strength sodium
hydroxide solution at 10.degree. C. with tert-butyl bromoacetate
and tetrabutylammonium hydrogensulfate to give compound A-4.
[0228] Compound A-4 is, in tetrahydrofuran, reacted with lithium
diisopropylamide and an alkyl iodide of the formula R6-I, where R6
has the meaning described above. In some examples, the compound
obtained in this manner is, in tetrahydrofuran, reacted with
lithium diisopropylamide and a further alkyl iodide of the formula
R7-I, where R7 has the meaning described above. The protective
group is removed, giving the compound of the formula A-5.
[0229] Compound A-5 is, in methyl tert-butyl ether or
dimethylformamide, converted into compound A-7 using sodium hydride
and the compound A-6 (see process A) where R1, R2, R3 and W have
the meanings described above.
[0230] The product A-7 is stirred in trifluoroacetic acid or
HCl/dioxane for a number of hours. This yields the compound of the
formula A-8.
[0231] According to this process, it is possible to synthesize
examples 31 to 51. Process B: ##STR13##
[0232] Compound A-2 where SG=tert-butyldimethylsilyl is, in
acetonitrile and at room temperature, converted into compound B-2
using bismuth tribromide, triethylsilane and a compound of the
formula B-1 in which R1, R2, W and R3 have the meanings described
above.
[0233] Using lithium aluminum hydride in diethyl ether or THF, the
compound B-2 is reduced to give compound B-3. Compound B-3 is
reacted at room temperature with triphenylphosphine and iodine in
toluene to give compound B-4.
[0234] Using the compound of the formula B-5 where R6 and R7 have
the meanings described above, the compound B-4 is converted into
compound B-6. The ester is hydrolyzed by stirring compound B-6 in a
mixture of methanol and concentrated aqueous potassium hydroxide
solution or lithium hydroxide in THF/methanol/water for a number of
hours. This gives the compound B-7.
[0235] In some examples, the compound B-7 is oxidized at room
temperature using one equivalent of hydrogen peroxide in
trifluoroacetic acid to give the compound of the formula B-8 in
which R1, R2, R3, R6, W and R7 have the meanings described
above.
[0236] In some examples, the compound B-7 is oxidized at room
temperature with three equivalents of hydrogen peroxide in
trifluoroacetic acid to give the compound of the formula B-9 in
which R1, R2, R3, R6, W and R7 have the meanings described
above.
[0237] According to this process, it is possible to synthesize
examples 52 to 71. Process C: ##STR14##
[0238] The compound B-3 (see process B) is oxidized at -78.degree.
C. with oxalyl chloride, triethylamine and dimethyl sulfoxide in
dichloromethane to give aldehyde C-1. This compound is, using
sodium triacetoxyborohydride and the compound of the formula C-2
where R6 and R7 have the meanings described above, converted into
compound C-3.
[0239] Compound C-3 is converted into compound C-4 by stirring in
trifluoroacetic acid for a number of hours.
[0240] In some examples, the compound C-3 is reacted with acyl
chlorides, sulfonyl chlorides or chloroformic esters of the formula
R9-Cl where R9 has the meaning described above in dichloromethane
in the presence of pyridine to give the compound C-5.
[0241] By stirring in trifluoroacetic acid for a number of hours,
the compound C-5 is converted into compound C-6.
[0242] According to this process, it is possible to synthesize
examples 72 to 78. Process D: ##STR15## ##STR16##
[0243] The compound D-1 is protected on the hydroxyl group with a
suitable protective group, for example with the methoxymethyl
protective group. The carboxyl group is then converted with lithium
aluminum hydride in diethyl ether into compound D-2. This compound
is reacted with tert-butyl bromoacetate and tetrabutylammonium
hydrogensulfate in a two-phase system of toluene/50% strength
aqueous sodium hydroxide solution to give compound D-3.
[0244] Compound D-3 is deprotected (using, for example,
concentrated hydrochloric acid in tetrahydrofuran in the case of
the methoxymethyl protective group) and then converted with
tert-butyldimethylsilyl chloride and imidazole in dimethylformamide
into compound D-4.
[0245] Compound D-4 is deprotonated at 0.degree. C. using lithium
diisopropylamide in tetrahydrofuran and reacted with an alkyl
iodide of the formula R6-I, where R6 has the meaning described
above. The resulting compound is then deprotonated at 0.degree. C.
using lithium diisopropylamide in tetrahydrofuran and reacted with
an alkyl iodide of the formula R7-I, where R7 has the meaning
described above, to give the compound D-5.
[0246] Compound D-5 is reacted with bismuth tribromide,
triethylsilane and the compound B-1 (see process B) in acetonitrile
at room temperature or--after removal of the silyl protective group
using TBAF in THF--with potassium tert-butoxide and the compound
A-6 (see process A) to give the compound D-6.
[0247] By stirring in trifluoroacetic acid, the compound D-6 is
converted into compound D-7.
[0248] Using this process, it is possible to synthesize examples 79
and 80. Process E: ##STR17## ##STR18##
[0249] Using diisobutylaluminum hydride and isopropanol in diethyl
ether, the compound E-1 is reduced to give compound E-2. This is
reacted with the compound of the formula A-6 and sodium hydride in
dimethylformamide to give compound E-3.
[0250] Using osmium tetroxide and sodium periodate in diethyl
ether, compound E-3 is converted into aldehyde E-4. In a
Horner-Emmons-Wadsworth reaction, using a triethyl phosphonoacetate
of the formula E-5 in which R6 is as defined above, this compound
is converted into compound E-6.
[0251] Using hydrogen, the compound E-6 is hydrogenated over
palladium/carbon to give compound E-7, and the ester is then
hydrolyzed using lithium hydroxide to give the acid E-8.
[0252] According to this process, it is possible to synthesize
examples 81 to 84. Process F: ##STR19##
[0253] Using tert-butyldiphenylsilyl chloride and imidazole as base
in dimethylformamide, the compound E-2 is reacted, worked up and
then reacted with osmium tetroxide and sodium periodate in diethyl
ether. The resulting compound is reacted with tert-butyl
triphenylphosphoranylidene-acetate and n-butyllithium in a Wittig
reaction and then hydrogenated with hydrogen over palladium/carbon
to give compound F-1.
[0254] At 0.degree. C., the compound F-1 is deprotonated using
lithium diisopropylamide in tetrahydrofuran and reacted with an
alkyl iodide of the formula R6-I, where R6 is as defined above. The
resulting compound is then deprotonated using lithium
diisopropylamide in tetrahydrofuran at 0.degree. C. and reacted
with an alkyl iodide of the formula R7-I where R7 is as defined
above to give the compound F-2.
[0255] For deprotection, the compound F-2 is reacted with
tetrabutylammonium fluoride in tetrahydrofuran. The resulting
alcohol is then reacted with sodium hydride and the compound A-6 in
dimethylformamide to give compound F-3.
[0256] The tert-butyl ester is cleaved by stirring compound F-3 for
a number of hours in trifluoroacetic acid, giving the compound
F-4.
[0257] Examples 85 to 92 were synthesized according to this
process. Process G: ##STR20##
[0258] Using an amino acid ester of the formula G-1 in which R6, R7
and R8 are as defined above in the presence of a borohydride
reagent (for example sodium triacetoxyborohydride), the compound
E-4 is converted into compound G-2.
[0259] Using a chloride R12-Cl in which R12 is as defined above,
compound G-2 is converted into compound G-3 (R12 may also be
isocyanate or isothiocyanate). Compound G-3 is then hydrolyzed with
LiOH to give compound G-4.
Process H:
[0260] This process is used for the synthesis of building blocks
A-6 and B-2 in which R1, R2, W and R3 are as defined above.
##STR21##
[0261] Using sodium nitrite and hydrochloric acid, the ester H-1 in
which R3 is as defined above is converted into oxime H-2 which is
reduced by hydrogenation with hydrogen over palladium/carbon to
give amine H-3.
[0262] Using acid chlorides of the formula H-4 in which R1, W and
R2 are as defined above and base (for example triethylamine), the
compound H-3 is converted into compound H-5.
[0263] By heating in phosphoryl chloride, the compound H-5 is
converted into compound H-6.
[0264] The ester H-6 is reduced with lithium aluminum hydride in
diethyl ether to give alcohol H-7. This is converted into the
iodide A-6 using iodine, imidazole (ImH) and
triphenylphosphine.
[0265] Alternatively, the compound H-7 is oxidized using oxalyl
chloride, dimethyl sulfoxide and triethylamine in dichloromethane
at -78.degree. C. to give aldehyde B-1.
Process J:
[0266] This process is used for synthesizing the building block A-6
in which R1, R2, W and R3 are as defined above. ##STR22##
[0267] In ethanol and using hydrogen chloride, the compound J-1 is
reacted with the aldehyde J-2 in which R1, R2, W and R3 are as
defined above, to give the compound J-3.
[0268] The compound J-3 is heated to the boil in phosphoryl
chloride, giving the compound J-4. This is heated to the boil with
sodium iodide in acetone. This gives the compound A-6.
[0269] The abbreviations used denote: [0270] Ac Acetyl [0271] Bn
Benzyl [0272] iBu Isobutyl [0273] tBu tert-Butyl [0274] BuLi
n-Butyllithium [0275] Bz Benzoyl [0276] Cy Cyclohexyl [0277] TLC
Thin-layer chromatography [0278] DCI Direct chemical ionization (in
MS) [0279] DCM Dichloromethane [0280] DMAP
4-N,N-Dimethylaminopyridine [0281] DMF N,N-Dimethylformamide [0282]
DMSO Dimethyl sulfoxide [0283] EA Ethyl acetate [0284] EDC
N'-(3-Dimethylaminopropyl)-N-ethylcarbodiimide x HCl [0285] El
Electron impact ionization (in MS) [0286] eq Equivalent [0287] ESI
Electrospray ionization (in MS) [0288] Et Ethyl [0289] sat.
Saturated [0290] h Hour [0291] HATU
O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium
hexafluorophosphate [0292] HOBt 1-Hydroxy-1H-benzotriazole x
H.sub.2O [0293] HPLC High pressure, high performance liquid
chromatography [0294] LC-MS Liquid chromatography-coupled mass
spectroscopy [0295] Me Methyl [0296] MS Mass spectroscopy [0297]
MsCl Methanesulfonyl chloride [0298] NMR Nuclear magnetic resonance
spectroscopy [0299] Pd/C Palladium on carbon [0300] iPr Isopropyl
[0301] nPr n-Propyl [0302] Rf Retention time (in TLC) [0303] RT
Room temperature [0304] TBAF Tetrabutylammonium fluoride [0305]
TBAl Tetrabutylammonium iodide [0306] TBDPSCl
tert-Butyldiphenylsilyl chloride [0307] TBDMSCl
tert-Butyldimethylsilyl chloride [0308] THF Tetrahydrofuran [0309]
Tr Trityl
[0310] It is possible to prepare other compounds by the processes
mentioned above. Building Block Synthesis According to Process H:
##STR23##
Ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate
[0311] ##STR24##
[0312] 42.4 g of ethyl 4-methyl-3-oxopentanoate are dissolved in
100 ml of glacial acetic acid, and 21 g of sodium nitrite,
dissolved in 100 ml of water, are added at 5.degree. C. Over a
period of one hour, the mixture is allowed to warm to room
temperature, 100 ml of water are added and the mixture is stirred
at room temperature for another hour. The mixture is extracted
three times with in each case 150 ml of methyl tert-butyl ether,
200 ml of water are added to the combined organic phases and the
mixture is neutralized by addition of solid NaHCO3. The organic
phase is removed, washed with saturated NaCl solution and dried
over MgSO4, and the solvent is removed under reduced pressure. This
gives 46 g of ethyl 2-hydroxyimino-4-methyl-3-oxopentanoate as an
oil. C8H13NO4 (187.20), MS (ESI)=188 (M+H.sup.+).
Ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloride
[0313] ##STR25##
[0314] 10 g of HCl are introduced into 200 ml of ethanol. 46 g of
ethyl 2-hydroxy-imino-4-methyl-3-oxopentanoate are dissolved in
this mixture, 5 g of Pd (10% on carbon) are added and the mixture
is stirred under atmosphere of hydrogen (5 bar) for 8 hours. The
reaction mixture is filtered through Celite and the solvent is
removed under reduced pressure. This gives 45 g of ethyl
2-amino-4-methyl-3-oxopentanoate hydrochloride as a white solid.
C8H15NO3*HCl (209.5), MS (ESI)=188 (M+H.sup.+).
Ethyl 4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate
[0315] ##STR26##
[0316] 10 g of ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloride
and 7.4 g of 4-methylbenzoyl chloride are dissolved in 250 ml of
dichloromethane, and 13.3 ml of triethylamine are slowly added
dropwise at 0.degree. C. The mixture is stirred at room temperature
for one hour and then washed with water, the organic phase is
separated off and dried over MgSO4 and the solvent is then removed
under reduced pressure. This gives 13 g of ethyl
4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate as an oil.
C16H21NO4 (291.35), MS (ESI)=292 (M+H.sup.+).
Ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate
[0317] ##STR27##
[0318] 13 g of ethyl
4-methyl-2-(4-methylbenzoylamino)-3-oxopentanoate in 80 ml of
phosphorus oxychloride are heated to the boil under reflux for 2 h.
The phosphorus oxychloride is removed under reduced pressure and
the resulting residue is dissolved in 200 ml of dichloromethane,
washed three times with saturated NaHCO.sub.3 solution and dried
over MgSO4, and the solvent is then removed under reduced pressure.
This gives 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate
as a brownish sold. C16H19NO3 (273.33), MS (ESI)=292 (M+H.sup.+),
Rf(n-heptane:ethyl acetate)=2:1)=0.43.
(5-Isopropyl-2-p-tolyloxazol-4-yl)methanol
[0319] ##STR28##
[0320] 11 g of ethyl 5-isopropyl-2-p-tolyloxazole-4-carboxylate are
dissolved in 100 ml of tetrahydrofuran, and 40 ml of a 1 molar
solution of lithium aluminum hydride in tetrahydrofuran are added
at 0.degree. C. After 30 min, 1N of HCl are added to the reaction
mixture, and the mixture is extracted five times with ethyl
acetate. The combined organic phases are dried over MgSO4 and the
solvent is then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=6:1=>1:1. This gives 4.3 g of
(5-isopropyl-2-p-tolyloxazol-4-yl)methanol as a light-yellow
solid.
[0321] C14H17NO2 (231.30), MS (ESI)=232 (M+H.sup.+),
Rf(n-heptane:ethyl acetate)=1:1)=0.17.
4-Iodomethyl-5-isopropyl-2-p-tolyloxazole
[0322] ##STR29##
[0323] 500 mg of (5-isopropyl-2-p-tolyloxazol-4-yl)methanol,
together with 690 mg of triphenylphosphine and 600 mg of imidazole,
are dissolved in 20 ml of toluene. 715 mg of iodine are added, and
the mixture is stirred at room temperature for 1 hour. 10 ml of
saturated sodium carbonate solution and 500 mg of iodine are then
added. After 10 minutes, the organic phase is separated off, washed
twice with saturated Na2S2O3 solution and dried over MgSO4, and the
solvents are then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=10:1. This gives 400 mg of
4-iodomethyl-5-isopropyl-2-p-tolyl-oxazole as a white solid.
C14H16INO (341.19), MS (ESI): 342 (M+H.sup.+), Rf(n-heptane:ethyl
acetate=1:1)=0.75.
[0324] Analogously to the building block synthesis according to
process K, ethyl 2-amino-4-methyl-3-oxopentanoate hydrochloride and
3-methoxybenzoyl chloride gave
4-iodomethyl-2-(3-methoxyphenyl)-5-isopropyloxazole. ##STR30##
[0325] C14H16INO2 (357.19), MS (ESI): 358 (M+H.sup.+),
Rf(n-heptane:ethyl acetate=1:1)=0.60.
[0326] Analogously to the building block synthesis of
4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl
4,4,4-trifluoro-3-oxobutyrate and 3-methoxybenzoyl chloride gave
4-iodomethyl-2-(3-methoxyphenyl)-5-trifluoromethyloxazole.
##STR31##
[0327] C12H9F3INO2 (383.11), MS (ESI): 384 (M+H.sup.+).
[0328] Analogously to the building block synthesis of
4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl
4,4,4-trifluoro-3-oxobutyrate and 3-trifluoromethyl-benzoyl
chloride gave
4-iodomethyl-2-(3-trifluoromethylphenyl)-5-trifluoro-methyloxazole.
##STR32##
[0329] C12H6F6INO (421.08), MS (ESI): 422 (M+H.sup.+).
[0330] Analogously to the building block synthesis of
4-iodomethyl-5-isopropyl-2-p-tolyloxazole, ethyl
4,4,4-trifluoro-3-oxobutyrate and 4-methylbenzoyl chloride gave
4-iodomethyl-5-trifluoromethyl-2-p-tolyloxazole. ##STR33##
[0331] C12H9F3INO (367.11), MS (ESI): 368 (M+H.sup.+). Building
Block Synthesis According to Process J: ##STR34##
4-Methyl-5-phenyl-2-p-tolyloxazole 3-oxide
[0332] ##STR35##
[0333] 12.5 g of 1-phenyl-1,2-propanedione-2-oxime and 10 ml of
p-tolualdehyde are added to 50 ml of glacial acetic acid, and HCl
gas is introduced for 30 minutes, with ice-cooling. The product is
precipitated as the hydrochloride by addition of methyl tert-butyl
ether and filtered off with suction, and the precipitate is washed
with methyl tert-butyl ether. The precipitate is suspended in water
and the pH is made alkaline using ammonia. The mixture is extracted
three times with in each case 200 ml of dichloromethane, the
combined organic phases are dried over MgSO4 and the solvent is
then removed under reduced pressure. This gives 6.4 g of
4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide as a white solid.
C17H15NO2 (265.31), MS (ESI)=266 (M+H.sup.+).
4-Chloromethyl-5-phenyl-2-p-tolyloxazole
[0334] ##STR36##
[0335] 6.4 g of 4-methyl-5-phenyl-2-p-tolyloxazole 3-oxide are
dissolved in 50 ml of chloroform, 2.4 ml of phosphorus oxychloride
are added and the mixture is, under reflux, heated at the boil for
30 minutes. The reaction mixture is cooled to 0.degree. C., the pH
is made slightly alkaline using ammonia and the mixture is
extracted three times with in each case 100 ml of ethyl acetate.
The combined organic phases are washed with water and dried over
MgSO4, and the solvent then removed under reduced pressure. This
gives 5.4 g of 4-chloromethyl-5-phenyl-2-p-tolyloxazole as a yellow
solid. C17H14ClNO (283.76), MS (ESI)=284 (M+H.sup.+),
Rf(n-heptane:ethyl acetate)=7:1)=0.41
4-Iodomethyl-5-phenyl-2-p-tolyloxazole
[0336] ##STR37##
[0337] Together with 3 g of sodium iodide, 1.8 g of
4-chloromethyl-5-phenyl-2-p-tolyloxazole are, in 150 ml of acetone,
heated at the boil under reflux for 2 hours. After cooling of the
reaction mixture, 300 ml of methyl tert-butyl ether are added, the
mixture is washed three times with saturated Na2S2O3 solution and
dried over MgSO4 and the solvents are then removed under reduced
pressure. This gives 2.7 g of
4-iodomethyl-5-phenyl-2-p-tolyloxazole as a light-yellow solid.
[0338] C17H14INO (375.21), MS (ESI): 376 (M+H.sup.+).
[0339] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole,
1-phenyl-1,2-propanedione-2-oxime and m-anisaldehyde gave
4-iodomethyl-2-(3-methoxyphenyl)-5-phenyloxazole. ##STR38##
[0340] C17H14INO2 (391.21), MS (ESI): 392 (M+H.sup.+).
[0341] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole,
1-ethyl-1,2-propanedione-2-oxime and m-anisaldehyde gave
4-iodomethyl-5-ethyl-2-(3-methoxyphenyl)oxazole. ##STR39##
[0342] C13H14INO2 (343.17), MS (ESI): 344 (M+H.sup.+).
[0343] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole,
1-ethyl-1,2-propanedione-2-oxime and p-tolualdehyde gave
4-iodomethyl-5-ethyl-2-p-tolylazole. ##STR40##
[0344] C13H14INO (327.17), MS (ESI): 328 (M+H.sup.+).
[0345] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole,
1-cyclohexyl-1,2-propanedione-2-oxime and m-anis-aldehyde gave
4-iodomethyl-5-cyclohexyl-2-(3-methoxyphenyl)oxazole. ##STR41##
[0346] C17H20INO2 (397.26), MS (ESI): 398 (M+H.sup.+).
[0347] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole,
1-cyclohexyl-1,2-propanedione-2-oxime and p-tolualdehyde gave
4-iodomethyl-5-cyclohexyl-2-p-tolyloxazole. ##STR42##
[0348] C17H20INO (381.26), MS (ESI): 382 (M+H.sup.+).
[0349] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
p-tolualdehyde gave 4-iodomethyl-5-methyl-2-p-tolyloxazole.
##STR43##
[0350] C12H12INO (313.14), MS (ESI): 314 (M+H.sup.+).
[0351] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
m-anisaldehyde gave
4-iodo-methyl-2-(3-methoxyphenyl)-5-methyloxazole. ##STR44##
[0352] C12H12INO2 (329.14), MS (ESI): 330 (M+H.sup.+).
[0353] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
3-bromobenzaldehyde gave
2-(3-bromophenyl)-4-iodomethyl-5-methyloxazole. ##STR45##
[0354] C11H9BrINO (377.01/379.01), MS (ESI): 378/380
(M+H.sup.+).
[0355] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
3-trifluoromethylbenzaldehyde gave
4-iodomethyl-5-methyl-2-(3-trifluoromethylphenyl)oxazole.
##STR46##
[0356] C12H9F3INO (367.11), MS (ESI): 368 (M+H.sup.+).
[0357] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
4-fluorobenzaldehyde gave
2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole. ##STR47##
[0358] CH11H9FINO (317.10), MS (ESI): 318 (M+H.sup.+).
[0359] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
4-methoxybenzaldehyde gave
4-iodomethyl-2-(4-methoxyphenyl)-5-methyloxazole. ##STR48##
[0360] C12H12INO2 (329.14), MS (ESI): 330 (M+H+).
[0361] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
4-trifluoromethylbenzaldehyde gave
4-iodomethyl-5-methyl-2-(4-trifluoromethylphenyl)oxazole.
##STR49##
[0362] C12H9F3INO (367.11), MS (ESI): 368 (M+H+).
[0363] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
m-tolualdehyde gave 4-iodomethyl-5-methyl-2-m-tolyloxazole.
##STR50##
[0364] C12H12INO (313.14), MS (ESI): 314 (M+H+).
[0365] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
benzaldehyde gave 4-chloro-methyl-5-methyl-2-phenyloxazole.
##STR51##
[0366] C11H10ClNO (299.15), MS (ESI): 300 (M+H+).
[0367] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
p-phenylbenzaldehyde gave 4-iodomethyl-5-methyl-2-p-biphenyloxazole
##STR52##
[0368] C18H13INO (375.21), MS (ESI):376 (M+H+).
[0369] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
3-trifluoromethoxybenzaldehyde gave
4-iodomethyl-5-methyl-2-(3-trifluoromethoxyphenyl)oxazole.
##STR53##
[0370] C12H9F3INO2 (383.11), MS (ESI): 384 (M+H+).
[0371] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
5-methylfuran-2-carbaldehyde gave
4-iodomethyl-5-methyl-2-(5-methylfuran-2-yl)oxazole. ##STR54##
[0372] C10H.sub.10INO2 (303.11), MS (ESI): 304 (M+H+).
[0373] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
thiophene-2-carbaldehyde gave
4-iodomethyl-5-methyl-2-thiophen-2-yloxazole ##STR55##
[0374] C9H81NOS (305.14), MS (ESI): 306 (M+H+).
[0375] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
4-isopropylbenzaldehyde gave
4-iodomethyl-2-(4-isopropylphenyl)-5-methyloxazole. ##STR56##
[0376] C14H16INO (341.19), MS (ESI): 342 (M+H+).
[0377] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, pentane-2,3-dione-2-oxime
and 3-trifluoromethyl-benzaldehyde gave
5-ethyl-4-iodomethyl-2-(3-trifluoromethylphenyl)-oxazole.
##STR57##
[0378] C13H11F3INO (381.14), MS (ESI):382 (M+H+).
[0379] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, pentane-2,3-dione-2-oxime
and naphthalene-2-carbaldehyde gave
5-ethyl-4-iodomethyl-2-naphthalen-2-yloxazole. ##STR58##
[0380] C16H14INO (363.20), MS (ESI):364 (M+H+).
[0381] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, butane-2,3-dione-2-oxime
and naphthalene-2-carbaldehyde gave
5-methyl-4-iodomethyl-2-naphthalen-2-yloxazole. ##STR59##
[0382] C15H12INO (349.20), MS (ESI):350 (M+H+).
[0383] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, pentane-2,3-dione-2-oxime
and 4-isopropylbenzaldehyde gave
5-ethyl-4-iodomethyl-2-(4-isopropylphenyl)oxazole. ##STR60##
[0384] C15H18INO (355.22), MS (ESI):356 (M+H+).
[0385] Analogously to the building block synthesis of
4-iodomethyl-5-phenyl-2-p-tolyloxazole, diacetylmonoxime and
3,4-dimethoxybenzaldehyde gave
4-iodomethyl-5-methyl-2-(3,4-dimethoxyphenyl)oxazole. ##STR61##
[0386] C13H14INO3 (359.17), MS (ESI): 360 (M+H+).
[0387] All substances described below have the cis-configuration on
the cyclohex-1,3-ylene.
EXAMPLE 1
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-pentanoi-
c acid
[0388] ##STR62## ##STR63##
Methyl cis-3-(methoxymethoxy)cyclohexanecarboxylate
[0389] ##STR64##
[0390] 15 g of 6-oxabicyclo[3.2.1]octan-7-one are dissolved in 150
ml of methanol, 13 g of sodium methoxide are added and the mixture
is stirred at room temperature for 2 h. 13.7 ml of glacial acetic
acid are then added, and most of the solvent is distilled off under
reduced pressure. The residue is taken up in water and extracted
three times with in each case 100 ml of ethyl acetate. The organic
phases are dried over MgSO4 and then concentrated under reduced
pressure. This gives 18.8 g of the methyl ester as a colorless oil.
This is dissolved in 150 ml of dichloromethane, 19.2 g of
methoxymethyl chloride and 23.2 g of diisopropylethylamine are
added and the mixture is stirred at room temperature for 15 h. 250
ml of saturated NH4Cl solution and 200 ml of water are added to the
solution, and the organic phase is separated off. The aqueous phase
is extracted with dichloromethane and the combined organic phases
are dried over magnesium sulfate and concentrated. This gives 22.2
g of methyl cis-3-(methoxymethoxy)cyclohexanecarboxylate as a
yellow oil. C10H18O4 (202), MS (ESI): 203 (MH.sup.+).
cis-(3-Methoxymethoxycyclohexyl)methanol
[0391] ##STR65##
[0392] 9.0 g of methyl cis-3-methoxymethoxycyclohexanecarboxylate
are dissolved in 280 ml of diethyl ether, 2.2 g of LiAlH4 are added
and the mixture is stirred at room temperature. After 4 h, at
0.degree. C., 10 ml of ethyl acetate and then 15 ml of 10N NaOH are
added dropwise. The suspension is stirred for 1 h, MgSO4 is added,
the mixture is filtered through Celite and the filtrate is
concentrated, giving 7.0 g of
(cis-3-methoxymethoxycyclo-hexyl)methanol as a colorless oil.
C9H18O3 (174), MS (ESI): 175 (MH.sup.+).
tert-Butyl (cis-3-methoxymethoxycyclohexylmethoxy)acetate
[0393] ##STR66##
[0394] 1.0 g of (cis-3-methoxymethoxycyclohexyl)methanol and 3.3 g
of tert-butylbromoacetate are dissolved in 30 ml of toluene, and
0.50 g of tetrabutylammonium hydrogensulfate is added. The
suspension is cooled to 10.degree. C. 10 ml of 50% strength NaOH
are added to the suspension. The mixture is allowed to warm to room
temperature, and after 3 h the aqueous phase is removed and
extracted with methyl tert-butyl ether. The combined organic phases
are dried over MgSO4 and concentrated. Flash column chromatography
on silica gel (heptane/ethyl acetate 10/1->2/1) gives 1.10 g of
tert-butyl (cis-3-methoxymethoxycyclohexylmethoxy)acetate as a
colorless oil. C15H28O5 (288), LCMS (ESI): 306 (M.sup.++H2O).
tert-Butyl 2-(cis-3-hydroxycyclohexylmethoxy)pentanoate
[0395] ##STR67##
[0396] 200 mg of tert-butyl
(cis-3-methoxymethoxycyclohexylmethoxy)acetate are dissolved in 5
ml of abs. tetrahydrofuran and cooled to -78.degree. C. (dry
ice/acetone bath). 0.7 ml of a 2M lithium diisopropylamide solution
in tetrahydrofuran/hexane is then added dropwise. The solution is
initially stirred at -78.degree. C. and then warmed to 0.degree. C.
(ice bath) and stirred at this temperature for 20 min. 600 mg of
propyl iodide in 2 ml of tetrahydrofuran are then added, and the
solution is stirred at 0.degree. C. for a further 2.5 h. 15 ml of a
saturated ammonium chloride solution are added, and the phases are
separated. The aqueous phase is extracted with methyl tert-butyl
ether. The combined organic phases are dried over MgSO4 and
concentrated (yield: 240 mg of crude product). The residue is taken
up in 2 ml of tetrahydrofuran, 0.5 ml of conc. HCl is added and the
mixture is stirred at room temperature for 18 h. The mixture is
diluted with water and methyl tert-butyl ether, the phases are
separated and the aqueous phase is extracted with methyl tert-butyl
ether. The combined organic phases are washed with saturated NaCl
solution, dried over MgSO4 and concentrated. This gives 130 mg of
tert-butyl 2-(cis-3-hydroxycyclohexylmethoxy)-pentanoate as a
yellow oil. NMR (CDCl3) diastereomer mixture: 3.55-3.67 (m, 2H),
3.41-3.48 (m, 1H), 3.07-3.18 (m, 1H), 1.91-2.13 (m, 2H), 1.11-1.82
(m, 14H), 1.48 (s, 9H).
tert-Butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-metho-
xy]pentanoate
[0397] ##STR68##
[0398] 130 mg of tert-butyl
2-(cis-3-hdyroxycyclohexylmethoxy)pentanoate are dissolved in 3 ml
of dimethylformamide, and 20 mg of NaH (95%) are added. After 60
min of stirring, 350 mg of 5-methyl-2-p-tolyloxazol-4-yl-methyl
iodide in 1 ml of dimethylformamide are added at 0.degree. C. The
mixture is stirred at room temperature for 2 h. 10 ml of methyl
tert-butyl ether, 5 ml of water and 10 ml of saturated NaCl
solution are then added. The phases are separated, the aqueous
phase is extracted once with methyl tert-butyl ether and the
organic phases are dried over MgSO4 and concentrated. The residue
is chromatographed on silica gel (heptane/ethyl acetate
99/1->10/1). This gives 20 mg of the crude tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]pentanoa-
te as a yellow oil. C28H41NO5 (471), LCMS (ESI): 472
(MH.sup.+).
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-pentanoi-
c acid
[0399] ##STR69##
[0400] 20 mg of tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-hexylmethoxy]pentano-
ate are stirred in 1 ml of trifluoroacetic acid overnight. The
solution is concentrated completely and purified by HPLC, giving 15
mg of
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-methoxy)cyclohexyl-methoxy]pentanoic
acid 7. C24H33NO5 (415), MS (ES+) 416 (MH.sup.+).
EXAMPLE 2
[0401] Analogously to Example 1, tert-butyl
(cis-3-methoxymethoxycyclohexyl-methoxy)acetate, methyl iodide and
5-methyl-2-p-tolyloxazol-4-ylmethyl iodide give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-methoxy]propion-
ic acid. C22H29NO5 (387), LCMS (ES+) 388 (MH.sup.+). ##STR70##
EXAMPLE 3
[0402] Analogously to Example 1, tert-butyl
(cis-3-methoxymethoxycyclohexyl-methoxy)acetate, ethyl iodide and
5-methyl-2-p-tolyloxazol-4-ylmethyl iodide give
2-[3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-butyric
acid.
[0403] C23H31NO5 (401), LCMS (ES+) 402 (MH.sup.+). ##STR71##
EXAMPLE 4
[0404] Analogously to Example 1, tert-butyl
(cis-3-methoxymethoxycyclohexyl-methoxy)acetate, benzyl bromide and
5-methyl-2-p-tolyloxazol-4-ylmethyl iodide give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-methoxy]-3-phen-
ylpropionic acid. C28H33NO5 (463), LCMS (ES+) 464 (MH.sup.+).
##STR72##
EXAMPLE 5
[0405] Analogously to Example 1, tert-butyl
(cis-3-methoxymethoxycyclohexyl-methoxy)acetate, methyl iodide and
5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethyl iodide give
2-[cis-3-(5-methyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxy)cyclohexylmethox-
y]propionic acid. C22H29NO6 (403), LCMS (ES+) 404 (MH.sup.+).
##STR73##
EXAMPLE 6
[0406] Analogously to Example 1, tert-butyl
cis-(3-methoxymethoxycyclohexyl-methoxy)acetate, methyl iodide and
5-methyl-2-m-tolyloxazol-4-ylmethyl iodide give
2-[cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclohexyl-methoxy]propion-
ic acid. C23H31NO5 (401), LCMS (ES+) 402 (MH.sup.+). ##STR74##
EXAMPLE 7
[0407] Analogously to Example 1, tert-butyl
cis-(3-methoxymethoxycyclohexyl-methoxy)acetate, methyl iodide and
5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethyl iodide give
2-[cis-3-(5-methyl-2-(3-trifluoromethylphenyl)-oxazol-4-ylmethyl)cyclohex-
ylmethoxy]propionic acid. C22H26F.sub.3NO5 (441), LCMS (ES+) 442
(MH.sup.+). ##STR75##
EXAMPLE 8
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methyl-
propionic acid
[0408] ##STR76##
tert-Butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate
[0409] ##STR77##
[0410] 300 mg of tert-butyl
(cis-3-methoxymethoxycyclohexylmethoxy)acetate are dissolved in 5
ml of abs. tetrahydrofuran and cooled to -78.degree. C. (dry
ice/acetone bath). 1.5 ml of a 2M lithium diisopropyl amide
solution in tetrahydrofuran/hexane are then added dropwise. The
solution is initially stirred at -78.degree. C. for 90 min and then
warmed to 0.degree. C. (ice bath), 1.41 g of methyl iodide and 1.5
ml of tetrahydrofuran are added and the solution is stirred at
0.degree. C. for 1 h. 1 ml of HCl (conc.) is added, and the phases
are separated. The aqueous phase is extracted with ethyl acetate.
The combined organic phases are dried over MgSO4 and concentrated
(yield: 320 mg of crude product). The crude product is dissolved in
5 ml of abs. tetrahydrofuran and cooled to -78.degree. C. (dry
ice/acetone bath). 1.5 ml of a 2M lithium diisopropylamide solution
in tetrahydrofuran/hexane are then added dropwise. The solution is
initially stirred at -78.degree. C. for 90 min and then warmed to
0.degree. C. (ice bath), 1.41 g of methyl iodide and 1.5 ml of
tetrahydrofuran are added and the solution is stirred at 0.degree.
C. for 1 h. 1 ml of HCl (conc.) is added, and the phases are
separated. The aqueous phase is extracted with ethyl acetate. The
combined organic phases are dried over MgSO4 and concentrated
(yield: 350 mg of crude product). The residue is taken up in 1 ml
of tetrahydrofuran, 1 ml of conc. HCl is added and the mixture is
stirred at room temperature for 3 d. The mixture is diluted with
water and ethyl acetate, the phases are separated and the aqueous
phase is extracted with ethyl acetate. The combined organic phases
are washed with saturated NaCl solution, dried over MgSO4 and
concentrated. The residue is chromatographed on silica gel
(heptane/ethyl acetate 2/1), giving 200 mg of tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methyl-propionate as a yellow
oil. C15H28O4 (272.20), MS (ESI): 273.4 (MH.sup.+).
tert-Butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-metho-
xy]-2-methylpropionate
[0411] ##STR78##
[0412] 200 mg of tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methyl-propionate are
dissolved in 5 ml of dimethylformamide, and 20 mg of NaH (95%) are
added. After 60 min of stirring at room temperature, 460 mg of
5-methyl-2-p-tolyloxazol-4-ylmethyl iodide in 1.5 ml of
dimethylformamide are added at 0.degree. C. The mixture is stirred
at room temperature for 2 h. 10 ml of methyl tert-butyl ether and
10 ml of saturated NH4Cl solution are then added. The phases are
separated, the aqueous phase is extracted once with methyl
tert-butyl ether and the organic phases are dried over MgSO4 and
concentrated. The residue is chromatographed on silica gel
(heptane/ethyl acetate 5/1->1/1). 200 mg of the crude tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methy-
lpropionate are obtained as a yellow oil. C27H39NO5 (457), LCMS
(ESI): 458 (MH.sup.+).
Improved synthesis of tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethoxy]-2-meth-
ylpropionate
[0413] ##STR79##
[0414] 50 mg of tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate are dissolved
in 0.5 ml of dimethylformamide and 22 mg of NaH (60%) are added.
After 30 min of stirring, 112 mg of
5-methyl-2-p-tolyloxazol-4-yl-methyl iodide are added at room
temperature. The mixture is placed in an ultrasonic bath for 10 min
and then stirred at room temperature for 3 h. 10 ml of methyl
tert-butyl ether and 10 ml of water are then added. The phases are
separated, the aqueous phase is extracted once with methyl
tert-butyl ether and the organic phases are dried over MgSO4 and
concentrated. The residue is chromatographed on silica gel
(heptane/ethyl acetate 5/1->1/1). 60 mg of the crude tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methy-
lpropionate are obtained as a yellow oil. C27H39NO5 (457), LCMS
(ESI): 458 (MH.sup.+).
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methyl-
propionic acid
[0415] ##STR80##
[0416] 200 mg of tert-butyl
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methy-
lpropionate are stirred in 2 ml of trifluoroacetic acid for 1 h.
The solution is concentrated completely and purified by flash
chromatography (heptane/ethyl acetate 5/1) giving 66 mg of
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-methy-
lpropionic acid.
[0417] C23H31NO5 (401.51), MS (ES+) 402.29 (MH.sup.+).
EXAMPLE 8A
2-[(1R,3S)-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-2-me-
thylpropionic acid
[0418] ##STR81##
[0419] Starting with an enantiomerically pure tert-butyl
2-[(1R,3S)-cis-3-hydroxy-cyclohexylmethoxy]-2-methylpropionate,
2-[(1R,3S)-cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]-
-2-methylpropionic acid is obtained. C23H31NO5 (401.51), MS (ES+)
402.29 (MH.sup.+).
EXAMPLE 9
1-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]cyclo-pen-
tanecarboxylic acid
[0420] ##STR82##
tert-Butyl
2-allyl-2-(cis-3-methoxymethoxycyclohexylmethoxy)pent-4-enoate
[0421] ##STR83##
[0422] 200 mg of tert-butyl
(cis-3-methoxymethoxycyclohexylmethoxy)acetate are dissolved in 6
ml of abs. tetrahydrofuran and cooled to -78.degree. C. (dry
ice/acetone bath). 1.05 ml of a 2M lithium diisopropylamide
solution in tetrahydrofuran/hexane are then added dropwise. The
solution is initially stirred at -78.degree. C. and then at
0.degree. C., in each case for 20 min, and 0.85 g of allyl bromide
in 1.5 ml of tetrahydrofuran is added at 0.degree. C. The solution
is stirred at 0.degree. C. for 30 min. 1 ml of a saturated NH4Cl
solution and 5 ml of ethyl acetate are added and the phases are
separated. The aqueous phase is extracted with ethyl acetate. The
combined organic phases are dried over MgSO4 and concentrated. The
residue is chromatographed on silica gel (heptane/ethyl acetate
10/1), giving 160 mg of monoallylated product. This is dissolved in
6 ml of abs. tetrahydrofuran and cooled to -78.degree. C. (dry
ice/acetone bath). 1.05 ml of a 2M lithium diisopropylamide
solution in tetrahydrofuran/hexane are then added dropwise. The
solution is initially stirred at -78.degree. C. and then at
0.degree. C., in each case for 20 min, and 0.85 g of allyl bromide
in 1.5 ml of tetrahydrofuran is added at 0.degree. C. The solution
is stirred at 0.degree. C. for 2 h. 1 ml of a saturated NH4Cl
solution and 5 ml of ethyl acetate are added and the phases are
separated. The aqueous phase is extracted with ethyl acetate. The
combined organic phases are dried over MgSO4 and concentrated. The
residue is chromatographed on silica gel (heptane/ethyl acetate
5/1), giving 140 mg of tert-butyl
2-allyl-2-(cis-3-methoxymethoxycyclohexylmethoxy)pent-4-enoate as a
yellow oil. C21H36O5 (368.52), MS (ESI): 296.25
(MH.sup.+-C4H9O).
tert-Butyl
(cis-3-hydroxycyclohexylmethoxy)cyclopentanecarboxylate
[0423] ##STR84##
[0424] 140 mg of tert-butyl
2-allyl-2-(cis-3-methoxymethoxycyclohexylmethoxy)pent-4-enoate are
dissolved in 5 ml of dichloromethane, 10 mg of Grubbs catalyst
(Cl.sub.2(Cy.sub.3P).sub.2Ru.dbd.CHPh) are added under an Ar
atmosphere and the mixture is stirred at 40.degree. C. for 48 h. 10
ml of heptane/ethyl acetate (3/1) are added and the solution is
filtered through silica gel. This gives 100 mg of tert-butyl
1-(cis-3-methoxymethoxy-cyclohexylmethoxy)cyclopent-3-enecarboxylate
as a brown oil. This is dissolved in 2 ml of MeOH, degassed and
saturated with Ar. 30 mg of Pd/C (10%) are then added, and the
mixture is degassed again. The solution is saturated with hydrogen
and stirred at room temperature overnight. Dilution with 20 ml of
ethyl acetate and filtration through Celite give 100 mg of crude
tert-butyl
1-(cis-3-methoxymethoxycyclohexylmethoxy)cyclopentane-carboxylate.
This is taken up in 2 ml of tetrahydrofuran, 0.5 ml of HCl (conc.)
is added and the mixture is stirred at room temperature overnight.
The solution is neutralized with saturated NaHCO3 solution and
extracted three times with ethyl acetate. The organic phases are
dried over MgSO4 and concentrated. Chromatography of the residue on
silica gel (heptane/ethyl acetate 10/1->1/1) gives 57 mg of
tert-butyl
1-(cis-3-hydroxycyclohexylmethoxy)cyclopentanecarboxylate as a
yellow oil. For the next step, this is used in crude form.
tert-Butyl
1-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-metho-
xy]cyclopentanecarboxylate
[0425] ##STR85##
[0426] 57 mg of tert-butyl
1-(cis-3-hydroxycyclohexylmethoxy)cyclopentane-carboxylate are
dissolved in 3 ml of dimethylformamide, and 10 mg of NaH are added.
The suspension is stirred at room temperature for 30 min and then
cooled to 0.degree. C., and 150 mg of methyl
2-p-tolyloxazol-4-ylmethyl iodide in 1 ml of dimethylformamide are
added dropwise. The suspension is stirred at room temperature for 2
h and diluted with methyl tert-butyl ether and saturated NaCl
solution. The aqueous phase is removed and extracted with methyl
tert-butyl ether. The combined organic phases are washed with
saturated NaCl solution, dried over MgSO4 and concentrated.
Chromatography of the residue on silica gel (heptane/ethyl acetate
99/->10/1) gives 20 mg of a product mixture which, according to
LCMS, contains the desired tert-butyl
1-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-methoxy]cyclope-
ntanecarboxylate. This mixture is used for the next step, without
further purification. C29H41NO5 (483.65), LCMS (ESI): 484.2
(MH.sup.+).
1-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]cyclo-pen-
tanecarboxylic acid
[0427] ##STR86##
[0428] 20 mg of impure tert-butyl
1-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexylmethoxy]cyclope-
ntanecarboxylate is stirred in 1 ml of trifluoroacetic acid at room
temperature overnight. The solution is concentrated completely and
the residue is chromatographed on silica gel (heptane/ethyl acetate
10/1->1/1->methyl tert-butyl ether), giving 7.5 mg of
1-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethoxy]cyclo-pe-
ntanecarboxylic acid. C25H33NO5 (427.55); LCMS 428.2 (MH+).
EXAMPLE 10
[0429] ##STR87## ##STR88##
tert-Butyl
cis-3-(tert-butyldiphenylsilanyloxy)cyclohexylmethoxy]acetate
[0430] ##STR89##
[0431] 25 g of
[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]methanol, together
with 40 g of tert-butyl bromoacetate and 6.9 g of
tetrabutylammonium hydrogensulfate, are dissolved in 300 ml of
toluene, and 200 ml of NaOH (50% strength) are then added dropwise
at 0.degree. C. The mixture is stirred at 0.degree. C. for 1 h and
then warmed to room temperature. The solvent is removed and the
mixture is extracted with 3.times.100 ml of methyl tert-butyl
ether. After the third extraction, the aqueous phase is acidified
and once more extracted with 200 ml of methyl tert-butyl ether. The
combined organic phases are extracted with saturated sodium
chloride solution and dried over magnesium sulfate, and the solvent
is removed under reduced pressure. This gives 27.8 g of tert-butyl
cis-3-(tert-butyldiphenylsilanyloxy)-cyclohexylmethoxy]acetate as a
yellow oil.
[0432] C29H42O4Si (482.74), MS (ESI): 483 (M+H.sup.+)
tert-Butyl
2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexylmethoxy]-2-met-
hylpropionate
[0433] ##STR90##
[0434] 20.0 g of tert-butyl
cis-3-(tert-butyldiphenylsilanyloxy)cyclohexylmethoxy]-acetate are
initially charged in a 1 l three-necked flask, which had been dried
by heating, dissolved in 200 ml of dry tetrahydrofuran and cooled
to -78.degree. C., and 83 ml of lithium diisopropylamide (2N in
tetrahydrofuran) are slowly added dropwise such that the internal
temperature does not exceed -65.degree. C. The mixture is then
warmed to 0.degree. C. and stirred for 1 h, during which the color
of the solution turns to yellow. The mixture is cooled again to
-70.degree. C., 35.27 g of methyl iodide are then added dropwise
and the mixture is stirred at 0.degree. C. for 3 h. The reaction is
checked (TLC and LCMS), showing the formation of a new product
(monomethyl compound). 200 ml of saturated ammonium chloride
solution are added to the reaction mixture, and the mixture is
extracted with water/methyl tert-butyl ether. This gives the crude
product as a dark-red oil which, without purification, is converted
in the same reaction sequence into the geminal dimethyl compound.
The crude product is purified on silica gel (heptane/ethyl acetate
50:1.fwdarw.10:1). This gives 16 g of tert-butyl
2-[cis-3-(tert-butyl-diphenylsilanyloxy)cyclohexylmethoxy]-2-methylpropio-
nate as a light-yellow oil.
[0435] C31H46O4Si (510.80), MS (ESI): 511 (M+H.sup.+).
tert-Butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate
[0436] ##STR91##
[0437] 16 g of tert-butyl
2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexylmethoxy]-2-methylpropion-
ate are dissolved in 100 ml of acetonitrile, and 62 ml of
tetrabutylammonium fluoride (1N solution in tetrahydrofuran) are
added. After 2 h of stirring at 60.degree. C., the reaction has
ended and the mixture is concentrated under reduced pressure. The
residue is extracted from water/ethyl acetate. The combined org.
phases are extracted with saturated sodium chloride solution and
dried over magnesium sulfate, and the solvent is removed under
reduced pressure. The crude product is purified on silica gel
(heptane/ethyl acetate 15:1.fwdarw.1:1). This gives 16 g of the
product tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate as a
colorless oil.
[0438] C15H28O4 (272.39), MS (ESI): 273 (M+H.sup.+)
tert-Butyl
2-{cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclo-h-
exylmethoxy}-2-methylpropionate
[0439] ##STR92##
[0440] 0.05 g of the alcohol tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate is dissolved
in methyl tert-butyl ether, and 15 mg of sodium hydride are added.
After 15 minutes of stirring at room temperature, 0.12 g of
2-(4-fluorophenyl)-4-iodomethyl-5-methyloxazole is added, and the
mixture is stirred at room temperature for 12 h. Following addition
of 2 ml of 1N HCl, the product is extracted with ethyl acetate
(2.times.5 ml), the solvent is removed under reduced pressure and
the crude product is then purified by HPLC. This gives 0.08 g of
the compound tert-butyl
2-{cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl-methox-
y}-2-methylpropionate as a colorless oil.
[0441] C.sub.26H.sub.36FNO.sub.5 (461.58), MS (ESI): 462
(M+H.sup.+)
2-{cis-3-[2-(4-Fluorophenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl-methoxy-
}-2-methylpropionic acid
[0442] ##STR93##
[0443] 0.07 g of tert-butyl
2-{cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-yl-methoxy]cyclohexylmethox-
y}-2-methylpropionate is dissolved in 1 ml of dichloromethane, 1 ml
of trifluoroacetic acid is added and the mixture is stirred at room
temperature. The reaction is monitored (LCMS), showing complete
conversion after 30 minutes. The reaction mixture is extracted with
water/dichloromethane and, after removal of the solvent under
reduced pressure, purified by preparative HPLC. This gives 0.06 g
of the carboxylic acid
2-{cis-3-[2-(4-fluorophenyl)-5-methyloxazol-4-ylmethoxy]-cyclohexylmethox-
y}-2-methylpropionic acid as a colorless oil.
[0444] C.sub.22H.sub.28FNO.sub.5 (405.47), MS (ESI): 406
(M+H.sup.+)
EXAMPLE 11
[0445] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethyl iodide give
2-{(1S,3R)-cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohex-
ylmethoxy}-2-methylpropionic acid. ##STR94##
[0446] C.sub.23H.sub.31NO.sub.6 (417.50) MS (ESI): 418
(M+H.sup.+)
EXAMPLE 12
[0447] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methyl propionate and
2-(3-trifluoromethylphenyl)-5-methyloxazol-4-yl-methyl iodide give
2-{(1S,3R)-3-[2-(cis-3-trifluoromethylphenyl)-5-methyl-oxazol-4-ylmethoxy-
]cyclohexylmethoxy)-2-methylpropionic acid. ##STR95##
[0448] C.sub.23H.sub.28F.sub.3NO.sub.5 (455.47) MS (ESI): 456
(M+H.sup.+)
EXAMPLE 13
[0449] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-methyl-2-(5-methylfuran-2-yl)oxazol-4-ylmethyl iodide give
2-methyl-2-{(1R,3S)-cis-3-[5-methyl-2-(5-methylfuran-2-yl)-oxazol-4-ylmet-
hoxy]cyclohexylmethoxy}propionic acid. ##STR96##
[0450] C.sub.21H.sub.29NO.sub.6 (391.46) MS (ESI): 392
(M+H.sup.+)
EXAMPLE 14
[0451] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
2-(3,4-dimethoxyphenyl)-5-methyloxazol-4-yl-methyl iodide give
2-{(1R,3S)-cis-3-[2-(3,4-dimethoxyphenyl)-5-methyl-oxazol-4-ylmethoxy]cyc-
lohexylmethoxy}-2-methylpropionic acid. ##STR97##
[0452] C.sub.24H.sub.33NO.sub.7 (447.53) MS (ESI): 448
(M+H.sup.+)
EXAMPLE 15
[0453] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-phenyl-2-p-tolyloxazol-4-ylmethyl iodide give
2-methyl-2-[(1R,3S)-cis-3-(5-phenyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-hex-
ylmethoxy]propionic acid. ##STR98##
[0454] C.sub.28H.sub.33NO.sub.5 (463.57) MS (ESI): 464
(M+H.sup.+)
EXAMPLE 16
[0455] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-methyl-2-(4-trifluoromethylphenyl)oxazol-4-yl-methyl iodide give
2-methyl-2-{(1R,3S)-cis-3-[5-methyl-2-(4-trifluoromethyl-phenyl)oxazol-4--
ylmethoxy]cyclohexylmethoxy}propionic acid ##STR99##
[0456] C.sub.23H.sub.28F.sub.3NO.sub.5 (455.47) MS (ESI): 456
(M+H.sup.+)
EXAMPLE 17
[0457] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
2-(4-methoxyphenyl)-5-methyloxazol-4-ylmethyl iodide give
2-{(1R,3S)-cis-3-[2-(4-methoxyphenyl)-5-methyloxazol-4-yl-methoxy]cyclohe-
xylmethoxy}-2-methylpropionic acid ##STR100##
[0458] C.sub.23H.sub.31NO.sub.6 (417.50) MS (ESI): 418
(M+H.sup.+)
EXAMPLE 18
[0459] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-methyl-2-thiophen-2-yloxazol-4-methyl iodide give
2-methyl-2-[(1R,3S)-cis-3-(5-methyl-2-thiophen-2-yloxazol-4-yl-methoxy)cy-
clohexylmethoxy]propionic acid ##STR101##
[0460] C.sub.20H.sub.27NO.sub.5S (393.50) MS (ESI): 394
(M+H.sup.+)
EXAMPLE 19
[0461] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
-methyl-2-(3-trifluoromethoxyphenyl)oxazol-4-ylmethyl iodide give
2-methyl-2-[(1R,3S)-cis-3-[5-methyl-2-(3-trifluoro-methoxyphenyl)oxazol-4-
-ylmethoxy]cyclohexylmethoxy]propionic acid ##STR102##
[0462] C.sub.23H.sub.28F.sub.3NO.sub.6 (471.47) MS (ESI): 472
(M+H.sup.+)
EXAMPLE 20
[0463] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-methyl-2-(4-isopropylphenyl)oxazol-4-ylmethyl iodide give
2-methyl-2-[(1R,3S)-cis-3-(5-methyl-2-(4-isopropylphenyl)-oxazol-4-ylmeth-
oxy)cyclohexylmethoxy]propionic acid. ##STR103##
[0464] C.sub.25H.sub.35NO.sub.5 (429.56) MS (ESI): 430
(M+H.sup.+)
EXAMPLE 21
[0465] Analogously to Example 10, tert-butyl
2-(cis-3-hydroxycyclohexylmethoxy)-2-methylpropionate and
5-methyl-2-m-tolyloxazol-4-ylmethyl iodide give
2-methyl-2-[(1R,3S)-cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)cyclo-hex-
ylmethoxy]propionic acid. ##STR104##
[0466] C.sub.25H.sub.31NO.sub.5 (401.50) MS (ESI): 402
(M+H.sup.+)
EXAMPLE 22
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]aceti-
c acid
[0467] ##STR105##
5-Methyl-2-p-tolyloxazole-4-carboxaldehyde
[0468] ##STR106##
[0469] In a dry four-necked flask with stirrer motor, internal
thermometer, dropping funnel with pressure equalizer and reflux
condenser with argon inlet (aspirator with tap), 9.3 g of LiAlH4
are covered with 600 ml of diethyl ether. The suspension is cooled
to 0.degree. C. 30 g of ethyl
5-methyl-2-p-tolyloxazole-4-carboxylate are dissolved in 100 ml of
diethyl ether and added dropwise to the suspension. After one hour
of stirring at room temperature, the reaction has ended (TLC
(heptane/ethyl acetate 1:1): R.sub.f, starting material=0.66,
R.sub.f, product=0.18). 80 g of MgSO.sub.4, 300 ml of methyl
tert-butyl ether and 30 ml of ethyl acetate are added successively,
and the suspension is stirred at room temperature. The mixture is
then cooled to 0.degree. C., 90 ml of 10N KOH are added dropwise
and the mixture is stirred for another 60 min. The solids are
filtered off, the residue is washed three times with ethyl acetate
and the filtrate is concentrated, giving 24 g of
5-methyl-2-p-tolyl-oxazole-4-methanol as a yellow solid. C12H13NO2
(203.24), LCMS (ESI): 204.1 (MH.sup.+).
[0470] At -78.degree. C., 22.2 ml of DMSO in 30 ml of
dichloromethane are added dropwise to a solution of 12 ml of oxalyl
chloride in 150 ml of dichloromethane such that the temperature
does not exceed -70.degree. C. The solution is then stirred at this
temperature for 30 min. 24 g of
5-methyl-2-p-tolyloxazole-4-methanol in 120 ml of
dichloromethane/chloroform (2/1) are then added dropwise, the
temperature not exceeding -70.degree. C. The solution is stirred at
this temperature for 30 min. 80 ml of NEt.sub.3 are then added
dropwise such that the temperature does not exceed -70.degree. C.
After the addition has ended, the cooling bath is removed and the
solution is, with stirring, warmed to 0.degree. C. At this
temperature, 100 ml of water are added and the mixture is stirred
vigorously at room temperature. The aqueous phase is separated off
and extracted with chloroform. The combined organic phases are
washed with saturated NH.sub.4Cl solution, dried over MgSO.sub.4
and concentrated, giving 23.8 g of
5-methyl-2-p-tolyloxazole-4-carbaldehyde as a yellow solid.
C12H11NO2 (201.23), LCMS (ESI): 202.1 (MH.sup.+).
Methyl
[cis-3-(tert-butyldimethylsilanyloxy)cyclohexyl]carboxylate
[0471] ##STR107##
[0472] 47 g of 6-oxabicyclo[3.2.1]octan-7-one are dissolved in 500
ml of MeOH, and 40.5 g of NaOMe are added. After 2.5 hours of
stirring at room temperature, 135 ml of acetic acid are added and
most of the methanol is distilled off. The residue is taken up in
ethyl acetate/water and the phases are separated. The aqueous phase
is extracted with ethyl acetate and the combined organic phases are
dried over MgSO4 and concentrated, the residue being the methyl
ester in quantitative yield.
[0473] 10.7 g of the residue are dissolved in 100 ml of
dimethylformamide, and 11.2 g of tert-butyldimethylsilyl chloride
are added. At 0.degree. C., 11.5 g of imidazole are added, and the
solution is stirred at room temperature overnight. 200 ml of
saturated NaCl solution are added and the solution is extracted
three times with methyl tert-butyl ether. The combined organic
phases are washed with saturated NaCl solution, dried over MgSO4
and concentrated. This gives 16.4 g of methyl
[cis-3-(tert-butyldimethylsilanyl-oxy)cyclohexyl]carboxylate as a
colorless oil. C14H28O3Si (272.46), MS (ESI): 273.13
(MH.sup.+).
Methyl
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexane-carboxylate
[0474] ##STR108##
[0475] At room temperature, 1.35 g of methyl
[cis-3-(tert-butyldimethylsilanyloxy)-cyclohexyl]acetate are added
dropwise to a mixture of 4.0 ml of HSiEt3 and 1.50 g of BiBr3 in 20
ml of acetonitrile. 1.51 g of
5-methyl-2-p-tolyloxazole-4-carbaldehyde in 5 ml of acetonitrile
are then added, and the mixture is stirred at room temperature for
4 h. The suspension is filtered and concentrated. The residue is
chromatographed on silica gel (dichloro-methane/methanol 100/1),
giving 1.20 g of methyl
cis-3-(5-methyl-2-p-tolyl-oxazol-4-ylmethoxy)cyclohexanecarboxylate
as a light-yellow oil. C20H25NO4 (343.43), LCMS (ESI): 344.1
(MH.sup.+).
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]methanol
[0476] ##STR109##
[0477] At 0.degree. C., 1.70 g of methyl
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-hexanecarboxylate
in 5 ml of tetrahydrofuran are added dropwise to a suspension of
380 mg of LiAlH4 in 50 ml of diethyl ether, and the mixture is
stirred at room temperature for 2 h. 3 g of MgSO.sub.4, 30 ml of
methyl tert-butyl ether and 3 ml of ethyl acetate are added
successively, and the suspension is stirred at room temperature.
The mixture is then cooled to 0.degree. C., 1 ml of 10N KOH is
added dropwise and the mixture is stirred for another 60 min. The
solids are filtered off, the residue is washed three times with
ethyl acetate and the filtrate is concentrated, giving 1.55 g of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]methanol as
a yellow oil. C19H25NO3 (315.42), MS (EI): 315.4 (M.sup.+).
4-(cis-3-Iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
[0478] ##STR110##
[0479] 1.56 g of PPh3, 0.87 g of imidazole and 1.64 g of iodine are
added to 1.55 g of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]methanol in
20 ml of toluene, and the mixture is stirred at room temperature
for 2 h. 10 ml of dichloromethane are then added, and the mixture
is stirred for another 60 min. The solution is diluted with 50 ml
of water and 50 ml of methyl tert-butyl ether, the phases are
separated and the organic phase is dried over MgSO4 and
concentrated. Filtration of the residue through silica gel using
dichloromethane gives 1.12 g of
4-(cis-3-iodomethylcyclohexyl-oxymethyl)-5-methyl-2-p-tolyloxazole
as a yellow solid. C19H24INO2 (425.31); LCMS (ESI): 426.0
(MH.sup.+).
Ethyl
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl-sulfany-
l]acetate
[0480] ##STR111##
[0481] 50 mg of KO.sup.tBu are added to 68 mg of ethyl
mercaptoacetate in 1.5 ml of dimethylformamide, and the mixture is
stirred at room temperature for 1 h. 120 mg of
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyl-oxazole
are then added, and the solution is stirred at room temperature.
After 1 h, 20 ml of methyl tert-butyl ether, 15 ml of saturated
NaCl solution and 15 ml of water are added and the phases are
separated. The aqueous phase is extracted with methyl tert-butyl
ether and the combined organic phases are washed with saturated
NaCl solution, dried over MgSO4 and concentrated, giving 117 mg of
ethyl
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]acet-
ate. C23H.sub.31NO4S (417.57); LCMS (ESI): 418.1 (MH.sup.+).
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]aceti-
c acid
[0482] ##STR112##
[0483] 117 mg of ethyl
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-methylsulfanyl]ace-
tate are dissolved in 3 ml of methanol, 1 ml of 2N KOH is added and
the mixture is stirred at room temperature overnight. 2 ml of 2N
HCl, 10 ml of saturated NaCl solution, 5 ml of water and 20 ml of
dichloromethane are then added, and the phases are separated. The
organic phase is dried over MgSO4 and concentrated, giving 100 mg
of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]acet-
ic acid. C21H27NO4S (389.52); LCMS (ESI): 390.1 (MH.sup.+).
EXAMPLE 23
[0484] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercaptopropionate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]p-
ropionic acid as a mixture of diastereomers. C22H29NO4S (403.54),
LCMS (ESI): 404.1 (MH.sup.+). ##STR113##
EXAMPLE 24
[0485] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and methyl 2-mercaptobutyrate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]b-
utyric acid as a mixture of diastereomers. C23H31NO4S (417.57),
LCMS (ESI): 418.1 (MH.sup.+). ##STR114##
EXAMPLE 25
[0486] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercaptoheptanoate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
heptanoic acid as a mixture of diastereomers. C26H37NO4S (459.65),
MS (ESI): 460.41 (MH.sup.+). ##STR115##
EXAMPLE 26
[0487] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercapto-3-methylbutyrate acid give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
3-methylbutyric acid as a mixture of diastereomers. C24H33NO4S
(431.60), LCMS (ESI): 432.2 (MH.sup.+). ##STR116##
EXAMPLE 27
[0488] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercapto-2-methylpropionate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
2-methylpropionic acid. C23H31NO45 (417.57), LCMS (ESI): 418.1
(MH.sup.+). ##STR117##
EXAMPLE 28
[0489] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercapto-2-phenylacetate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
2-phenylacetic acid as a mixture of diastereomers. C27H31NO4S
(465.62), MS (ESI): 466.39 (MH.sup.+). ##STR118##
EXAMPLE 29
[0490] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercapto-2-cyclohexylacetate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
2-cyclohexylacetic acid as a mixture of diastereomers. C27H37NO4S
(471.66), LCMS (ESI): 472.2 (MH.sup.+). ##STR119##
EXAMPLE 30
[0491] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 2-mercaptovalerate give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]v-
aleric acid as a mixture of diastereomers. C24H33NO4S (431.60), MS
(ESI): 432.39 (MH.sup.+). ##STR120##
EXAMPLE 31
[0492] Analogously to Example 22,
4-(cis-3-iodomethylcyclohexyloxymethyl)-5-methyl-2-p-tolyloxazole
and ethyl 1-mercaptocyclobutanecarboxylate give
1-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
cyclobutanecarboxylic acid. C24H31NO4S (429.58), MS (ESI): 430.35
(MH.sup.+). ##STR121## Building Block Synthesis of the Methyl
2-mercaptobutyrates
Methyl 2-mercaptobutyrate
[0493] ##STR122##
[0494] 1.43 g of KSAc are added to 1.81 g of methyl 2-bromobutyrate
in 5 ml of dimethylformamide, and the mixture is stirred at room
temperature for 12 h. 25 ml of methyl tert-butyl ether, 10 ml of
water and 15 ml of saturated NaCl solution are then added, and the
phases are separated. The aqueous phase is extracted with methyl
tert-butyl ether and the combined organic phases are washed with
saturated NaCl solution, dried over MgSO4 and concentrated, giving
methyl 2-acetylsulfanylbutyrate as a yellow oil. This is taken up
in 10 ml of methanol, 11 ml of a 1M NaSMe solution in methanol are
added and the mixture is stirred at room temperature overnight. The
solvent is distilled off completely under reduced pressure, the
residue is taken up in 15 ml of methyl tert-butyl ether and 20 ml
of water, the phases are separated and the organic phase is washed
with saturated NaCl solution and dried over MgSO4. The solution is
concentrated under reduced pressure, giving 1.30 g of methyl
2-mercaptobutyrate as a yellow oil.
[0495] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 2-bromoheptanoate gives ethyl
2-mercapto-heptanoate. ##STR123##
[0496] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 2-bromo-3-methylbutyrate acid gives
ethyl 2-mercapto-3-methylbutyrate acid. ##STR124##
[0497] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 2-bromo-2-methylpropionate acid gives
ethyl 2-mercapto-2-methylpropionate acid. ##STR125##
[0498] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 2-bromo-2-phenylacetate gives ethyl
2-mercapto-2-phenylacetate. ##STR126##
[0499] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, methyl 2-bromo-2-cyclohexylacetate gives
methyl 2-mercapto-2-cyclohexylacetate. ##STR127##
[0500] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 2-bromovalerate gives ethyl
2-mercapto-valerate. ##STR128##
[0501] Analogously to the building block synthesis of the methyl
2-mercaptobutyrates, ethyl 1-bromocyclobutanecarboxylate gives
ethyl 1-mercaptocyclobutanecarboxylate. ##STR129##
EXAMPLE 32
[0502] ##STR130##
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfinyl]aceti-
c acid
[0503] 65 mg of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl-sulfanyl]ace-
tic acid are dissolved in 1.5 ml of trifluoroacetic acid, 6.3 .mu.l
of 35% H2O2 are added at 0.degree. C. and the mixture is stirred
overnight at room temperature. Saturated NH4Cl solution and methyl
tert-butyl ether are added, the phases are separated, the aqueous
phase is extracted with methyl tert-butyl ether and the combined
organic phases are washed with saturated NaCl solution, dried over
MgSO4 and concentrated. The residue is purified by HPLC, which gave
6.6 mg of a colorless solid. C21H27NO5S (405.52), LCMS (ESI): 406.1
(MH.sup.+).
EXAMPLE 33
[0504] Analogously to Example 32,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]h-
eptanoic acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfinyl]h-
eptanoic acid as a mixture of diastereomers.
[0505] C26H37NO5S (475.65), MS (ESI): 476.18 (MH.sup.+).
##STR131##
EXAMPLE 34
[0506] Analogously to Example 32,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]--
2-methylpropionic acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfinyl]--
2-methylpropionic acid. C23H31NO5S (433.57), LCMS (ESI): 434.1
(MH.sup.+). ##STR132##
EXAMPLE 35
[0507] Analogously to Example 32,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethylsulfanyl]-
-3-methylbutyric acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfinyl]--
3-methylbutyric acid as a mixture of diastereomers. C24H33NO5S
(447.60), MS (ESI): 448.43 (MH.sup.+). ##STR133##
EXAMPLE 36
[0508] Analogously to Example 32,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfanyl]v-
aleric acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfinyl]v-
aleric acid as a mixture of diastereomers. C24H33NO5S (447.60), MS
(ESI): 448.14 (MH.sup.+). ##STR134##
EXAMPLE 37
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfonyl]aceti-
c acid
[0509] ##STR135##
[0510] 65 mg of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl-sulfanyl]ace-
tic acid are dissolved in 1.5 ml of trifluoroacetic acid, 21.5
.mu.l of 35% H2O2 are added at 0.degree. C. and the mixture is
stirred at room temperature overnight. Saturated NH4Cl solution and
methyl tert-butyl ether are added, the phases are separated, the
aqueous phase is extracted with methyl tert-butyl ether and the
combined organic phases are washed with saturated NaCl solution,
dried over MgSO4 and concentrated. The residue is purified by HPLC,
which gave 6.6 mg of a colorless solid. C21H27NO6S (421.52), LCMS
(ESI): 422.1 (MH.sup.+).
EXAMPLE 38
[0511] Analogously to Example 37,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethylsulfanyl]-
heptanoic acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfonyl]h-
eptanoic acid as a mixture of diastereomers. C26H37NO6S (491.65),
MS (ESI): 492.42 (MH.sup.+). ##STR136##
EXAMPLE 39
[0512] Analogously to Example 37,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethylsulfanyl]-
-2-methylbutyric acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfonyl]--
2-methylbutyric acid. C23H31NO6S (449.57), LCMS (ESI): 450.1
(MH.sup.+). ##STR137##
EXAMPLE 40
[0513] Analogously to Example 37,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethylsulfanyl]-
-3-methylbutyric acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfonyl]--
3-methyl-butyric acid as a mixture of diastereomers. C24H33NO6S
(463.60), LCMS (ESI): 464.1 (MH.sup.+). ##STR138##
EXAMPLE 41
[0514] Analogously to Example 37,
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylmethylsulfanyl]-
valeric acid gives
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethylsulfonyl]v-
aleric acid as a mixture of diastereomers. C24H33NO6S (463.60), MS
(ESI): 464.14 (MH.sup.+). ##STR139##
EXAMPLE 42
(S)-3-Methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-me-
thyl]amino}butyric acid
[0515] ##STR140##
cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexanecarbaldehyde
[0516] ##STR141##
[0517] At -78.degree. C., 089 ml of DMSO in 1 ml of dichloromethane
are added dropwise to 0.48 ml of oxalyl chloride in 15 ml of
dichloromethane such that the temperature does not exceed
-70.degree. C. After the end of the addition, the solution is
stirred at this temperature for 30 min. 1.5 g of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]methanol in
2 ml of dichloromethane are then added dropwise such that the
temperature remains below -78.degree. C. The solution is stirred at
this temperature for 30 min. 3.2 ml of NEt3 are then added
dropwise, the cooling bath is removed and the solution is warmed to
0.degree. C. At this temperature, 10 ml of water are added, and the
mixture is stirred vigorously at room temperature. The aqueous
phase is removed and extracted with dichloromethane. The combined
organic phases are washed with saturated NH.sub.4Cl solution, dried
over MgSO.sub.4 and concentrated, giving 1.50 g of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexanecarbaldehyde-
. C19H23NO3 (313.40); LCMS (ESI): 314.1 (MH.sup.+).
tert-Butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-c-
yclohexylmethyl]amino}butyrate
[0518] ##STR142##
[0519] 511 mg of
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexanecarb-aldehyde,
0.9 ml of HOAc and 310 mg of tert-butyl (S)-valinate are dissolved
in 5 ml of abs. dichloromethane. 500 mg of molecular sieve 4 .ANG.
are then added, and the suspension is cooled to 0.degree. C. 414 mg
of sodium triacetoxyborohydride are added a little at a time. This
suspension is stirred at 0.degree. C. for 2 h, 3 ml of saturated
NH4Cl solution are then added and the suspension is stirred for a
further 10 min. In each case 10 ml of water and dichloromethane are
added, the phases are separated, the aqueous phase is extracted
with dichloromethane and the combined organic phases are dried over
MgSO4 and concentrated, which gives 760 mg of tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]-amino}butyrate. C28H42N2O4 (470.66); MS (ESI): 471.50
(MH.sup.+).
(S)-3-Methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-me-
thyl]amino}butyric acid
[0520] ##STR143##
[0521] 40 mg of tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate are dissolved in 1 ml of formic acid, and 0.5
ml of trifluoroacetic acid is added. The solution is stirred at
room temperature for 18 and then concentrated completely. The
residue is purified by HPLC, which gives 28.2 mg of
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyric acid trifluoroacetic acid salt as a colorless
solid. C24H34N2O2.C2HF3O2 (414.55); MS (ES-): 413.28
(M.sup.+-H).
EXAMPLE 43
(S)-2-{Acetyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-meth-
yl]amino}-3-methylbutyric acid
[0522] ##STR144##
(S)-2-{Acetyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-meth-
yl]amino}-3-methylbutyric acid
[0523] ##STR145##
[0524] 12 .mu.l of acetyl chloride and 22 .mu.l of pyridine are
added to 40 mg of tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate in 0.5 ml of dichloromethane, and the mixture
is stirred at room temperature for 18 h. The solution is then
diluted with water and dichloromethane, the aqueous phase is
removed and extracted with dichloromethane and the combined phases
are dried over MgSO4 and concentrated. The residue is taken up in
0.5 ml of trifluoroacetic acid and allowed to stand at room
temperature overnight. The solvent is distilled off completely and
the residue is purified by HPLC, which gives 17 mg of
(S)-2-{acetyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-
hexylmethyl]amino}-3-methylbutyric acid. C26H36N2O5 (456.59); LCMS
(ESI): 457.36 (MH.sup.+).
EXAMPLE 44
[0525] Analogously to Example 43, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and benzoyl chloride give
(S)-2-{benzoyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexylme-
thyl]amino}-3-methylbutyric acid. C31H38N2O5 (518.29); LCMS (ESI):
519.54 (MH.sup.+). ##STR146##
EXAMPLE 45
[0526] Analogously to Example 43, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and methyl-sulfonyl chloride give
(S)-2-{methylsulfonyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cycloh-
exylmethyl]amino}-3-methylbutyric acid. C25H36N2O6S (492.23); LCMS
(ESI): 493.26 (MH.sup.+). ##STR147##
EXAMPLE 46
[0527] Analogously to Example 43, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and methyl-sulfonyl chloride in triethylamine
give
(S)-2-{methylsulfonylmethylsulfonyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-
methoxy)cyclohexylmethyl]amino}-3-methylbutyric acid. C26H38N2O8S2
(570.21); LCMS (ES-): 569.23 (M.sup.+-H). ##STR148##
EXAMPLE 47
[0528] Analogously to Example 43, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and p-toluenesulfonyl chloride give
(S)-2-{p-toluenesulfonyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyc-
lohexylmethyl]amino}-3-methylbutyric acid. C31H40N2O6S (568.26);
LCMS (ESI): 569.35 (MH.sup.+). ##STR149##
EXAMPLE 48
[0529] Analogously to Example 43, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and methyl chloroformate give
(S)-2-{methoxycarbonyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-
hexylmethyl]amino}-3-methylbutyric acid. C26H36N2O6 (472.26), LCMS
(ESI): 473.37 (MH.sup.+). ##STR150##
EXAMPLE 49
[0530] Analogously to 42,
cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexanecarbaldehyde
and isopropyl glycinate hydrochloride give
2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]amino}-a-
cetic acid trifluoroacetic acid salt. C21H28N2O4 (486.49), MS
(ESI): 487 (MH.sup.+). ##STR151##
EXAMPLE 50
(S)-2-{Methyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl-meth-
yl]amino}-3-methylbutyric acid trifluoroacetic acid salt
[0531] ##STR152##
[0532] 60 mg of methyl iodide and 12 mg of potassium carbonate are
added to 40 mg of tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyclohexylm-
ethyl]amino}butyrate (see Example 42) in 0.5 ml of DMF, and the
mixture is stirred at RT overnight. 1 ml of TFA is added to the
reaction solution, and the mixture is stirred for a further 1 h.
The solution is purified by preparative HPLC, yielding 6.4 mg of
(S)-2-{methyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmeth-
yl]amino}-3-methyl-butyric acid trifluoroacetic acid salt.
C25H36N2O4 (542.60); MS (ESI): 543 (MH+).
EXAMPLE 51
[0533] Analogously to Example 50, tert-butyl
(S)-3-methyl-2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylme-
thyl]amino}butyrate and benzyl bromide give
(S)-2-{benzyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexylmet-
hyl]amino}-3-methylbutyric acid trifluoroacetic acid salt.
C31H40N2O4 (618.70), MS (ESI): 619 (MH+). ##STR153##
EXAMPLE 52
2-{Benzyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]-a-
mino}acetic acid
[0534] ##STR154##
[0535] 120 mg of isopropyl
2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohexylmethyl]amino}a-
cetate are dissolved in 1.5 ml of dichloromethane, and 62 mg of
benzaldehyde, a spatula tip of MgSO4 and 68 mg of sodium
triacetoxyborohyride are added successively. The suspension is
stirred at RT overnight, and water is then added. The organic phase
is separated off, washed with Na2CO3 solution, dried over MgSO4 and
concentrated. The residue is dissolved in 0.7 ml of methanol and
0.23 ml of water, 20 mg of LiOH are added and the mixture is
stirred at RT overnight. The solution is concentrated and the
residue is purified by preparative HPLC, yielding 15 mg of
2-{benzyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexy-
lmethyl]amino}acetic acid. C28H34N2O4 (462.59); MS (ESI): 463
(MH+).
EXAMPLE 53
[0536] Analogously to Example 52, isopropyl
2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]amino}ac-
etate and thiophene-2-carbaldehyde give
2-{2-thienylmethyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohex-
ylmethyl]amino}acetic acid trifluoroacetic acid salt. C26H32N2O4
(468.62), MS (ESI): 469 (MH+). ##STR155##
EXAMPLE 54
[0537] Analogously to Example 52, isopropyl
2-{[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexylmethyl]amino}ac-
etate and cyclohexanecarbaldehyde give
2-{cyclohexylmethyl-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)-cyclohe-
xylmethyl]amino}acetic acid trifluoroacetic acid salt. C28H40N2O4
(468.64), MS (ESI): 469 (MH.sup.+). ##STR156##
EXAMPLE 55
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxymethyl)cyclohexylmethoxy]-2--
methylpropionic acid
[0538] ##STR157## ##STR158##
(cis-3-Methoxymethoxymethylcyclohexylmethyl)methanol
[0539] ##STR159##
[0540] 1.70 g of methyl cis-3-hydroxymethylcyclohexanecarboxylate
are dissolved in 20 ml of dichloromethane, 1.60 g of methoxymethyl
chloride and 2.60 g of diisopropylamine are added and the mixture
is stirred at room temperature for 15 h. 50 ml of saturated NH4Cl
solution and 50 ml of water are added to the solution, and the
organic phase is separated off. The aqueous phase is extracted with
dichloromethane and the combined organic phases are dried over
magnesium sulfate and concentrated. This gives 2.0 g of methyl
cis-3-methoxymethoxymethylcyclohexanecarboxylate as a yellow oil.
This is dissolved in 50 ml of diethyl ether, 350 mg of LiAlH4 are
added and the mixture is stirred at room temperature. After 2 h at
0.degree. C., 5 ml of ethyl acetate, 40 ml of methyl tert-butyl
ether and 3 g of MgSO4 are added. 15 ml of 10N KOH are then added
dropwise. The suspension is stirred for 3 h and filtered through
Celite and the filtrate is concentrated, which gives 1.65 g of
(cis-3-methoxymethoxymethylcyclohexyl)methanol as a colorless
oil.
[0541] C10H20O3 (188.27), MS (ESI): 189.2 (MH.sup.+).
tert-Butyl
[cis-3-(methoxymethoxymethyl)cyclohexylmethoxy]acetate
[0542] ##STR160##
[0543] 1.65 g of (cis-3-methoxymethoxymethylcyclohexyl)methanol and
5.1 g of tert-butyl bromoacetate are dissolved in 20 ml of toluene,
and 1.50 g of tetrabutylammonium hydrogensulfate are added. The
suspension is cooled to 10.degree. C. 20 ml of 50% NaOH are added
to the suspension. The mixture is stirred at 10.degree. C. for 6 h
and the aqueous phase is then removed and extracted with methyl
tert-butyl ether. The combined organic phases are dried over MgSO4
and concentrated. Flash column chromatography on silica gel
(heptane/ethyl acetate 10/1.fwdarw.2/1) gives 2.23 g of tert-butyl
[cis-3-(methoxymethoxymethyl)cyclohexylmethoxy]acetate as a
colorless oil. C16H30O5 (302.41), MS (ESI): 320.30
(M+NH.sub.4.sup.+).
tert-Butyl
[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexylmethoxy]-a-
cetate
[0544] ##STR161##
[0545] 1.9 g of tert-butyl
[cis-3-(methoxymethoxymethyl)cyclohexylmethoxy]-acetate are
dissolved in 10 ml of tetrahydrofuran, 5 ml of conc. HCl are added
and the mixture is stirred at room temperature for 2 h. 10 ml of
sat. NaCl solution, 10 ml of water and 30 ml of methyl tert-butyl
ether are then added, the phases are separated and the aqueous
phase is extracted with methyl tert-butyl ether. The combined
organic phases are dried over MgSO4 and concentrated. Flash
chromatography on silica gel (heptane/ethyl acetate 3/1) gives 600
mg of tert-butyl (cis-3-hydroxymethyl-cyclohexylmethoxy)acetate as
a colorless oil (TLC (heptane/ethyl acetate 2/1): R.sub.f, starting
material=0.68, R.sub.f, product=0.18). 260 mg of this are dissolved
in 5 ml of dimethylformamide, and 170 mg of tert-butyldimethylsilyl
chloride are added. The solution is then cooled to 0.degree. C.,
and 160 mg of imidazole are added. The solution is stirred at room
temperature for 15 h, and 20 ml of sat. NaCl solution, 10 ml of
water and 30 ml of methyl tert-butyl ether are then added. The
phases are separated and the organic phase is washed with sat. NaCl
solution, dried over MgSO4 and concentrated. This gives 350 mg of
tert-butyl
[cis-3-(tert-butyldimethyl-silanyloxymethyl)cyclohexylmethoxy]acetate
as a colorless oil. C20H40O4Si (372.36); LCMS (ESI): 390.3
(M+NH.sub.4.sup.+).
tert-Butyl
2-[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexylmethoxy]-
-2-methylpropionate
[0546] ##STR162##
[0547] 250 mg of tert-butyl
[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexyl-methoxy]acetate
are dissolved in 10 ml of abs. tetrahydrofuran and cooled to
-78.degree. C. (dry ice/acetone bath). 1.70 ml of a 2M lithium
diisopropylamide solution in tetrahydrofuran/hexane are then added
dropwise. The solution is initially stirred at -78.degree. C. for
20 min and then warmed to 0.degree. C. (ice bath), and 950 mg of
methyl iodide are added. The solution is stirred at 0.degree. C.
for 1 h. 1 ml of sat. NH4Cl solution and 10 ml of water are added,
and the phases are separated. The aqueous phase is extracted with
ethyl acetate. The combined organic phases are dried over MgSO4 and
concentrated. The crude product is dissolved in 10 ml of abs.
tetrahydrofuran and cooled to -78.degree. C. (dry ice/acetone
bath). 1.70 ml of a 2M lithium diisopropylamide solution in
tetrahydrofuran/hexane are then added dropwise. The solution is
initially stirred at -78.degree. C. for 20 min and then warmed to
0.degree. C. (ice bath), and 950 mg of methyl iodide are added. The
solution is stirred at 0.degree. C. for 1 h. 1 ml of sat. NH4Cl
solution and 10 ml of water are added and the phases are separated.
The aqueous phase is extracted with ethyl acetate. The combined
organic phases are dried over MgSO4 and concentrated. This gives
220 mg of tert-butyl
2-[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclo-hexylmethoxy]-2-methyl-
propionate as a light-yellow oil. TLC (heptane/ethyl acetate 4/1):
R.sub.f, starting material=0.66, R.sub.f, product=0.80.
[0548]
2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxymethyl)cyclohexylmet-
hoxy]-2-methylpropionic acid: ##STR163##
[0549] 50 mg of tert-butyl
2-[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexyl-methoxy]-2-methyl-
propionate are added to a mixture of 20 mg of BiBr3 and 30 mg of
HSiEt.sub.3 in 0.5 ml of acetonitrile. 38 mg of
5-methyl-2-p-tolyloxazole-4-carbaldehyde in 0.2 ml of acetonitrile
are added dropwise, and the mixture is stirred at room temperature
overnight. The resulting black solid is filtered and the filtrate
is concentrated and taken up in 1 ml of trifluoroacetic acid. The
solution is stirred at room temperature overnight. The solvent is
distilled off under reduced pressure and the residue is purified by
HPLC. This gives 3.4 mg of
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxymethyl)cyclohexylmethoxy]-2-
-methylpropionic acid as a colorless oil. C24H33NO5 (415.24); MS
(ES-): 414.25 (M-H.sup.+).
EXAMPLE 56
[0550] Analogously to Example 55, tert-butyl
[cis-3-(methoxymethoxymethyl)cyclo-hexylmethoxy)acetate, methyl
iodide, ethyl iodide and 5-methyl-2-p-tolyloxazole-4-carbaldehyde
give
2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxymethyl)cyclohexylmethoxy]-3-
-methylbutyric acid. C25H35NO5 (429.25); MS (ES-): 428.22
(M-H.sup.+). ##STR164##
EXAMPLE 57
[0551] ##STR165## ##STR166##
tert-Butyl
2-[cis-3-hydroxymethylcyclohexylmethoxy]-2-methylpropionate
[0552] ##STR167##
[0553] 4.5 g of tert-butyl
2-[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexyl-methoxy]-2-methyl-
propionate (synthesis analogously to tert-butyl
2-[cis-3-(tert-butyldimethylsilanyloxymethyl)cyclohexylmethoxy]-2-methylp-
ropionate in Example 55) are dissolved in 85 ml of THF, 2.24 g of
TBAF trihydrate are added and the mixture is stirred at 60.degree.
C. for 90 min. Water and MTBE are added, the phases are separated
and the organic phase is dried over MgSO4 and concentrated. The
residue is chromatographed on silica gel (heptane/ethyl acetate
1:1), which gives 1.45 g of tert-butyl
2-[cis-3-hydroxymethylcyclohexylmethoxy]-2-methylpropionate.
C16H30O4 (286.42), MS (ESI): 287 (MH+).
2-[cis-3-(5-Methyl-2-(4-biphenyl)oxazol-4-ylmethoxymethyl)cyclohexyl-metho-
xy]-2-methylpropionic acid
[0554] ##STR168##
[0555] 50 mg of tert-butyl
2-[cis-3-hydroxymethylcyclohexylmethoxy]-2-methylpropionate and 200
mg of 5-methyl-2-(4-biphenyl)oxazol-4-yl-methoxymethyl iodide are
dissolved in 2 ml of chlorobenzene, and 59 mg of potassium
tert-butoxide are added. The suspension is stirred at RT for 24 h,
2.5 ml of TFA are then added and the solution is stirred at RT for
another 24 h. The solvent is distilled off under reduced pressure
and the residue is purified by preparative HPLC, which gives 20 mg
of
2-[cis-3-(5-methyl-2-(4-biphenyl)oxazol-4-ylmethoxymethyl)cyclohexylmetho-
xy]-2-methylpropionic acid. C29H35NO5 (477.61), MS (ESI): 478
(MH+).
EXAMPLE 58
[0556] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-methyl-2-phenyloxazol-4-ylmethoxy-methyl chloride give
2-[cis-3-(5-methyl-2-phenyloxazol-4-ylmethoxymethyl)-cyclohexylmethoxy]-2-
-methylpropionic acid. C23H31NO5 (401.51); MS (ESI): 402
(MH.sup.+). ##STR169##
EXAMPLE 59
[0557] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-methyl-2-naphthyloxazol-4-ylmethoxy-methyl chloride give
2-[cis-3-(5-methyl-2-naphthyloxazol-4-ylmethoxy-methyl)cyclohexylmethoxy]-
-2-methylpropionic acid. C27H33NO5 (451.57); MS (ESI): 458
(MH.sup.+). ##STR170##
EXAMPLE 60
[0558] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-ethyl-2-(3-methoxyphenyl)oxazol-4-yl-methoxymethyl chloride give
2-[cis-3-(5-ethyl-2-(3-methoxyphenyl)oxazol-4-ylmethoxymethyl)cyclohexylm-
ethoxy]-2-methylpropionic acid. C25H35NO5 (445.56); MS (ESI): 446
(MH.sup.+). ##STR171##
EXAMPLE 61
[0559] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-methyl-2-(4-isopropylphenyl)-oxazol-4-ylmethoxymethyl chloride
give
2-[cis-3-(5-ethyl-2-(4-isopropylphenyl)-oxazol-4-ylmethoxymethyl)cyclohex-
ylmethoxy]-2-methylpropionic acid. C26H37NO5 (443.59); MS (ESI):
444 (MH.sup.+). ##STR172##
EXAMPLE 62
[0560] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-cyclohexyl-2-p-tolyloxazol-4-yl-methoxymethyl chloride give
2-[cis-3-(5-ethyl-2-p-tolyloxazol-4-ylmethoxy-methyl)cyclohexylmethoxy]-2-
-methylpropionic acid. C29H41NO5 (483.65); MS (ESI): 484
(MH.sup.+). ##STR173##
EXAMPLE 63
[0561] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-ethyl-2-p-isopropyloxazol-4-ylmethoxy-methyl chloride give
2-[cis-3-(5-ethyl-2-p-isopropyloxazol-4-ylmethoxy-methyl)cyclohexylmethox-
y]-2-methylpropionic acid. C27H39NO5 (457.62); MS (ESI): 458
(MH.sup.+). ##STR174##
EXAMPLE 64
[0562] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-ethyl-2-(2-naphthyl)oxazol-4-yl-methoxymethyl chloride give
2-[cis-3-(5-ethyl-2-(2-naphthyl)oxazol-4-yl-methoxymethyl)cyclohexylmetho-
xy]-2-methylpropionic acid. C28H35NO5 (465.59); MS (ESI): 466
(MH.sup.+). ##STR175##
EXAMPLE 65
[0563] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-ethyl-2-p-tolyloxazol-4-ylmethoxy-methyl chloride give
2-[cis-3-(5-ethyl-2-p-tolyloxazol-4-ylmethoxy-methyl)cyclohexylmethoxy]-2-
-methylpropionic acid. C25H35NO5 (429.56); MS (ESI): 430
(MH.sup.+). ##STR176##
EXAMPLE 66
[0564] Analogously to Example 57, tert-butyl
2-[cis-3-hydroxymethylcyclohexyl-methoxy]-2-methylpropionate and
5-ethyl-2-(3-trifluoromethyl)oxazol-4-yl-methoxymethyl chloride
give
2-[cis-3-(5-ethyl-2-(3-trifluoromethyl)oxazol-4-ylmethoxymethyl)cyclohexy-
lmethoxy]-2-methylpropionic acid. C26H34F3NO5 (497.56); MS (ESI):
498 (MH.sup.+). ##STR177##
EXAMPLE 67
4-{cis-3-[2-(3-Methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}-butyr-
ic acid
[0565] ##STR178## ##STR179##
cis-3-Allylcyclohexanol
[0566] ##STR180##
[0567] 87 ml of a 1 molar solution of lithium diisobutylaluminum
hydride in n-hexane are dissolved in 100 ml of diethyl ether, and 7
ml of isopropanol are added at 0.degree. C. After the evolution of
gas has ceased, 12.4 g of cis-3-allylcylohexanone, dissolved in 50
ml of diethyl ether, are added. The mixture is stirred at room
temperature for 48 hours. The reaction mixture is quenched by
addition of 1M HCl and the aqueous phase is saturated with sodium
chloride and extracted five times with in each case 200 ml of ethyl
acetate. The combined organic phases are washed with 2N NaOH and
dried over MgSO4, and the solvent is then removed under reduced
pressure. The residue is purified on silica gel using the mobile
phase n-heptane:ethyl acetate=15:1=>5:1. This gives 6.8 g of
cis-3-allylcyclohexanol as an oil. C9H16O (140.23), MS (ESI): 141
(M+H.sup.+), R.sub.f(n-heptane:ethyl acetate=2:1)=0.22.
4-(cis-3-Allylcyclohexyloxymethyl)-2-(3-methoxyphenyl)-5-methyloxazole
[0568] ##STR181##
[0569] 1.8 g of cis-3-allylcyclohexanol are dissolved in 20 ml of
dimethyl-formamide, and 770 mg of sodium hydride (60% strength
suspension in paraffin oil) are added. After 30 minutes, 4 g of
4-iodomethyl-5-methyl-2-(3-methoxyphenyl)oxazole, dissolved in 20
ml of dimethylformamide, are added dropwise. The mixture is stirred
at room temperature for 1 hour. 200 ml of methy tert-butyl ether
are then added to the reaction mixture, and the mixture is washed
three times with water. The organic phase is dried over MgSO4 and
the solvent is then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=10:1. This gives 750 mg of
4-(cis-3-allylcyclohexyloxymethyl)-2-(3-methoxyphenyl)-5-methyloxazole
as an oil.
[0570] C21H27NO3 (341.45), MS (ESI): 342 (M+H.sup.+),
R.sub.f(n-heptane:ethyl acetate=2:1)=0.26.
{cis-3-[2-(3-Methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}-acetald-
ehyde
[0571] ##STR182##
[0572] 750 mg of
4-(cis-3-allylcyclohexyloxymethyl)-2-(3-methoxyphenyl)-5-methyloxazole
are dissolved in 20 ml of diethyl ether, and 1.4 g of sodium
periodate, dissolved in 20 ml of water, are added. At 0.degree. C.,
1 ml of an osmium tetroxide solution (2.5% by weight in
tert-butanol) is added, and the mixture is stirred vigorously at
room temperature. After 8 hours, 100 ml of methyl tert-butyl ether
are added and the mixture is washed with a saturated sodium
thiosulfate solution. The organic phase is dried over MgSO4 and the
solvent is then removed under reduced pressure. This gives 740 mg
of {cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]-cyclohe-
xyl}acetaldehyde as a yellow-brown oil. C20H25NO4 (343.43), MS
(ESI): 344 (M+H.sup.+), R.sub.f(n-heptane:ethyl
acetate=2:1)=0.10.
Ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyl-
}but-2-enoate
[0573] ##STR183##
[0574] 280 mg of
{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyl}acetal-
dehyde are dissolved in 10 ml of dichloromethane, and 370 mg of
ethyl (triphenylphosphoranylidene)acetate are added. The mixture is
stirred at room temperature for 3 hours. The mixture is washed with
saturated sodium chloride solution and dried over MgSO4, and the
solvent is then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=5:1. This gives 190 mg of ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}but-2-
-enoate as an oil. C24H31NO5 (413.52), MS (ESI): 414 (M+H.sup.+),
R.sub.f(n-heptane:ethyl acetate=2:1)=0.30.
Ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyl-
}butyrate
[0575] ##STR184##
[0576] 190 mg of ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-yl-methoxy]cyclohexyl}but--
2-enoate are dissolved in 25 ml of methanol, and mg of Pd (10% on
activated carbon) are added. The mixture is stirred at room
temperature and under an atmosphere of hydrogen for 7 hours. The
catalyst is filtered off through Celite and the filtrate is
concentrated under reduced pressure. This gives 110 mg of ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}butyr-
ate as an oil. C24H33NO5 (415.53), MS (ESI): 416 (M+H.sup.+).
4-{cis-3-[2-(3-Methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}-butyr-
ic acid
[0577] ##STR185##
[0578] 110 mg of ethyl
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}butyr-
ate are dissolved in 5 ml of a mixture of tetrahydrofuran and water
in a ratio of 2:1, and 20 mg of lithium hydroxide are added. The
mixture is stirred at room temperature for 12 hours. The mixture is
acidified by addition of 1N HCl and extracted with ethyl acetate.
The organic phase is dried over MgSO4, and the solvent is then
removed under reduced pressure. The residue is purified by RP-HPLC.
Freeze-drying gives 24 mg of
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}butyr-
ic acid as a lyophilizate. C22H29NO5 (387.48), MS (ESI): 388
(M+H.sup.+).
EXAMPLE 68
[0579] Analogously to Example 67,
{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}acetald-
ehyde and ethyl 2-(triphenylphosphoranylidene)propionate gave
4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}-2-me-
thylbutyric acid. ##STR186##
[0580] C23H31NO5 (401.51), MS (ESI): 402 (M+H.sup.+).
EXAMPLE 69
2-Ethyl-4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hex-
yl}butyric acid
Ethyl
2-ethyl-4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]-cy-
clohexyl}but-2-enoate
[0581] ##STR187##
[0582] 0.4 ml of triethyl phosphonobutyrate is dissolved in 5 ml of
tetrahydrofuran, and 0.5 ml of a 2.5 M n-butyllithium solution in
n-hexane is added at -20.degree. C. The mixture is stirred at
-20.degree. C. for 1 hour, and 386 mg of
{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}acetald-
ehyde, dissolved in 4 ml of tetrahydrofuran, are then added. After
30 minutes, the reaction mixture is slowly warmed to room
temperature, 0.5 ml of water is added, the residue is diluted with
ethyl acetate and dried over MgSO4 and the solvent is then removed
under reduced pressure. This gives 750 mg of ethyl
2-ethyl-4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]-cyclohe-
xyl}but-2-enoate as an oil. C26H35NO5 (441.57), MS (ESI): 442
(M+H.sup.+).
[0583] Analogously to Example 67, ethyl
2-ethyl-4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohex-
yl}but-2-enoate gave
2-ethyl-4-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohex-
yl}butyric acid. ##STR188##
[0584] C24H33NO5 (415.53), MS (ESI): 416 (M+H.sup.+).
EXAMPLE 70
[0585] Analogously to Example 69,
{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}acetald-
ehyde and triethyl phosphonopentanoate gave
2-(2-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyclo-hexyl}e-
thyl)pentanoic acid. ##STR189##
[0586] C25H35NO5 (429.56), MS (ESI): 430 (M+H.sup.+).
EXAMPLE 71
2,2-Dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-bu-
tyric acid
[0587] ##STR190## ##STR191##
(cis-3-Allylcyclohexyloxy)-tert-butyldiphenylsilane
[0588] ##STR192##
[0589] 6.8 g of cis-3-allylcyclohexanol are, together with 15 ml of
tert-butyl-diphenylsilyl chloride, 5 g of imidazole and 200 mg of
dimethyl-aminopyridine, dissolved in 100 ml of dimethylformamide,
and the mixture is stirred at room temperature for 12 h. 400 ml of
methyl tert-butyl ether are added to the reaction mixture, and the
mixture is washed three times with water. The organic phase is
dried over MgSO4 and the solvent is then removed under reduced
pressure. This gives 20.5 g of
(cis-3-allylcyclohexyloxy)-tert-butyl-diphenyl-silane as an oil.
C25H34OSi (378.64), MS (ESI): 379 (M+H.sup.+),
R.sub.f(n-heptane:ethyl acetate=2:1)=0.93.
[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]acetaldehyde
[0590] ##STR193##
[0591] 5.5 g of
(cis-3-allylcyclohexyloxy)-tert-butyl-diphenyl-silane are dissolved
in 100 ml of diethyl ether, and 9.4 g of sodium periodate,
dissolved in 100 ml of water, are added. At 0.degree. C., 15 ml of
an osmium tetroxide solution (2.5% by weight in tert-butanol) are
added, and the mixture is stirred vigorously at room temperature.
After 5 hours, a further 5 g of sodium periodate are added, and the
mixture is stirred at room temperature for another 3 hours. The
reaction mixture is then diluted by addition of 300 ml of methyl
tert-butyl ether and washed with saturated sodium thiosulfate
solution. The organic phase is dried over MgSO4 and the solvent is
then removed under reduced pressure. This gives 6 g of
[cis-3-(tert-butyldiphenylsilanyloxy)-cyclohexyl]acetaldehyde as a
yellow-brown oil.
[0592] C24H32O2Si (380.61), MS (ESI): 381 (M+H.sup.+),
R.sub.f(n-heptane:ethyl acetate=5:1)=0.44.
tert-Butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]but-2-enoate
[0593] ##STR194##
[0594] 3.4 g of
[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]acetaldehyde are
dissolved in 100 ml of dichloromethane, and 5 g of tert-butyl
(triphenylphosphoranylidene)acetate are added. Under reflux, the
mixture is heated at the boil for 1 hour. The mixture is washed
with saturated sodium chloride solution and dried over MgSO4, and
the solvent is then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=20:1. This gives 2.4 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]but-2-enoate as
an oil. C30H42O3Si (478.75), MS (ESI): 479 (M+H.sup.+),
R.sub.f(n-heptane:ethyl acetate=5:1)=0.56.
tert-Butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]butanoate
[0595] ##STR195##
[0596] 2.4 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]but-2-enoate are
dissolved in 35 ml of methanol, and 200 mg of PD (10% on activated
carbon) are added. At room temperature, the mixture is stirred
under an atmosphere of hydrogen for 7 hours. The catalyst is
filtered off through Celite and the filtrate is concentrated under
reduced pressure. This gives 2.3 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-butanoate as an
oil. C30H44O3Si (480.75), MS (ESI): 481 (M+H.sup.+).
tert-Butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2,2-dimethyl-
-butyrate
[0597] ##STR196##
[0598] 2 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]butanoate are
dissolved in 20 ml of tetrahydrofuran, and 3.1 ml of a 2M solution
of lithium diisopropylamide in tetrahydrofuran are added at
-78.degree. C. The reaction mixture is stirred at -78.degree. C.
for 2 hours and then warmed to -30.degree. C., and 1.6 ml of methyl
iodide are added. Over a period of 12 hours, the mixture is allowed
to warm to room temperature. The reaction mixture is then diluted
by addition of 150 ml of methyl tert-butyl ether and washed with
saturated NaCl solution. The organic phase is dried over MgSO4 and
the solvent is then removed under reduced pressure. The residue is
purified on silica gel using the mobile phase n-heptane:ethyl
acetate 10:1. This gives 2.1 g of the monomethylated product. This
product is dissolved in 20 ml of tetrahydrofuran, and 6 ml of a 2M
solution of lithium diisopropylamide in tetrahydrofuran are added
at -78.degree. C. The reaction mixture is stirred at -78.degree. C.
for 2 hours and then warmed to 0.degree. C., and, after 10 minutes
at 0.degree. C., 2.5 ml of methyl iodide are added. Over a period
of 12 hours, the mixture is allowed to warm to room temperature.
The reaction mixture is then diluted by addition of 150 ml of
methyl tert-butyl ether and washed with saturated NaCl solution.
The organic phase is dried over MgSO4 and the solvent is then
removed under reduced pressure. The residue is purified on silica
gel using the mobile phase n-heptane:ethyl acetate=10:1. This gives
1.8 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2,2-dimethylbutyrate
as an oil. C32H48O3Si (508.82), R.sub.f(n-heptane:ethyl
acetate=5:1)=0.49.
tert-Butyl 4-(cis-3-hydroxycyclohexyl)-2,2-dimethylbutyrate
[0599] ##STR197##
[0600] 2 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2,2-dimethylbutyrate
are dissolved in 10 ml of tetrahydrofuran, and 8 ml of a 1M
solution of tetrabutylammonium fluoride in tetrahydrofuran are
added. The mixture is stirred at 60.degree. C. for 2 hours. The
reaction mixture is concentrated under reduced pressure and
purified on silica gel using the mobile phase n-heptane:ethyl
acetate=20:1=>1:1. This gives 730 mg of tert-butyl
4-(cis-3-hydroxycyclohexyl)-2,2-dimethylbutyrate as an oil.
C16H30O3 (270.42), R.sub.f(n-heptane:ethyl acetate=5:1)=0.22.
tert-Butyl
2,2-dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyc-
lo-hexyl]butyrate
[0601] ##STR198##
[0602] 365 mg of tert-butyl
4-(cis-3-hydroxycyclohexyl)-2,2-dimethylbutyrate are, together with
850 mg of 4-iodomethyl-5-methyl-2-(4 methylphenyl)oxazole,
dissolved in 5 ml of dimethylformamide, and 110 mg of sodium
hydride (60% strength in paraffin) are added. After 1 hour of
stirring at room temperature, 100 ml of methyl tert-butyl ether are
added and the reaction mixture is washed three times with water.
The organic phase is dried over MgSO4 and the solvent is then
removed under reduced pressure. The residue is purified by RP-HPLC.
This gives 330 mg of tert-butyl
2,2-dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]bu-
tyrate as a white solid. C28H41NO4 (455.64), MS (ESI): 456
(M+H.sup.+).
2,2-Dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-bu-
tyric acid
[0603] ##STR199##
[0604] 300 mg of tert-butyl
2,2-dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]bu-
tyrate are dissolved in 20 ml of dichloromethane, and 10 ml of
trifluoroacetic acid are added. The reaction mixture is stirred at
room temperature for 1 hour. 200 ml of toluene are added and the
solvents are then concentrated under reduced pressure. The residue
is purified by RP-HPLC. This gives 180 mg of
2,2-dimethyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]bu-
tyric acid as an oil. C24H33NO4 (399.53), MS (ESI): 400
(M+H.sup.+).
EXAMPLE 72
[0605] Analogously to Example 71, tert-butyl
4-(cis-3-hydroxycyclohexyl)-2,2-dimethylbutyrate and
4-iodomethyl-5-methyl-2-(3-trifluoromethylphenyl)-oxazole gave
2,2-dimethyl-4-{3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy-
]cyclohexyl}butyric acid. ##STR200##
[0606] C24H30F3NO4 (453.50), MS (ESI): 454 (M+H.sup.+).
EXAMPLE 73
3-Methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-eth-
yl}butyric acid
tert-Butyl 2-(diethoxyphosphoryl)-3-methylbutyrate
[0607] ##STR201##
[0608] 5.5 ml of tert-butyl diethylphosphonoacetate are dissolved
in 20 ml of dimethylformamide, and 820 mg of sodium hydride (60%
strength in paraffin oil) are added a little at a time at 0.degree.
C. The suspension is stirred at 0.degree. C. for 15 minutes, and
2.4 ml of isopropyl iodide are then added. The mixture is stirred
at room temperature for 12 hours. 250 ml of ethyl acetate are then
added, and the reaction mixture is washed three times with in each
case 150 ml of water. The organic phase is dried over MgSO4 and
concentrated under reduced pressure. The residue is purified on
silica gel using the mobile phase n-heptane:ethyl acetate=5:1. This
gives 4.2 g of tert-butyl 2-(diethoxyphosphoryl)-3-methylbutyrate
as an oil. C13H27O5P (294.33), MS (ESI): 239
(M-C.sub.4H.sub.8+H.sup.+), R.sub.f(n-heptane:ethyl
acetate=1:1)=0.34.
tert-Butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropylb-
utyr-2-enoate
[0609] ##STR202##
[0610] 770 mg of tert-butyl 2-(diethoxyphosphoryl)-3-methylbutyrate
are dissolved in 10 ml of tetrahydrofuran, and 0.73 ml of a 2.7 M
solution of n-butyllithium in n-hexane is added at -20.degree. C.
After 1 hour of stirring at -20.degree. C., 500 mg of
[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]acetaldehyde,
dissolved in 5 ml of tetrahydrofuran, are added dropwise. The
reaction mixture is slowly warmed to room temperature. 20 ml of
water are then added, and the mixture is extracted three times with
in each case 50 ml of ethyl acetate. The combined organic phases
are dried over MgSO4 and the solvent is then removed under reduced
pressure. The residue is purified on silica gel using the mobile
phase n-heptane:ethyl acetate=30:1. This gives 340 mg of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropyl-butyr-2-en-
oate as an oil. C33H48O3Si (520.83), R.sub.f(n-heptane:ethyl
acetate=5:1)=0.70.
4-[cis-3-(tert-Butyldiphenylsilanyloxy)cyclohexyl]-2-isopropylbutyric
acid
[0611] ##STR203##
[0612] 1.5 g of tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropylbutyr-2-eno-
ate are dissolved in 30 ml of ethyl acetate, and 200 mg of
Perlman's catalyst are added. The mixture is stirred under an
atmosphere of hydrogen (5 bar) for 5 hours. The catalyst is
filtered off through Celite and the filtrate is concentrated under
reduced pressure. The residue is dissolved in 15 ml of
tetrahydrofuran, and 3 ml of a 1M solution of tetrabutylammonium
fluoride in tetrahydrofuran are added. The mixture is stirred at
60.degree. C. for 2 hours. The reaction mixture is concentrated
under reduced pressure and purified on silica gel using the mobile
phase n-heptane:ethyl acetate=40:1=>10:1. This gives 400 mg of
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropylbutyric
acid as an oil. C17H32O3 (284.44), MS (ESI): 211
(M-C.sub.4H.sub.9O.sup.-), R.sub.f(n-heptane:ethyl
acetate=10:1)=0.15.
[0613] Analogously to Example 73, 4-iodomethyl-5-methyl-2-(4
methylphenyl)-oxazole and
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropyl-butyric
acid gave
3-methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-yl-methoxy)cyc-
lohexyl]ethyl}butyric acid. ##STR204##
[0614] C25H35NO4 (413.56), MS (ESI): 414 (M+H.sup.+).
EXAMPLE 74
[0615] Analogously to Example 73, 4-iodomethyl-5-methyl-2-(3
methoxyphenyl)-oxazole and
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-2-isopropyl-butyric
acid gave
2-(2-{cis-3-[2-(3-methoxyphenyl)-5-methyloxazol-4-ylmethoxy]cyc-
lohexyl}ethyl)-3-methylbutyric acid. ##STR205##
[0616] C25H35NO5 (429.56), MS (ESI): 430 (M+H.sup.+).
EXAMPLE 75
2-Benzyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]butyric
acid
[0617] Analogously to Example 73, tert-butyl
diethylphosphonoacetate and benzyl bromide gave tert-butyl
2-(diethoxyphosphoryl)-3-phenylpropionate. ##STR206##
[0618] C17H27O5P (342.38), R.sub.f(n-heptane:ethyl
acetate=1:1)=0.53.
[0619] Analogously to Example 73, tert-butyl
2-(diethoxyphosphoryl)-3-phenylpropionate,
[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-acetaldehyde and
4-iodomethyl-5-methyl-2-(4 methylphenyl)oxazole gave
2-benzyl-4-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]butyri-
c acid. ##STR207##
[0620] C29H35NO4 (461.61), MS (ESI): 462 (M+H.sup.+).
EXAMPLE 76
4-Methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]-eth-
yl}pentanoic acid
[0621] Analogously to Example 73, tert-butyl
4-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]butanoate,
3-bromo-2-methylpropene and 4-iodomethyl-5-methyl-2-(4
methylphenyl)oxazole gave tert-butyl
4-methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]eth-
yl}pent-4-enoate. ##STR208##
[0622] C30H43NO4 (481.68), MS (ESI): 482 (M+H.sup.+).
4-Methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclo-hexyl]eth-
yl}pentanoic acid
[0623] ##STR209##
[0624] 500 mg of tert-butyl
4-methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]eth-
yl}pent-4-enoate are dissolved in 20 ml of ethyl acetate, and 50 mg
of palladium (10% on activated carbon) are added. The mixture is
stirred under an atmosphere of hydrogen (5 bar) for 5 hours. The
catalyst is filtered off through Celite and the filtrate is
concentrated under reduced pressure. The residue is dissolved in 20
ml of dichloromethane, and 10 ml of trifluoroacetic acid are added.
The mixture is stirred at room temperature for 1 hour. 100 ml of
toluene are added, and the solvents are then removed under reduced
pressure. The residue is purified by RP-HPLC. This gives 100 mg of
4-methyl-2-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]eth-
yl}pentanoic acid as an oil. C26H37NO4 (427.59), MS (ESI): 428
(M+H.sup.+).
EXAMPLE 77
2-(2-{cis-3-[5-Methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo--
hexyl}ethyl)-2-propylpentanoic acid
[0625] Analogously to Example 71, tert-butyl
4-[cis-3-(tert-butydiphenylsilanyloxy)cyclohexyl]butanoate and
allyl bromide gave tert-butyl
2-allyl-2-{2-[3-(tert-butyldiphenylsilanyloxy)cyclohexyl]ethyl}pent-4-eno-
ate. ##STR210##
[0626] C36H52O3Si (560.90), R.sub.f(n-heptane:ethyl
acetate=20:1)=0.60.
[0627] Analogously to Example 71 and Example 76, tert-butyl
2-allyl-2-{2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]ethyl}pent-4-
-enoate and
4-iodomethyl-5-methyl-2-(3-trifluoromethylphenyl)oxazole gave
2-(2-{cis-3-[5-methyl-2-(3-trifluoromethylphenyl)oxazol-4-ylmethoxy]cyclo-
hexyl}ethyl)-2-propylpentanoic acid. ##STR211##
[0628] C28H38F3NO4 (509.61), MS (ESI): 510 (M+H.sup.+).
EXAMPLE 78
1-{2-[cis-3-(5-Methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]ethyl}cyclo-p-
entanecarboxylic acid
tert-Butyl
1-{2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]ethyl}cycl-
o-pent-3-enecarboxylate
[0629] ##STR212##
[0630] 2 g of tert-butyl
2-allyl-2-{2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]-ethyl}pent--
4-enoate are dissolved in 100 ml of dichloromethane. For 5 minutes,
argon is passed through the solution. 100 mg of Grubbs' catalyst
are then added. The mixture is stirred at 40.degree. C. for 2
hours. The solvent is then removed under reduced pressure and the
residue is purified on silica gel using the mobile phase
n-heptane:ethyl acetate=40:1. This gives 1.4 g of tert-butyl
1-{2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclo-hexyl]ethyl}cyclopent-3-e-
necarboxylate as an oil. C34H48O3Si (532.85),
R.sub.f(n-heptane:ethyl acetate=20:1)=0.56.
[0631] Analogously to Example 77, tert-butyl
1-{2-[cis-3-(tert-butyldiphenylsilanyloxy)cyclohexyl]ethyl}cyclopent-3-en-
ecarboxylate and 4-iodomethyl-5-methyl-2-(4-methylphenyl)oxazole
gave
1-{2-[cis-3-(5-methyl-2-p-tolyloxazol-4-ylmethoxy)cyclohexyl]ethyl}cyclop-
entanecarboxylic acid. ##STR213##
[0632] C26H35NO4 (425.57), MS (ESI): 426 (M+H.sup.+).
EXAMPLE 79
2-(4-Methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-yl-meth-
oxy)cyclohexyl]ethyl}amino)-3-methylbutyric acid
[0633] ##STR214## ##STR215##
[0634] 0.1 g of
{cis-3-[2-(3-methylphenyl)-5-methyloxazol-4-ylmethoxy]cyclohexyl}-acetald-
ehyde (prepared according to process E4) is initially charged in
methylene chloride, and a spatula tip of magnesium sulfate is
added. 64 mg of amine are then added, the mixture is cooled to
0.degree. C., 30 mg of sodium acetate are added and the mixture is
stirred for 30 min. 84 mg of sodium triacetoxyborohydride are
added, and the mixture is stirred at RT overnight. 8 ml of water
are added to the reaction and the mixture is filtered through a
kieselguhr cartridge, the cartridge is washed with 50 ml of
methylene chloride and the solvent is removed under reduced
pressure. This gives 0.13 g of tert-butyl
(S)-3-methyl-2-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-yl-methoxy)cyclohexy-
l]ethylamino}butyrate. C29H44N2O4 (484), MS (ESI): 485 (M+H).
tert-Butyl
(S)-2-((4-methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyl-
-oxazol-4-ylmethoxy)cyclohexyl]ethyl}amino)-3-methylbutyrate
[0635] ##STR216##
[0636] 130 mg of tert-butyl
(S)-3-methyl-2-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-yl-methoxy)cyclohexy-
l]ethylamino}butyrate are dissolved in 1 ml of methylene chloride,
2 ml of a sat. sodium carbonate solution are added and the mixture
is cooled to 0.degree. C., an excess of the acid chloride is then
added and the mixture is stirred at RT for 1 h. The entire reaction
solution is applied to a kieselguhr cartridge and the cartridge is
washed with 20 ml of methylene chloride. The solvent is removed
under reduced pressure. This gives 0.1 g of tert-butyl
(S)-2-((4-methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-y-
lmethoxy)cyclohexyl]ethyl}amino)-3-methylbutyrate. C37H50N2O7
(635), MS (ESI):636 (M+H)
(S)-2-((4-Methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-yl-
methoxy)cyclohexyl]ethyl}amino)-3-methylbutyric acid
[0637] ##STR217##
[0638] 0.10 g of tert-butyl
(S)-2-((4-methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-y-
lmethoxy)cyclohexyl]ethyl}amino)-3-methylbutyrate are dissolved in
2 ml of dichloromethane, and the solution is stirred with 1 ml of
trichloroacetic acid at RT overnight. The solvent is then removed
completely and the residue is purified by preparative HPLC. This
gives 15.6 mg of
(S)-2-((4-methoxyphenoxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-y-
lmethoxy)cyclohexyl]ethyl}amino)-3-methylbutyric acid. C33H42N2O7
(579), MS (ESI): 580 (M+H)
EXAMPLE 80
[0639] Analogously to Example 79,
[cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl 1-aminocyclopentanecarboxylate gave
1-(benzyloxycarbonyl-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyc-
lohexyl]ethyl}amino)cyclopentanecarboxylic acid. ##STR218##
[0640] C34H42N2O6 (574.7), MS (ESI): 575 (M+H)
EXAMPLE 81
[0641] Analogously to Example 79,
cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl 1-aminocyclopentanecarboxylate gave
1-((4-methoxybenzyloxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-yl--
methoxy)cyclohexyl]ethyl}amino)cyclopentanecarboxylic acid.
##STR219##
[0642] C35H44N2O7 (604.7), MS (ESI): 605 (M+H)
EXAMPLE 82
[0643] Analogously to Example 79,
cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl (S)-2-amino-2-methyl-3-phenyl-propionate gave
(R)-2-((4-methoxybenzyloxycarbonyl)-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-
-ylmethoxy)cyclohexyl]ethyl}amino)-2-methyl-3-phenylpropionic acid.
##STR220##
[0644] C39H46N2O7 (654.8), MS (ESI): 656 (M+H)
EXAMPLE 83
[0645] Analogously to Example 79,
cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl (S)-2-amino-2-methyl-3-phenylpropionate gave
(benzyloxycarbonyl-{2-[cis-3-(5-methyl-2-m-tolyl-oxazol-4-ylmethoxy)cyclo-
hexyl]ethyl}amino)acetic acid ##STR221##
[0646] C30H36N2O7 (520.6), MS (ESI): 521 (M+H)
EXAMPLE 84
[0647] Analogously to Example 79,
cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl (S)-2-amino-2-methyl-3-phenyl-propionate gave
({2-[cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]ethyl}phenyl-
acetylamino)acetic acid. ##STR222##
[0648] C30H36N2O5 (504.6), MS (ESI): 505 (M+H)
EXAMPLE 85
[0649] Analogously to Example 79,
cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]acetaldehyde
and methyl (S)-2-amino-2-methyl-3-phenyl-propionate gave
(1-{2-[cis-3-(5-methyl-2-m-tolyloxazol-4-ylmethoxy)-cyclohexyl]ethyl}-3-p-
henylureido)acetic acid. ##STR223##
[0650] C29H35N2O5 (505.6), MS (ESI): 506 (M+H)
[0651] The present invention is not to be limited in scope by the
specific embodiments described herein. Indeed, various
modifications of the invention in addition to those described
herein will become apparent to those skilled in the art from the
foregoing description and the accompanying figures. Such
modifications are intended to fall within the scope of the appended
claims.
[0652] Various publications are cited herein, the disclosures of
which are incorporated by reference in their entireties.
* * * * *
References